ROS and mitochondrial genetic abnormalities as novel indicators to predict anticancer drug efficacy by Zaidieh, Tarek
 
 
ROS and mitochondrial genetic abnormalities as novel 
indicators to predict anticancer drug efficacy 
 
By 
Tarek Zaidieh 
School of Pharmacy and Biomedical Sciences 
University of Portsmouth 
White Swan Road 
Portsmouth, United Kingdom 
 
April 2020 
 
The thesis is submitted in partial fulfilment of the requirement for the 
award of the degree of Doctor of Philosophy of the  
University of Portsmouth
i 
 
Abstract 
Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) 
generation. Mitochondrial genetic abnormalities (mutations and copy number change) 
have been reported in various cancer types that might be associated with elevated ROS 
levels in cancer cells compared to normal cells. Since high levels of ROS can trigger 
apoptosis, treating cancer cells with ROS-stimulating agents may enhance cell death. This 
study aimed to investigate: 1) how baseline ROS levels might influence cancer cells’ 
response to ROS-stimulating therapy; 2) the link between mitochondrial genetic 
abnormalities and baseline ROS levels; 3) how specific mitochondrial DNA mutations 
might be utilised to predict cancer cells’ response to ROS-stimulating therapy.  
Sanger sequencing was used to screen for mitochondrial DNA (mtDNA) mutations and 
qPCR to measure mtDNA copy number (mtDNAcn) in four cancer and one non-
cancerous cell lines. Three-dimensional structural mapping and analysis of all the non-
synonymous mutations were then performed to assess their functional importance. The 
overall baseline intracellular ROS levels and mitochondrial superoxide were measured 
using the 2’,7’-dichlorofluorescin diacetate assay and MitoSOX indicator, respectively. 
Cells were treated with a conventional drug (cisplatin) and a mitochondria-targeting agent 
(dequalinium chloride hydrate) separately and jointly. Cell viability was assessed using 
MTS assays and drug combination synergisms were analysed using the Combination 
Index method. Apoptosis events were detected and the relative expression levels of the 
genes and proteins involved in ROS-mediated apoptosis pathways were also investigated. 
Greater numbers of non-synonymous mutations in the mitochondrial complexes I/III 
coding regions were detected in cancer cells with higher ROS levels. Our data showed a 
positive correlation between the baseline ROS levels, number of non-synonymous 
mutations, mtDNAcn and drug resistance levels in the tested cells. Synergistic effect of 
both drugs was also observed with ROS being the key contributor in cell death. 
Our findings assert that cancer cells with low levels of ROS are more sensitive to  ROS-
stimulating agents, while cells with high levels of ROS are more resistant. Moreover, 
specific mutations in the complexes I/III coding regions, A10398G, T11120C, C12084T, 
A13681G, G13708A, C13802T, A13966G and T14798C, could be used to indicate 
elevated intracellular ROS and therefore to predict drug resistance. Patient-derived 
ii 
 
primary cell cultures and tissues, and in vivo experiments will be required to validate the 
present findings. 
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1.1 Mitochondria 
1.1.1 Mitochondria structure and functions 
Mitochondria are semiautonomous organelles that are present in almost all eukaryotic 
cells. Each mitochondrion is enclosed by double lipid membrane: the outer membrane 
(OMM) that covers the organelle and the inner membrane (IMM) that markedly folds and 
creates layered structures called cristae which extend into the matrix; the space between 
the outer membrane and the inner membrane is called the intermembrane space (IMS) 
(reviewed in Ref. [1]). One unique feature of mitochondria is that they contain their own 
genome, mitochondrial DNA (mtDNA; a small circular DNA of 16569 bp), independent 
of nuclear DNA (nDNA) (reviewed in Ref. [2]) (Figure 1.1). 
Each human cell can contain hundreds to thousands mitochondria, and each 
mitochondrion contains 2–10 mtDNA copies [3]. The synthesis and degradation of 
mtDNA is rapid and independent of the cell cycle so the dynamic equilibrium between 
them determines the mitochondrial DNA copy number (mtDNAcn) (reviewed in Ref. 
[4]). 
 
Figure 1.1. Structure of human mitochondria [2].  
Mitochondria are considered the energy powerhouse of the cells since the majority of the 
adenosine triphosphate (ATP) is generated by the mitochondria via fatty acid oxidation 
(FAO), tricarboxylic acid cycle (TCA) also known as the Krebs cycle and oxidative 
phosphorylation (OXPHOS). The amount of produced ATP is influenced by the 
abundance of mitochondria and number of mtDNA copies according to the cell types and 
the physiological conditions. Furthermore, mitochondrial double lipid membrane 
contains various types of ion channels responsible for the maintenance of the homeostatic 
levels of Ca2+, Na+, and K+ ions, which regulate the cellular homeostasis, TCA cycle 
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activity and ATP production, mitochondrial transmembrane potential (ΔΨm), 
mitochondrial permeability transition pore (MPTP) opening and cross-talk between the 
inside and outside of the mitochondria. Moreover, mitochondria are implicated in 
multiple cellular processes such as cell communication, cell differentiation, cell apoptosis 
and they have anabolic functions in the biosynthesis of lipids, amino acids and 
nucleotides. 
Mitochondria are dynamic organelles that can rapidly sense stress signals and 
subsequently coordinate several biochemical pathways required to adapt to 
environmental changes (reviewed in Ref. [5]). 
Communication between mitochondria and nucleus is essential for maintaining 
mitochondrial function and cellular homeostasis. In response to environmental stressful 
conditions, the nucleus regulates the transcription and translation of genes responsible for 
mitochondrial biogenesis and OXPHOS functions directly via the anterograde pathway. 
On the other hand, dysfunctional mitochondria interact with the nucleus via the retrograde 
signalling pathway to activate various nuclear responses, consequently promoting 
multiple pathways that regulate energy homeostasis, oxidative stress, mitophagy and 
other functions to facilitate cellular-adaptation strategies (reviewed in Ref. [6]). 
 
1.1.2 Mitochondrial dynamics 
To survive from external and internal stressors, cells are required to preserve a balance of 
the main intracellular parameters to regain homeostasis. Mitochondria are the key players 
in this process as their responses to stress are essential to cell maintenance and fate. The 
mitochondrial adaptation mechanisms involve a reshape provided by mitochondrial 
motility, fusion and fission processes and other homotypic/heterotypic interactions (such 
as tethering with the endoplasmic reticulum) [7,8]. 
Mitochondria fusion is characterised by the union of two mitochondria forming one 
mitochondrion. This process helps cells to moderate stress by sharing multiple elements 
which sustain mitochondrial biology [9]. It is regulated by large Guanosine 
triphosphatases (GTPases) of the dynamin family. Membrane-anchored dynamin family 
members called Mitofusin 1 and 2 (MFN1 and MFN2) mediate the fusion of the outer 
membrane whereas a single dynamin family member called Optic Atrophy type 1 (OPA1) 
mediates the fusion of the inner membrane [10–12]. 
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On the contrary, mitochondrial fission is the division of one mitochondrion in two 
mitochondria. It is regulated by dynamin-related protein 1 (DRP1) and fission protein 
homolog 1 (FIS1), which are located at the OMM during the fission process [13]. This 
process is required for mitochondrial genome replication and redistribution and motility 
of mitochondria during cell division (reviewed in Ref. [14]). 
Several studies have evidenced that mitochondrial fission is also essential for the 
separation of damaged mitochondria via mitochondria-specific autophagy (mitophagy) 
triggered by DRP1. Mitophagy is well known as a substantial process for the maintenance 
of mitochondria and cellular physiology. It also appears to act as a pro-survival 
mechanism in cell metabolism. Various mitophagy effectors have been identified in 
mammalian cells, including proteins involved in the PINK1/Parkin pathway and the 
mitophagy receptors NIX, BNIP3, and FUDNC1 [15,16]. The balance between 
mitochondrial fusion and fission controls mitochondrial abundance, size, and distribution 
within the cytoplasm, and allows remodelling when cells are stressed (reviewed in Ref. 
[17]). 
Given the critical role of mitochondria in cellular bioenergetic and in many other 
important physiological processes such as cell communication, differentiation and 
apoptosis, mitochondrial dysfunction can be involved in the development of various 
human disease, including cancers [18]. 
 
1.1.3 Mitochondrial genome 
1.1.3.1 Mitochondrial DNA structure 
Mitochondrial DNA (mtDNA) is a small circular and double-stranded DNA of 16569 bp 
and characterised by high gene density and absence of intron. The two strands of 
mitochondrial DNA are named the heavy strand (H-strand) and the light strand (L-strand), 
the former being guanine rich and the latter cytosine rich (reviewed in Ref. [19]). MtDNA 
contains 38 regions that encodes for 13 protein subunits for four of the five complexes of 
the oxidative phosphorylation system (OXPHOS) namely (ND1, ND2, ND3, ND4, 
ND4L, ND5, ND6, CYB, COI, COII, COIII, ATP6 and ATP8), which generates the 
majority of cellular ATP. Of these genes, 12 are located on the heavy strand and one on 
the light strand. MtDNA also encodes 2 rRNAs (12S and 16S) and 22 tRNAs which are 
involved in the translation of the mitochondrial encoded subunits within the 
mitoribosomes.  
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The displacement-loop region (D-loop) is a long non-coding region (NCR) of 
approximately 1.1k bp long and plays a fundamental role in controlling the initiation of 
mtDNA transcription and replication via the interaction of its regulatory elements with 
several nuclear DNA-encoded factors that are imported into the mitochondria [20,21]. In 
the D-loop region, there are polycistronic transcription promoters for each mitochondrial 
genome strand; the heavy strand promotor (HSP) and the light strand promotor (LSP). It 
also contains the origin for the heavy strand DNA replication (OH), whereas the origin of 
the light strand DNA replication (OL) is harboured outside the D-loop region 
approximately 11,000 bp  downstream of OH within a tRNA cluster [22] (Figure 1.2). 
 
Figure 1.2. Structure of the human mitochondrial genome; a double-stranded DNA that encodes 13 
essential OXPHOS subunits. The diagram also shows the two ribosomal RNA (12S rRNA and 16S rRNA) 
genes and the 22 transfer RNA genes (red spheres depicted by single-letter amino acid code abbreviations) 
required for mitochondrial protein synthesis. F = Phenylalanine; V = Valine; L = Leucine; I = Isoleucine; 
Q = Glutamine; M = Methionine; W = Tryptophan; A = Alanine; N = Asparagine; C = Cysteine; Y = 
Tyrosine; S = Serine; D = Aspartic acid; K = Lysine; G = Glycine; R = Arginine; H = Histidine; E = 
Glutamic acid; T = Threonine; P = Proline. HSP 1, 2: heavy strand promoter 1 and 2, LSP: light strand 
promoter, OH: origin of replication of heavy strand; OL: origin of replication of light strand [23].  
Several proteins are involved in mtDNA replication or transcription, and mitochondrial 
transcriptional factor A (TFAM) plays dual roles in mtDNA replication and transcription 
through binding to D-loop [24]. Notably, mtDNA was initially thought to be naked, 
unprotected, and vulnerable to damage, but a recent report (reviewed in Ref. [25]) has 
suggested that the mitochondrial genome is protein-coated and packaged into nucleoids 
by TFAM due to its ability to bind, wrap, bend and unwind DNA without sequence 
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specificity. Mice with overexpression of TFAM showed a higher mtDNAcn while a 
decrease of mtDNAcn was observed with the knockdown of TFAM expression. 
Moreover, phosphorylation of TFAM evidenced to define its activity therefore, might be 
involved in the regulation of mtDNAcn [26,27]. 
Another nuclear DNA encoded protein, Ribonucleotide reductase regulatory TP53 
inducible subunit M2B (RRM2B), has also been implicated in mtDNA replication and 
maintenance of mitochondrial DNA content by supplying deoxyribonucleoside 
triphosphates (dNTPs) for DNA damage repair [28,29]. It has been shown that 
abnormalities in its gene are one of the causes of the Mitochondrial DNA Depletion 
Syndrome (MDDS) [30]. 
Generally, cellular mtDNA content ranges from 103 copies to 104 copies per cell and is 
strictly regulated during differentiation. The actual mtDNA copy number (mtDNAcn) is 
determined by the demand for ATP generated through OXPHOS, and this is associated 
with other internal and external factors. Cells with higher requirement for ATP have 
larger mtDNAcn, whereas those with lower requirement have fewer mtDNA copies. 
Moreover, the synthesis and degradation of mtDNA are rapid and independent of the cell 
cycle so the dynamic equilibrium between them also influences the overall mitochondrial 
content [18,20,26]. 
1.1.3.2 Mitochondrial DNA replication and transcription 
Mitochondrial DNA is replicated by proteins different from the ones used by the nuclear 
genome (reviewed in Ref. [31]). DNA polymerase γ (POLγ) is the replicative polymerase 
in mitochondria. In human, POLγ is a heterotrimer with one catalytic subunit (POLγA) 
that acts to proofread the newly synthesised DNA strand and two accessory subunits 
(POLγB), which promote the interactions with the DNA template and increase the activity 
of POLγA. Additional polymerases have also been reported to be involved in 
mitochondrial DNA replication such as PrimPol, DNA polymerase β, DNA polymerase 
θ, and DNA polymerase ζ [22]. Since POLγA is not able to use double-stranded DNA as 
a template, the DNA helicase TWINKLE moves in front of the POLγ to unwind the 
mtDNA and form the required single-stranded DNA (ssDNA). The exposed ssDNA will 
be protected against nucleases by its binding to mitochondrial single strand DNA binding 
protein (mtSSB), which also plays a role in preventing secondary structure formation and 
stimulating activities of TWINKLE and POLγA [22,32]. 
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Mitochondrial DNA replication is initiated at OH and a new H-strand will be synthesised 
while the parental H-strand is covered by mtSSB (Figure 1.3). Once the replication passes 
the OL, parental H-strand forms a stem-loop structure at OL to block the binding to mtSSB 
and a short singlestranded DNA in the loop region will be presented where mitochondrial 
RNA polymerase (POLRMT) can initiate primer synthesis [22,32]. Directly after 25 
nucleotides, POLRMT will be replaced by POLγA at the 3/-end of the primer and               
L-strand will be initiated. Synthesis of the two strands proceeds continuously until they 
both reach the full circle. When the synthesis of the two strands is complete, the new 
strands will be ligated by DNA ligase III after the removal of the RNA primers used for 
the initiation of mtDNA synthesis by RNASEH1 [22,32]. 
 
Figure 1.3. Replication of the human mitochondrial DNA [33].  
Generally, 95% of the replication events initiated at OH do not reach the full circle, and 
they usually terminate after 650 nucleotides at the termination associated sequences 
(TAS). This newly formed short DNA fragment (called 7S DNA) remains attached to the 
parental L-strand while the parental H-strand is displaced (Figure 1.4). As a result, a 
triple-stranded displacement loop structure, a D-loop, is formed [22]. 
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Figure 1.4. Structure of the triple-stranded displacement-loop (D-loop) region. The major noncoding 
region, which is shown enlarged at the top, contains the heavy and light strand promoters (HSP & LSP), 
three conserved sequence boxes (CSB1-3, orange), the H-strand origin of replication (OH), and the 
termination-associated sequence (TAS, yellow). The triple-stranded DNA (D-loop) is formed by an early 
termination of nascent H-strand DNA synthesis at TAS. The short H-strand replication product formed in 
this manner is termed 7S DNA. Another minor NCR (non-coding region), located approximately 11,000 
bp downstream of OH, contains the L-strand origin of replication (OL) [22].  
Transcription of the mitochondrial DNA initiates in the D-loop region which contains the 
L-strand promotor (LSP) and the H-strand promotor (HSP). The transcription of eight of 
the tRNAs and the MT-ND6 gene are controlled by light strand promoter. Whereas the 
transcription of the two rRNAs (12S and 16S), the remaining 14 tRNAs and almost the 
entire OXPHOS subunits are produced by HSP transcription. The machinery needed for 
transcription initiation requires the association of three proteins: mitochondrial RNA 
polymerase (POLRMT), mitochondrial transcription factor A (TFAM) and mitochondrial 
transcription factor B2 (TFB2M). Recent studies [32,34] have shown that in the 
transcription initiation complex, TFAM bounds to DNA and facilitates the recruitment of 
POLRMT to the promoter via its large N-terminal extension, then TFB2M modifies the 
structure of POLRMT to induce opening of the promoter. The elongation stage requires 
an additional transcription elongation factor (TEFM) which significantly enhances 
POLRMT activity and promotes the formation of longer transcripts. Mitochondrial 
termination factor 1 (MTERF1) is responsible for transcription termination through DNA 
binding, which prevent the transcription from progressing [32,34]. 
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1.1.4 ATP generation 
ATP is the energy currency of cells and mainly produced by the oxidation of glucose 
which is a two-stage process: glycolysis at the cytosol and oxidative phosphorylation 
(OXPHOS) at the mitochondria. Since most of the ATP is produced inside the 
mitochondria, they are considered as the primary source of ATP production in human 
cells (reviewed in Ref. [35]). 
Generally, glycolysis is an anaerobic process (does not require O2) and triggered by a 
sequence of multiple reactions that metabolises one molecule of glucose to two molecules 
of pyruvate with the net production of two molecules of ATP. Produced pyruvate can be 
later processed anaerobically to lactate (lactic acid fermentation) or ethanol (ethanol 
fermentation). However, pyruvate under aerobic condition is transported to mitochondria 
and can be fully oxidised into carbon dioxide and water resulting in much more ATP 
generation through TCA cycle and electron transport chain (reviewed in Ref. [19]).  
The starting point of this oxidative pathway is acetyl coenzyme A (acetyl-CoA) that is 
produced inside the mitochondrial matrix by the oxidative decarboxylation of pyruvate. 
Subsequently, citric acid cycle removes electrons from acetyl-CoA and uses these 
electrons to form NADH and FADH2. During the OXPHOS process, electrons released 
from acetyl-CoA flow through a series of membrane proteins (known as electron transport 
chain, ETC) which consists of approximately 100 protein subunits clustered in four 
specific ‘complexes’ housed within the mitochondrial inner membrane to produce a 
proton gradient across the mitochondrial membrane. These protons flow through ATP 
synthase to generate the ATP from ADP (reviewed in Ref. [19]) (Figure 1.5).  
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Figure 1.5. Overview of ATP generation [35].  
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1.1.5 Mitochondrial respiratory chain 
Electron transport chain (ETC) is also known as mitochondrial respiratory chain (MRC). 
There are 13 protein subunits for four of the five MRC complexes encoded by the 
mitochondrial genome, namely seven subunits of NADH dehydrogenase (complex I), one 
of cytochrome c oxidoreductase (complex III), three of cytochrome c oxidase (complex 
IV) and two of ATP synthase (complex V). The four subunits of respiratory enzyme 
complex II are totally encoded by nuclear DNA (nDNA), transcribed and translated in the 
cytoplasm and then transported into the mitochondria. Over 70 nuclear subunits complete 
this elegant molecular machine, and  the interaction between these complexes enables the 
production of the majority of ATP through OXPHOS [21,36].  
As mentioned earlier, the process of OXPHOS initiates when electrons are received from 
electron donors produced from the glycolysis and citric acid cycle (e.g. nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2)). These 
molecules donate electrons to complexes I and II in the respiratory chain, and the 
electrons flow on to complexes III and IV. A small amount of energy is released at each 
of these steps that is used to pump protons (H+) across the inner mitochondrial membrane 
creating an excess of hydrogen ions in the intermembrane space and an electrochemical 
proton gradient (Figure 1.6). The energy stored in this electrochemical potential is then 
able to flow down this gradient, through complex V (ATP synthase) resulting in the 
production of ATP in a phosphorylation reaction utilising ADP and inorganic phosphate 
(Pi). The electrons reaching the end of this chain at complex IV are accepted by oxygen 
and eventually form water (H2O) (reviewed in Ref. [19]). 
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Figure 1.6. Mitochondrial respiratory chain. NADH and FADH2 donate electrons (e-) to complex I and 
complex II. They then pass through co-enzyme Q (CoQ) onto complexes III, IV and cytochrome c oxidase. 
These stages allow hydrogen ions (H+) to be pumped into the IMS which then flow back through complex 
V into the mitochondrial matrix generating ATP [37].  
 
1.1.5.1 Complex I 
Complex I (NADH dehydrogenase; ND), also known as NADH: ubiquinone 
oxidoreductase, is one of the largest membrane-bound enzymes in the cell. It contains 45 
subunits resolved in the L-shaped molecule, comprising 14 core subunits that house the 
catalytic machinery with their nine cofactors (a flavin mononucleotide (FMN) and eight 
iron sulfur (FeS) clusters) and 31 supernumerary subunits that are central to the structure 
stability and assembly of the complex, and some of which also have regulatory or 
independent metabolic roles [38]. Seven subunits of the core subunits are totally encoded 
by the mitochondrial genome (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) and 
harboured in the hydrophobic membrane domain whereas the hydrophilic matrix arm 
harbours the nuclear DNA-encoded core subunits and the FMN and FeS clusters [39] 
(Figure 1.7). 
 
 
 
Chapter 1 
 
13 
 
Complex I powers the ATP synthesis in mitochondria via the oxidation of NADH into 
NAD+ by the FMN, and two electrons released from NADH are transferred along a chain 
of FeS to the highly hydrophobic exogenous ubiquinone (Q). The latter lies at the 
interface of the hydrophilic nuclear subunits (49 KDa/PSST) and the membrane 
ND1/ND3 subunits which will be reduced to ubiquinol (QH2) (Figure 1.7). Coupled with 
the electron transport during this step of OXPHOS, four protons are translocated across 
the inner mitochondrial membrane through four different routes structured inside ND2, 
ND4, ND5 individually and ND1+ND4L+ND6 jointly [38–40]. 
This step of reaction can be presented in the following formulation:  
NADH + H+ + Q + 4H+in            NAD
+ + QH2 + 4H
+
out. 
 
Figure 1.7. Crystal structure of the core subunits and ubiquinone-binding site of mammalian complex I 
[38].  
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1.1.5.2 Complex II 
Complex II (Succinate dehydrogenase; SDH) comprises four subunits (SDHA, SDHB, 
SDHC and SDHD) which are totally encoded by the nuclear DNA (Figure 1.8). In 
addition to its role in OXPHOS, SDH is a component of the TCA cycle, making a 
functional link between these two essential processes. In the TCA cycle, complex II 
oxidises succinate to fumarate. As part of OXPHOS, SDH transfers electrons from 
succinate via FAD and its FeS clusters to ubiquinone (reviewed in Ref. [41]). 
 
Figure 1.8. Crystal Structure of complex II. (a) shows subunits of SDH: SDHA (blue), SDHB (green), 
SDHC (brown) and SDHD (red). (b) highlights three iron sulfur (FeS) clusters of SDH [41].  
1.1.5.3 Complex III 
Complex III (ubiquinol-cytochrome c oxidoreductase), also known as the cytochrome bc1 
complex, occupies the middle position of the OXPHOS system. It catalyses the transfer 
of electrons to cytochrome c (Cyt c) from ubiquinol which is coupled with protons 
translocation across the mitochondrial inner membrane [42]. Complex III exists as a 
functional dimer where each monomer is composed of 11 different subunits. All subunits 
are encoded by the nuclear genome except cytochrome b (Cyt b), a predominantly 
hydrophobic protein which is encoded by the mitochondrial gene, MT-CYB [43]. At least 
three redox active subunits are existing in each half of complex III: iron-sulfur protein 
(ISP) containing 2Fe-2S cluster, cytochrome c1 and cytochrome b with two hemes           
(bH and bL) and two separate quinone binding sites called Qo site for ubiquinol oxidation 
and Qi site for ubiquinone reduction (Figure 1.9) [44]. 
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Figure 1.9. The catalytic core complex III. Redox active groups are located within three subunits that form 
the catalytic core: cytochrome c1 (purple), ISP (yellow) and cytochrome b (blue) which contains two hemes 
(bH and bL) and forms the two quinol binding sites: Qo and Qi [43].  
There is a bifurcated electron flow at the Qo site where two electrons are transferred from 
ubiquinol to two different chains. The first electron is transferred to the ISP, then to 
cytochrome c1 and finally to Cyt c. The second electron is transferred sequentially to 
heme bL then bH, and later to the ubiquinone at Qi site. In the full catalytic cycle, two     
cyt c molecules are reduced, and two ubiquinol molecules are oxidised at the Qo into 
ubiquinone and one molecule of ubiquinone is reduced to ubiquinol at the Qi site.  A total 
of four protons are translocated across the inner mitochondrial membrane from the matrix 
to the intermembrane space during this cycle [43,45] 
Finally, both reduced Cyt c molecules are released from complex III and diffuse to 
complex IV to transfer their electrons to complex IV where the O2 is reduced to H2O 
accompanied with the translocation of two protons [46]. 
1.1.5.4 Complex IV 
Complex IV (cytochrome c oxidase; CO) is the terminal oxidase of the electron transport 
chain. It is composed of 13 subunits: three subunits (COI, COII and COIII) are encoded 
by the mitochondrial DNA and form the central core, and 10 subunits are encoded by the 
nuclear genome and form a structural scaffold around the core [45]. Complex IV also 
contains two iron sites (heme a and a3), two copper sites (CuA and CuB), one zinc ion, one 
magnesium ion and several phospholipid molecules [47]. There are three main parts of 
complex IV: an inner region that faces the matrix side, an outer area that faces the inter 
membrane space and a large transmembrane region which contains the three 
mitochondrial subunits [45].  
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Among the three mitochondrial subunits, COIII forms a homodimer at the centre of 
complex IV. Although COIII does not have any binding pocket or active site, it plays an 
important role in the formation and stabilisation of the complex IV dimer [42]. On the 
other hand, COI is the major subunit of complex IV and along with COII, responsible for 
electron and proton transfer. COI and COII create the channels for O2 to reach the 
dioxygen reduction site and for the produced water to be removed from the same site 
[45,48]. 
In a complete catalytic cycle, complex IV accepts 4 electrons from 4 reduced Cyt c 
produced by complex III to reduce oxygen (O2) and form 2 molecules of water. This 
process is coupled with 6 protons being removed from the matrix of which two are 
translocated across the inner mitochondrial membrane [45,47,49]  (Figure 1.10). 
 
Figure 1.10. Overall structure and cofactors of mammalian cytochrome c oxidase. The three mitochondrial 
subunits (COI, COII and COIII) are shown in green, purple and blue respectively.  Cytochrome c in the 
IMS sequentially donates four electrons which are accepted initially by CuA and later transferred via the 
low spin heme a into the haem a3/CuB. Molecular oxygen enters complex IV from the membrane phase to 
be reduced to two water molecules with the uptake of four protons [50].  
Complex I, complexes III and IV preserve the cross-membrane proton gradient that is the 
driving force behind ATP generation in the mitochondrial respiratory chain via the FOF1 
ATP synthase [45]. 
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1.1.5.5 Complex V 
Complex V (ATP synthase) is the primary producer of adenosine triphosphate (ATP). It 
is composed of a hydrophobic membrane inserted region FO that traverses the inner 
mitochondrial membrane and a soluble hydrophilic catalytic F1-ATPase region that 
protrudes into the matrix. Two mitochondrial encoded subunits, ATP6 and ATP8 (also 
known as subunit a and A6L respectively), form the FO region with the presence of several 
nuclear encoded subunits (e, f, g, DAPIT and the two hydrophobic alpha-helices of 
subunit b), a proteolipid and the c8-ring (known as the rotor), whereas the F1-ATPase 
region is formed by the α, β, γ, δ, ε subunits. The FO and F1-ATPase regions are linked 
via subunits OSCP, F6, d and the hydrophilic portion of subunit b (Figure 1.11) [42,51].    
Complex V drives the protons from the IMS to the matrix through two half channels 
formed by ATP6 and the rotor. The first half channel allows protons to move half way 
from the IMS across the lipid bilayer and protonate the Glu85 residue in one of the               
c subunits and consequently induce c-ring to rotate. Once the protonated Glu residues 
have moved full circle around the rotor, the other half channel provides an exit for the 
proton into the matrix [42,51].   
 
Figure 1.11. Crystal structure of complex V shown in different orientations with the c8-ring removed for 
better clarity in panel (b) [51].  
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Oxidative phosphorylation (OXPHOS) is a pivotal system for the production of cellular 
energy in the form of ATP. Various other processes coupled to the electron transfer and 
proton translocation of the MRC include the regulation of nucleotide pools, tricarboxylic 
acid-cycle (TCA) flux, reactive oxygen species (ROS) production and signalling, calcium 
homeostasis, mitochondrial transmembrane potential and apoptosis. Due to the 
importance of OXPHOS, genetic mutations (germ-line or somatic) in both the mtDNA 
and nDNA sequences that result in aberrant protein subunits of the OXPHOS system may 
not only affect the mitochondrial function but also contribute to numerous human diseases 
[21]. 
 
1.1.6 Mitochondrial role in apoptosis 
Mitochondria are essential for life due to their vital role in biosynthetic processes such as 
ATP generation. Paradoxically, mitochondria play a central role in apoptotic cell death 
(reviewed in Ref. [52]). They contain a number of proteins implicated in cell death 
initiation following their release from IMS to the cytosol. Specific pro-apoptotic proteins 
have been confirmed to be converged at mitochondrial level such as cytochrome c, second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein 
with low pI (Smac/DIABLO), apoptosis-inducing factor (AIF) and endonuclease G (Endo 
G) [53,54]. 
Apoptosis is a programmed cell death characterised by controlled auto digestion of the 
cell. It differs from necrosis by specific morphological features including chromatin 
condensation, DNA fragmentation and the breakdown of the cell into a series of 
membrane-bound fragments called apoptotic bodies [55]. Moreover, apoptosis is also 
sub-classified into two pathways, namely the extrinsic pathway and the intrinsic 
mitochondria-mediated pathway (Figure 1.12). The extrinsic pathway requires effective 
engagement between the death receptors such as tumour necrosis factor receptor (TNFR), 
CD95 (also known as first apoptosis signal/Fas) and TNF-related apoptosis inducing 
ligand (TRAIL) receptors found on the surface of the cell membranes and their respective 
ligands. Activation of CD95 or TNF receptors leads to the activation of initiator caspase, 
procaspase 8. Subsequently, activated caspase 8 triggers the execution phase of apoptosis 
by activating the downstream effector caspase, caspase 3 (reviewed in Ref. [35]). 
Caspases are family of cysteine proteases that play a major role in the regulation of cell 
survival and the execution of apoptotic events [56]. 
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On the contrary, the intrinsic pathway (illustrated in Figure 1.12) is activated by several 
receptor-independent stimuli such as radiation, free radicals and viral infections. In this 
process, the defining event is mitochondrial outer membrane permeabilisation (MOMP). 
This event results in the release of pro-apoptotic proteins that facilitate the activation of 
caspase 9, an initiator caspase to the apoptotic pathway  [26]. 
 
Figure 1.12. Overview of apoptosis pathways. FADD: Fas-associated protein with death domain, TRADD: 
Tumour necrosis factor receptor type 1-associated death domain.  
Cytochrome c binds to the apoptosis protease-activating factor (APAF-1) and causes its 
oligomerisation with pro-caspase 9. This active Cyt c/APAF-1/pro-caspase 9 activates 
caspase 9 that in turn cleaves and activates executioner caspases 3 (Figure 1.13).  
A proteolytic cascade is then initiated with the cleavage of procaspases 6 and 7 leading 
to the dismantling of the cell with distinctive biochemical and morphological hallmark 
(reviewed in ref [54]). On the other hand, Smac/DIABLO binds to IAPs (inhibitor of 
apoptosis proteins) and deactivates them, thus preventing IAPs from binding to the 
activated forms of caspase 3 and caspase 9, as well as preventing their block of the 
apoptosome-mediated caspase activation, and consequently permitting apoptotic 
progression. In some models, the release of AIF and Endo G is a late event in apoptosis, 
which occurs once the cells are committed to apoptosis. Both AIF and Endo G provoke 
caspase independent DNA degradation and execute cell death. Alterations in this natural 
death mechanism can lead to diseases such as cancer (reviewed in Ref. [35]). 
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Figure 1.13. Intrinsic pathway of apoptosis [57].  
MOMP effectively represents a point of no return, and it is highly regulated by members 
of the BCL-2 protein family. This family is subdivided into anti-apoptotic BCL-2 proteins 
(BCL-2, BCL-XL, MCL-1, A1, BCL-B, BCL-w), pro-apoptotic proteins (BAK and 
BAX) and pro-apoptotic BH3-only proteins (BID, BIM, PUMA, Noxa, HRK, BIK, BMF, 
BAD) which can be further subdivided into activators that are able to directly activate 
BAX/BAK or sensitisers that neutralise the apoptotic brake regulated by anti-apoptotic 
BCL-2 proteins (reviewed in Ref. [52]). Activation and oligomerisation of BAX or BAK 
require direct interaction with a member of the BH3-only protein family (e.g. BID). Such 
conformational changes lead to the formation of the mitochondrial permeability transition 
pore (MPTP) [35,54].  
The MPTP consists of ANT (adenine nucleotide translocator), CypD (cyclophilin D), 
PBR (peripheral benzodiazepine receptor) and VDAC (voltage-dependent anion channel) 
(reviewed in Ref. [35]). VDAC1, the most abundantly expressed protein of the three 
isoforms of the mammalian VDAC, has been reported to be a target for both pro-apoptotic 
(BAX and BAK) and anti-apoptotic (BCL-XL) proteins [58,59]. Interaction of VDAC1 
with the pro-apoptotic BCL-2 members is thought to result in OMM permeabilisation that 
is potentially linked with the release of cytochrome c from the IMS, whereas interaction 
with the anti-apoptotic BCL-2 proteins supresses VDAC1 oligomerisation and prevents 
OMM permeabilisation (reviewed in Ref. [60]). 
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It has been demonstrated that once BAX binds to VDAC1, this assembly facilitates the 
formation of a channel complex with sufficient pore size capable of releasing 
cytochrome c from the IMS to the cytosol and consequently triggers caspase-initiated 
apoptosis [61]. The formation of the MPTP has also been linked to the interaction of BAX 
with ANT, as well as the BID-induced channel closure of VDAC (reviewed in ref [54]). 
Anti-apoptotic BCL-2 proteins counteract the activity of BAK/BAX and prevent the 
formation of the MPTP by either binding to the activated BAK/BAX directly or binding 
to BID and consequently blocking its interaction with BAK/BAX (reviewed in Ref. [52]). 
It has also been shown that BCL-XL can protect the cells from apoptosis by maintaining 
mitochondrial membrane integrity and therefore avoiding the release of apoptogenic 
factors such as Cyt c. This is through the interaction of BCL-XL with ANT/VDAC which 
prevents the latter from forming the mitochondrial pores (reviewed in Ref. [35]). 
The inner membrane transmembrane potential is often used as an indicator for cellular 
viability, as the proton gradient across the IMM is essential for the ATP synthase activity 
in the OXPHOS process, as well as for the import of mitochondrial proteins and the 
regulation of metabolite transport. Thus, disruptions to this transmembrane potential have 
severe consequences in mitochondrial respiration, energy production, and consequently, 
cell survival (reviewed in Ref. [54]).  
Apoptosis is an energy-dependent phenomenon as the complete apoptotic program 
involves the formation of apoptosome (when Cyt c and ATP bind to APAF-1 and 
activates pro-caspase-9) and hydrolysis of macromolecules. However, the inhibition of 
ATP production occurs relatively late in apoptosis compared to other types of cell death 
where necrosis is characterised by an early loss of ATP synthesise [54]. Leist et al. [62] 
reported that depletion of cellular ATP using oligomycin, an ATP synthase inhibitor, 
resulted in the switch from apoptosis to necrosis in leukemic cells. Similar results were 
observed when rat fibroblastic cells were treated with antimycin, inhibitors of complex 
III [63]. Thus, ATP demonstrates a key role in determining the cell death pathway 
engaged under various metabolic conditions (reviewed in Ref. [54]). 
Given the important role of mitochondria in apoptosis, it is not surprising that 
downregulated, suppressed or mutated pro-apoptotic proteins as well as overexpressed 
anti-apoptotic proteins have the propensity to allow cells to acquire resistance to 
apoptosis, and develop diseases as cancer (reviewed in Ref. [35]). 
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1.1.7 MtDNA Mutations 
MtDNA is protein-coated and packaged into nucleoids by mitochondrial transcription 
factor A (TFAM) due to its ability to bind, wrap, bend and unwind DNA without sequence 
specificity. Unlike nuclear DNA, mtDNA lacks introns and protective histones due to the 
poor fidelity of DNA polymerase, hence the mutation rate of mtDNA is substantially 
greater than that of nuclear DNA [64]. In addition, because mtDNA is close to 
mitochondrial respiratory chain that continuously generates oxidizing products known as 
reactive oxygen species (ROS), mtDNA is more susceptible to ROS-induced mutations. 
As a result, the incidence of mtDNA mutation can be 10 times higher than that of nDNA 
mutation (reviewed in Ref. [65]). However, beside its dual roles in mtDNA replication 
and transcription through binding to D-loop, TFAM is believed to exert the histone-like 
protection and provide proper architecture to mtDNA, so downregulation of TFAM may 
promote mtDNA mutations [18,25]. 
Both point mutations and deletions in mtDNA can occur either due to mtDNA replication 
aberrations or induced by chemical and physical mutagenic agents such as UV or X 
radiation, ROS and RNS (reactive nitrogen species) [19,66].  
In most animals, as in humans, the mitochondrial genome does not follow the Mendelian 
rules of inheritance. It is maternally inherited, and therefore a mother carrying a germline 
mtDNA mutation can transmit it to her children, and only her daughters can further 
transfer it to the next generation (reviewed in Ref. [25]). 
Somatic mutations in human mtDNA have been proposed to accumulate during the life 
span. Accordingly, it has been observed that the mitochondrial genome in the heart, brain 
and skeletal muscle of ageing humans harbour higher numbers of mutations compared to 
the corresponding tissues of young subjects. The age-correlated accumulation of mtDNA 
mutations has been suggested to be the progressive result of a mitochondrial vicious circle 
[53,67,68]. According to this theory, mutations in either mitochondrial or nuclear genes 
encoding subunits of the ETC will impair electron transfer leading to increased ROS 
production. Eventual oxidative damage to mtDNA induces further impairments of the 
mitochondrial subunits of the ETC, which in turn results in higher ROS production and 
further mtDNA damage, thus establishing a vicious circle rendering an accumulation of 
mtDNA mutations (reviewed in Ref. [69]). 
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Five different types of DNA repair mechanisms are present in the cell to avoid the 
accumulation of DNA defects: base excision repair (BER), nucleotide excision repair 
(NER), DNA double-strand break repair, direct reversal and mismatch repair (MMR). 
BER is the most documented mechanism in mitochondria, and it has been recently 
suggested that it is modulated by TFAM (reviewed in Ref. [25]). It is a fundamental 
weapon in correcting alkylated, hydrolytic and oxidative lesions as well as ROS induced 
DNA breaks. BER repairs a wide range of base modifications, fixes abasic sites (also 
known as apurinic/apyrimidinic site; AP site) and single-strand breaks in DNA. The 
mitochondrial BER machinery includes DNA glycosylases (OGG1, MUTYH, UNG1, 
NTHL1, NEILI1/2, MTH1) that recognise and remove mutated base [70]. 
OGG1, also known as 8-oxoguanine DNA glycosylase, mainly removes 8oxoG adducts, 
the most remarkable mutagenic lesions generated by ROS resulting in mismatch pairing 
with adenine or thymine during replication thus generating the G:C → T:A transversions 
[71]. Since OGG1 does not recognise adenines mispaired with 8oxoG bases, MUTYH 
are required to firstly remove the adenine and allow subsequent BER [72] (Figure 1.14). 
 
Figure 1.14. The 8oxoG base excision repair. The presence of 8oxoG in DNA results in G:C to T:A 
transversion mutations during DNA replication or inaccurate DNA repair. Human DNA glycosylases 
OGG1 and MUTYH are involved in the excision of bases (O and A) from the DNA [73].  
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Moreover, MTH1, an 8-oxoGTPase, primarily prevents oxidised purine dGTP from being 
incorporated into DNA and consequently eliminates A:T to C:G and G:C to T:A 
transversions caused by oxidised purines (reviewed in Ref. [25]). UNG1, uracil DNA 
glycosylase, removes uracil bases that appear in DNA strands as a result of 
misincorporation of dUMP instead of dTMP during replication or due to spontaneous 
deamination of cytosine [74].  
On the other hand, NEIL1 and NEIL2 (Nei endonuclease VIII-like 1 and 2) are DNA 
glycosylases that recognise oxidised pyrimidine, formamidopyrimidine and                          
5-hydroxyuracil. Both proteins have associated DNA glycosylase/lyase activity towards 
mismatched thymine and uracil favouring removal of T:C and U:C mismatches. In 
addition, NTHL1 (endonuclease III-like protein 1) also recognises the oxidised ring 
pyrimidine residues and initiates the BER repair to remove the lesion that results in an 
AP site [75]. 
BER also includes AP endonuclease (APE1) that processes the abasic site. In addition, 
BER repairs single-strand breaks in DNA employing polymerase gamma (POLG) and 
DNA ligase (LIG3). POLG re-synthesises missing DNA fragments whereas LIG3 seals 
the gaps between newly synthesised DNA fragments (reviewed in Ref. [25]). 
MtDNA exists in a large number of copies, and it may be all of the same type 
(homoplasmy) being wild type or mutant, or different genotypes may coexist 
(heteroplasmy) in the cell or tissue (reviewed in Ref. [36]). Threshold effect represents 
the minimal critical level of a mutation in mtDNA to manifest a pathogenic phenotype 
when wild type molecules cannot compensate for mutant mtDNA molecules within the 
cell (reviewed in Ref. [19]). The thresholds  of various types of mtDNA mutations range 
from 60% for large mtDNA deletions to 90% for certain tRNA mutations (reviewed in 
Ref. [25]) (Figure 1.15). 
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Figure 1.15. Mitotic segregation of mtDNA. Heteroplasmy in a cell is created by a single mutation. Red 
dots represent the level of mutated mtDNA. Green dots represent the level of wild type mtDNA. The 
accumulation of mutated mtDNA during cell division above a certain threshold will lead to impaired 
respiratory chain function [34].  
Mitochondrial dysfunction resulted from mtDNA mutations has been implicated in over 
production of ROS which induces genomic instability (reviewed in Ref. [76]). Moreover, 
mtDNA mutations have been strongly linked to oxidative stress and associated with 
increased cancer susceptibility and resistance to apoptosis [53,65,77,78]. To date, 
mitochondrial genetic abnormalities such as point mutations and large deletions within 
the displacement loop and coding regions as well as mtDNA copy number changes have 
been reported in several human cancers including breast, colon, stomach, kidney, thyroid, 
head and neck and ovarian cancers [18,79–81].  
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1.2 Mitochondria and cancer 
1.2.1 The hallmarks of cancer 
Cancer is a devastating disease. It starts when abnormal cells begin to grow and reproduce 
uncontrollably. Usually the human body has just the right number of each type of cells 
because they produce signals which control how much cells should divide [82]. Evidently, 
cancer is considered as a group of multi-process and multifactorial genetic diseases since 
it is caused by accumulation of mutations in a number of genes in both nDNA and mtDNA  
that drives normal cells to become progressively malignant (reviewed in Ref. [83]). 
Hanahan and Weinberg [19,84] firstly suggested a series of common characteristics of 
cancer called ‘hallmarks of cancer’ which included: sustained proliferative signals, 
activation of metastasis and invasion, induction of angiogenesis, evasion of growth 
suppression, replicative immortality and evasion of programmed cell death (apoptosis). 
Recently, new cancer hallmarks were proposed including tumour-promoting 
inflammation, reprogramming of energy metabolism, evading immune destruction and 
genome instability (summarised in Figure 1.16).  
 
Figure 1.16. A graphic representation of the ‘Hallmarks of Cancer’ from Hanahan and Wienberg [84].  
Furthermore, cancers have the ability to develop resistance through different mechanisms 
such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell 
death inhibition and the epithelial-mesenchymal transition (EMT). The increasing 
prevalence of these drug resistant cancers necessitates further research and novel 
treatment development (reviewed in Ref. [85]). 
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Mitochondria are fundamental intracellular organelles that regulate energy production, 
cell death and vital signalling pathways that are essential for cell differentiation and 
proliferation. Thus, mitochondria are fundamentally involved in cancer biology and a set 
of orchestrated mitochondria functional modifications are implicated in cancer initiation, 
growth, metastasis, relapse and acquired drug resistance. Those modifications include a 
shift of energy production mechanisms, increased ROS production and equivalently 
increased antioxidant activity, disruption of apoptotic signalling and increased mtDNA 
mutation (reviewed in Ref. [19]). Indeed, mitochondria of cancer cells are structurally 
and functionally different from their non-cancerous counterparts, and their dysfunctions 
result in many defects and grant key roles in the development and progression of cancer 
(reviewed in Ref. [86]). 
 
1.2.2 Cancer as a mitochondrial metabolic disease 
The somatic mutation theory, the most accepted view of the origin of cancer, states that 
cancer is a genetic disease, as it is caused by changes in genes that control cell functions 
especially how they grow and divide. However, emerging evidence suggests that cancer 
is primarily a mitochondrial metabolic disease and the origin of cancer is due to damages 
to the mitochondria in the cytoplasm rather than damages to the genome in the nucleus. 
This is supported by observations that although the imbalance between oncogenes and 
tumour suppressor genes is predominantly the result of nuclear DNA damage in tumour 
cells, such genomic abnormalities follows, rather than precedes, the disturbance in 
cellular respiration [87].  
Several nuclear-cytoplasmic transfer experiments examined the influence of cytoplasm 
on the expression of tumorigenicity in cytoplasmic hybrids (cybrids). For example, Koura 
and co-authors [88] fused intact B16 mouse melanoma cells with cytoplasts (absent 
nucleus) from non-tumorigenic rat myoblasts, and their finding showed that normal 
cytoplasm containing mitochondria from non-tumorigenic cells could suppress the 
malignant phenotype of tumour cells. Israel and Schaeffer [89] also demonstrated 100% 
suppression of malignancy in cybrids containing tumorigenic nucleus and normal 
cytoplasm, whereas normal cell nucleus was unable to supress the tumorigenesis when 
fused in tumour cell cytoplasm. These observations are in agreement with the view of 
Darlington [87] who showed that the cytoplasm, rather than the nucleus, determined the 
tumorigenic state of the cells.  
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Moreover, Singh and co-authors [90] provided evidence for the role of mitochondria in 
suppressing tumorigenic phenotype when wild type mitochondria were transferred into 
cells with their own mitochondria DNA depleted (i.e. the rho0 cells). Wallace and co-
authors [91] also provided evidence for the role of mitochondrial respiration in the origin 
of prostate cancer by introducing specific pathogenic mtDNA mutation into PC-3 prostate 
cancer cells through cybrid transfer. More recent experiments from the Wallace and Cruz-
Bermudez groups [91,92] showed that introduction of mtDNA mutations could alter the 
anti-tumorigenic effect of normal mitochondria in cybrids. These findings indicate that 
mitochondrial respiration is fundamental in cancer prevention and specific mtDNA 
mutations can play an important role in cancer aetiology [87]. Similar findings were also 
obtained from in vivo experiments. Morgan et al. [93] observed no malignancies or 
abnormal cell growth in any of the recipient mice when nuclei from mouse brain tumour 
cells were transplanted into enucleated non-cancerous somatic cells. All previous 
experiments showed that somatic nuclear mutations alone could not account for the origin 
of cancer, and cytoplasm containing normal mitochondria could suppress tumorigenicity 
(Figure 1.17). It is now well known that the Ras oncogene induces tumorigenesis through 
an inhibitory effect on mitochondrial oxidative phosphorylation [94].  
 
Figure 1.17. Summary of the role of mitochondria in the origin of tumorigenesis. Normal cells with normal 
nuclear and mitochondrial morphology indicative of normal gene expression and respiration are shown in 
green. Tumour cells with abnormal nuclear and mitochondrial morphology indicative of genomic instability 
and abnormal respiration are shown in red. (1) Normal cells beget normal cells. (2) Tumour cells beget 
tumour cells. (3) Transfer of a tumour cell nucleus into a normal cytoplasm begets normal cells, despite the 
presence of the tumour-associated genomic abnormalities. (4) Transfer of a normal cell nucleus into a 
tumour cell cytoplasm begets dead cells or tumour cells, but not normal cells. The results suggest that 
nuclear genomic defects alone cannot account for the origin of tumours, and that normal mitochondria can 
suppress tumorigenesis [87].  
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However, the role of mitochondrial DNA abnormalities in the origin and progression of 
cancer is still controversial. Various studies have failed to evidence the initiator role of 
mitochondria, and rather suggest that nDNA, not mtDNA, is responsible for carcinogen-
induced malignant transformation [87]. Further studies are still needed to reconcile 
variations in results gained from some in vitro and in vivo transfer experiments, and also 
to identify specific pathogenic mtDNA mutations responsible for the origin of cancer. 
Although the aforementioned nuclear-cytoplasmic transfer experiments do not support 
the somatic mutation theory, they strongly favour the Warburg theory of cancer, i.e. 
cancer is primarily a mitochondrial metabolic disease [87]. It would be expected that the 
existence of normal mitochondria in cancer cells would retrieve the redox state, 
downregulate the mitochondrial stress response, and ultimately reduce or eliminate the 
need for fermentation to preserve viability [87]. In conclusion, normal mitochondria 
would maintain the differentiated state by enhancing respiration and thereby suppressing 
oncogene expression and tumorigenicity, whereas dysfunctional mitochondria lead to 
glycolysis and enhance cellular dedifferentiation thereby facilitating carcinogenesis [87]. 
 
1.2.3 Mitochondrial metabolic reprograming in cancers 
The first characterisation of tumour metabolism is attributed to Warburg who was the first 
to elucidate that cancer cells exhibit an altered energy metabolism by depending more on 
glycolysis with regard to OXPHOS even with enough oxygen supply (i.e. aerobic 
glycolysis). Warburg hypothesised that cancer cells rely more on glycolysis for ATP 
production due to mitochondrial dysfunction [95]. Currently, this “Warburg effect” is 
referred to as “metabolic reprogramming in cancer” [96,97]. 
Cancer cells are well characterised with their fast proliferation and high growth rate, 
however tumour tissue readily becomes hypoxic due to the lack of oxygen supply by local 
vasculature. These conditions are usually lethal to non-cancerous cells because of the 
hypoxia-induced p53-mediated apoptosis [98], but cancer cells can avoid hypoxia-
mediated death due to down regulation or mutation of p53 [99]. The insufficiency of 
mitochondria under hypoxic conditions to generate adequate ATP for cell survival leads 
to the upregulation of glycolytic pathway. This pathway takes place by the induction of 
hypoxia-inducible factor 1 (HIF-1) that catalyses key steps of glycolysis and regulates 
genes that control angiogenesis, invasion and cell survival [100]. 
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Normally, transformation between OXPHOS and glycolysis is controlled by the relative 
activities of pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH). HIF-1 has 
been reported to induce pyruvate dehydrogenase kinase 1 (PDK1) that inactivates PDH 
and consequently supresses the Krebs cycle and mitochondrial respiration. It has been 
shown that HIF-1 also facilitates the conversion of pyruvate to lactate by catalysing the 
expression of LDH. As a result, the contribution of mitochondria in ATP production 
declines, although the mitochondrial function might remain intact [99]. On the other hand, 
the activities of Krebs cycle proteins and OXPHOS in cancer are significantly altered due 
to mutations in nuclear and mitochondrial DNA that encode for Krebs cycle proteins and 
mitochondrial respiratory complexes. TCA cycle dysfunction and the resultant oxidative 
stress activate HIF-1 signalling pathway leading to tumour growth and vascularisation, 
even in the absence of hypoxic conditions (Figure 1.18) [101]. 
 
Figure 1.18. TCA cycle modifications in cancers. Metabolic alteration by mutations in TCA cycle enzymes 
(a, b, and c) and inhibition of pyruvate dehydrogenase complex (PDC) activity (d) are shown. (a) Isocitrate 
dehydrogenase (IDH) mutations can catalyse the NADPH-dependent reduction of α-ketoglutarate to (R)-
2-hydroxyglutarate (2HG), which decreases NADPH and GSH but increases (R)-2HG and ROS 
accumulation. (R)-2HG also regulates the activity of prolyl hydroxylase (PHD), a negative regulator of 
oncogenic HIF-1α [102]. (b) Succinate dehydrogenase (SDH) mutations supress complex II activity, 
subsequently activating HIF-1α and ROS generation. SDH mutations also increase the accumulation of 
succinate which suppresses the PHD activity, triggering HIF-1α-mediated carcinogenesis. (c) Mutations of 
fumarate hydratase enhance Nrf2 nuclear translocation causing the transcription of oncogenic genes and 
antioxidants which increases both tumorigenesis and tumour cell survival. (d) PDC activity is suppressed 
via downregulation of pyruvate dehydrogenase phosphatase (PDP) and upregulation of pyruvate 
dehydrogenase kinase (PDK) in various cancer cells. Inhibition of PDC reduces acetyl-CoA level, TCA 
cycle activity and oxidative phosphorylation but increases glycolysis, lactate production and acidification 
in cancer cells. These metabolic shifts facilitate carcinogenesis and tumour survival [101].  
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Several oncogenes have also been involved in the induction of glycolysis in human cancer 
including v-akt murine thymoma viral oncogene homolog 1 gene (AKT) and v-myc 
myelocytomatosis viral oncogene homolog gene (MYC)-encoded MYC. AKT and MYC 
can activate various genes coding for glycolytic enzymes including hexokinase II        
(HK-II), LDH and enolase to enhance glycolysis [103–105]. Aerobic glycolysis not only 
produces ATP for cells but also provides glycolytic intermediates required for the 
biosynthesis of nucleotides and proteins to support fast cell proliferation. This shift in 
cellular metabolism can also protect cancer cells from oxidative damage caused by ROS, 
side products of OXPHOS [106]  
Since cancer cells depend on different metabolic pathways for energy production for their 
survival, these metabolic alterations can affect the capacity of cancer cells to engage in 
catabolic processes including apoptosis (reviewed in Ref. [86]). 
 
1.2.4 Apoptosis in cancer 
As mentioned earlier, mitochondria control the intrinsic pathway of apoptosis. They 
regulate the translocation and release of pro-apoptotic proteins from the IMS to the 
cytosol (reviewed in Ref. [107]). Several studies have shown that cancer cells over 
express anti-apoptotic BCL-2 proteins through different mechanisms including gene 
amplification, transcriptional upregulation (driven by oncogenic signalling) or 
downregulation of microRNAs that suppress anti-apoptotic BCL-2 protein expression. 
Besides inhibiting the function of key apoptotic effectors such as BAX or BAK by        
anti-apoptotic proteins, expression of the BAX, BAK and other pro-apoptotic BH3-only 
genes such as PUMA, NOXA and BIM can be downregulated in a variety of cancer types 
through either DNA deletion or promoter hypermethylation leading to transcriptional 
silencing [52,108]. 
It has also been shown that anti-apoptotic proteins BCL-2 and BCL-XL can protect cells 
from apoptosis by interacting with mitochondrial proteins such as ANT or VDAC thus 
preventing them from forming mitochondrial pores [109]. 
Maintaining genetic integrity is one of the functions of the tumour suppressor gene p53 
[55]. It also contributes to other cellular processes such as differentiation, DNA repair 
and angiogenesis, which also appear to be vital for tumour suppression (reviewed in Ref. 
[110]).  
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The p53 protein is activated by internal and external stress signals that induce its nuclear 
accumulation in an active form. Consequently, activated p53 induces either cell cycle 
arrest or apoptosis by downregulating anti-apoptotic protein BCL-2 and upregulating  
pro-apoptotic proteins including BAX, APAF-1, the BH3-only proteins, and notably 
PUMA [55,110].  
However, the tumour suppressor gene p53 is inactivated in the majority of human cancers; 
50% of human cancers carry mutated p53 gene and the majority of the remaining cancer 
cases have a compromised p53 activity due to overexpression of p53 inhibitors. Murine 
double minute 2 (MDM2), a negative regulator of the p53 protein, inhibits the 
transcription factor activity of p53 and triggers its degradation by proteolysis (reviewed 
in Ref. [110]).  
Moreover, cancer cells incur significant alterations in the components of the permeability 
transition pore complex (PTPC). PTPC mediates the mitochondrial permeability 
transition (MPT) to trigger the release of cytochrome c, a key step in the intrinsic 
apoptosis pathway [111]. Alterations in PTPC can interfere with apoptosis regulation and 
therefore promote cancer cell survival. 
Cancer cells also inhibit caspase function following MOMP allowing them to survive 
under these conditions. They inhibit caspase activity via downregulation of apoptosome 
activity through epigenetic silencing or inhibitory phosphorylation of APAF-1. Cancer 
cells can also abolish the pro-apoptotic activity of cytochrome c by its ubiquitination and 
proteasome-dependent degradation following MOMP [112]. Caspase function can be 
directly inhibited by the X-linked inhibitor of apoptosis protein (XIAP) or indirectly by 
c-IAP1 and c-IAP2 (cellular inhibitor of apoptosis protein 1 and 2) through their ability 
to bind and neutralise the XIAP inhibitor, Smac (Figure 1.19) (reviewed in Ref. [52]). 
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Figure 1.19. Execution of mitochondrial apoptosis pathway and escape mechanisms in cancer cells. 
Apoptotic stresses trigger the accumulation of the BH3-only proteins resulting in BAX/BAK 
oligomerisation, MOMP and release of pro-apoptotic proteins. Release of cytochrome c results in 
apoptosome formation, which leads to caspase activation and apoptosis. Smac neutralises the activity of 
caspase inhibitor XIAP. Various strategies to escape apoptosis by inhibiting either MOMP or caspase 
activity are presented in red [52].  
Due to various mitochondrial dysfunctions that have been linked to multiple aspects of 
tumorigenesis and tumour progression, mitochondria represent a promising target for 
cancer-specific therapies (reviewed in Ref. [86]). 
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1.2.5 Mitochondrial DNA mutation and epigenetics in tumorigenesis 
Somatic mutation within the mitochondrial genome is a common phenomenon in the 
process of cell transformation. Indeed, point mutations or deletions within the 
displacement loop and coding regions have been observed in various types of cancer such 
as colon, breast, kidney, thyroid, and head and neck [81,113,114] (Figure 1.20). 
Mutations within the protein-coding region have been proved to affect the stability, 
assembly and function of the complexes in the respiratory chain causing OXPHOS 
deficiency. Hence, the frequency of mutations observed in the mitochondrial genome of 
various types of cancer is thought to be correlated to the extent of respiratory dysfunction 
(reviewed in Ref. [66]). 
 
Figure 1.20. Regions of mitochondrial DNA mutations and related cancers [101].  
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A previous study on colorectal cancer showed that certain mtDNA mutations in the ND5 
subunit in complex I demonstrated not only gradual decreases in OXPHOS but also 
increased glucose-dependent lactate production and progression in tumour growth [80]. 
Moreover, the ND5 mutation-induced complex I dysfunction activates the AKT 
signalling pathway to enhance tumorigenesis [115]. These results suggest that mutated 
mtDNA genes are not just innocent victims to the oxidative stress, but in fact they are 
major initiation factors in tumorigenesis [101]. 
A total of 635 mutations have been reported in the D-loop region, including 510 point 
mutations, 56 deletions and 69 insertions, which cause alterations in mtDNAcn and 
mtDNA gene expression. More mutations have been identified in the coding region: 593 
mutations in complex I subunits, 343 mutations in complex III, IV and V subunits, and 
165 mutations in tRNA and rRNA genes [116]. 
1.2.5.1 D-loop mutations in human cancer 
The D-loop region is well known to be a hotspot for mtDNA mutation in tumour cells 
with the majority of somatic mutations occurring in the hypervariable regions (HV1 and 
HV2) [117]. Mutations in this region have been identified in several types of cancer: 
breast cancer, ovarian carcinomas, prostate cancer, hepatocellular carcinoma, endometrial 
cancer and bladder cancer (reviewed in Ref. [66]). It has been reported that D-loop 
mutations have consequences on cell physiology. For example, mtDNA copy number was 
significantly reduced in patients with hepatocellular carcinoma (HCC) due to the 
occurrence of point mutations near the replication origin of the heavy strand [118]. 
Moreover, HCC tissues containing D-loop mutations had higher ROS levels than their 
adjacent tissues with the wild type D-loop region [119]. On the other hand, clinical 
implications were contributed to D-loop mutations. Correlation between mitochondrial 
D-loop mutations and cancer characteristics has been observed in HCC, lung and 
colorectal cancers, and the frequency of mutations was higher in later tumour stage than 
early stage [120]. Mutations in this region were also associated with the response to 
chemotherapy. Stage III colon cancer with mutations in the D-loop region showed 
resistance to fluoruracil-based adjuvant therapy [121]. Most importantly, D-loop 
mutations have been suggested as biomarkers for early detection strategy of cancer. 
Sequence variants within the D-loop region have been implicated in the development of 
familial breast cancer as specific polymorphisms that occur more frequently in patients 
with family history could be responsible for inherited cancer susceptibility [122].   
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1.2.5.2 tRNA and rRNA mutations in human cancers 
A few somatic mutations localised in the tRNA genes have been reported in cancer cases 
such as  A3243G in colon cancer [123]; G4450A in splenic lymphoma [124]; G3244A in 
lung tumour and gastric carcinoma [123] and C4312T, C5633T, G7521A and G12236A 
in thyroid tumours [125]. Several mutations in 12S and 16S ribosomal RNA have also  
been reported in various types of cancer including T2664C and C2998CT in lung cancer 
[123,126]; T2445C and G3054A in bladder cancer [90]; A1811G in head and neck cancer 
[126]; G2923A in prostate cancer [127]; G687A, T1243C, T1406C, A1676G, G2015A, 
T2222C, A2805T and A2905G in pancreatic cancer [128]. It has been suggested that 
mutations in the tRNA and rRNA genes can impact on cell physiology because such 
mutations impair mitochondrial protein synthesis and therefore result in defective 
activities of respiratory chain enzymes (reviewed in Ref. [66]). 
1.2.5.3 OXPHOS complex I mutations in human cancer 
Colon cancer was the first type of cancer to be reported with mutations in the ND genes 
among known human cancers (reviewed in Ref. [66]). Missense T10563C and frameshift 
A12418AA (located in ND4L and ND5, respectively) in colorectal cancer were reported 
by Polyak et al. in 1998 [113]. Since then, a number of complex I mutations have been 
identified in other cancer types: G3421A, A3505G, G3670A, T10970C, T11703C, 
T11781C, A14552G, G14603A and G10176A in pancreatic cancer [128]; A4986C, 
A10398G and A5026G in head and neck cancer [129]. The ND2 gene was believed to be 
a hotspot for mutation in squamous cell carcinoma (SCC) [130] whereas ND1, 4 and 5 
mutations were found in early stage of prostate cancer [127].  
Mutations in complex I have been indicated to be correlated with loss of complex I 
activity and assembly, and also involved in overproduction of ROS [131,132]. Moreover, 
complex I mutations have been suggested to be metastasis promoting factors. Ishikawa 
and co-authors [77] proposed that G13997A and 13885insC (mutations located in ND6) 
were responsible for promoting metastasis, based on their cytoplasmic hybrid data using 
mouse tumour cell lines with different metastatic potentials. Those mutations cause 
downregulation of complex I activity and overproduction of ROS, accompanied with 
upregulation of the HIF-1, MCL-1 and vascular endothelial growth factor (VEGF) genes 
[77].  
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Since several subunits within complex I are necessary for the assembly of the complex, 
lack of individual subunits or an assemble factor will lead to the degradation of the 
remaining subunits [133]. Recently, NDUFS1, a nuclear DNA subunit and part of the iron 
sulfur clusters of complex I, was shown to be proteolytically cleaved by caspase-3. This 
indicates that complex I may have a dual function: creating the proton gradient across the 
membrane and participating in apoptosis after caspase cleavage. Hence, any loss of this 
step during apoptosis caused by complex I deficiency might lead to an advantage for 
cancer cells [134].  
1.2.5.4 OXPHOS complex III mutations in human cancer 
Mutated cytochrome b (MT-CYB) has been reported in various types of cancer such as 
C14866T, C15646T and G15884C in pancreatic cancer [128]; G14869A in breast cancer 
[135]; G14985A, G14963A and T15572C in colon cancer [136]; G15179A, T15312G 
and A15182G in thyroid tumour [137]; G15761A in ovarian cancer [138].  
A study on human model of bladder cancer showed that overexpression of mutated       
MT-CYB was correlated with overproduction of ROS, increased oxygen consumption 
and lactate production [139].  
Moreover, the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
signalling pathway was upregulated in cells with mutated MT-CYB, promoting rapid 
tumour growth and progression both in vitro and in vivo, which supported the conclusion 
that mitochondrial gene mutations play critical roles in cancer progression [139]. 
1.2.5.5 OXPHOS complex IV mutations in human cancer 
Somatic mutations within mitochondrial DNA encoded cytochrome c oxidase subunit I, 
II and III are frequent in various human cancers [140] such as A8701G, A8716G and 
T9137C in thyroid cancer [66]; G8557A in colon cancer [136]; T9070G and T8696C in 
pancreatic cancer [128]. COI mutations were identified in 12 % of prostate cancer patients 
in a study reported by Petros et al. [91].  
Notably, an investigation conducted by Vives-Bauza and colleagues employing cybrids 
revealed that cells with mutated complex IV did not demonstrate any increase in ROS 
production and oxidative stress, nor any elevation of antioxidants [141]. This may not be 
surprising since complexes I and III are considered the main sites of ROS production in 
the OXPHOS system. 
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1.2.5.6 OXPHOS complex V mutations in human cancer 
Mutations in the mitochondrial genome encoding for complex V have also been reported 
in human cancers such as A8701G, A8716G and T9137C in thyroid cancer [125]; 
T8696C and T9070G in pancreatic cancer [128]. Complex V is vital not only for ATP 
production but also for other processes such as apoptosis, and therefore it is not 
unexpected that complex V mutations have been identified in cancer cells [66].  
A study on cybrids with a T8993G or T9176G mutation derived from patients with 
mitochondrial encephalomyopathy showed that when transplanted into nude mice, those 
cybrids containing the above complex V mutations granted an advantage in the early stage 
of tumour growth by their contributing to the prevention of apoptosis and hence resulting 
in tumour development [142]. Moreover, complex V activity is important to the 
maintenance of mitochondrial transmembrane potential (MMP) that is required  for the 
normal mitochondrial matrix activity, so although complex V-mutant cells can switch to 
glycolysis for ATP generation, those cells may still maintain the MMP required  for the 
mitochondrial matrix activity [143]. 
1.2.5.7 Large mitochondrial deletions in human cancers 
Large deletions within mtDNA have also been associated with cancer. For instance, 
deletion of a 4977-bp fragment within mtDNA was observed in HCC which removed all 
or part of the genes encoding four complex I subunits, one complex IV subunit and two 
complex V subunits, as well as five tRNA genes [144]. HCC patients carrying this 
deletion showed a marked increase in ROS level and elevated mtDNAcn compared with 
the healthy controls, which indicates that this deletion may play an important role in the 
carcinogenesis of HCC [144]. Another deletion of a 4981-bp fragment was observed in 
nasopharyngeal carcinoma (NPC) and proposed to be involved in the development and 
progression of NPC (reviewed in Ref. [66]). 
 
1.2.6 MtDNA copy number in human cancers 
The mtDNAcn per cell is preserved within a stable range to achieve the required energy 
of the cell and hence ensure normal physiological functions. It ranges among the 
population from 103 to 104 per cell type [145]. Such variations also reflect the imbalance 
between ROS production and antioxidant capacity, so mtDNAcn has been considered as 
a potential diagnostic and prognostic biomarker for several cancer types [146]. Several 
factors in cancer possibly alter mtDNAcn such as mutations in the D-loop region (highly 
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susceptible site for oxidative damage compared with other regions of mtDNA), 
methylation profile of D-loop and the expression level of mitochondrial transcription 
factor A (TFAM) [147].  
MtDNAcn is strictly regulated during differentiation, and cells with a high demand for 
ATP by OXPHOS have higher mtDNAcn than cells with a low ATP requirement [20]. 
An increased mtDNAcn was observed in endometrial [148], untreated head and neck 
[149], prostate [149], pancreatic [150] and colorectal [151] cancers. Such an increase is 
assumed to compensate for the damaged mtDNA and maintain adequate ATP supply by 
mitochondrial respiration [105]. On the contrary,  a decrease of mtDNAcn was noticed in 
renal [152], thyroid [153], breast [154], previously treated head and neck [81], hepatic 
[155] and ovarian cancers [156]. Such a decrease would result in the reduction of 
mitochondrial function [105]. 
Generally, decline in mitochondrial activity appears to be an adaptation to hypoxic 
conditions during tumour development since low oxygen initiates lower oxidative stress 
[146]. The preservation of low mtDNAcn promotes aerobic glycolysis for ATP 
generation, and a combination of glycolysis with a small contribution from OXPHOS 
promotes cell proliferation, invasion, metastasis whereas prevents differentiation [20]. 
Alterations of mtDNAcn were also shown to be associated with tumour development. 
A recent study by Dang and co-authors [18] on laryngeal cancer patients showed that 
tumours with low mtDNA content were more aggressive compared with those with high 
mtDNA content. In addition, patients with late-stage tumours had a remarkably lower 
mtDNA content than those with early-stage tumours. 
On the other hand, increased mtDNAcn could be a defensive mechanism to avoid 
apoptosis [26]. Studies on transgenic mice with mtDNA depletions showed that mice 
could not survive the embryonic period accompanied with high numbers of apoptotic cells 
in these embryos [157,158]. Another study by Wang et al. [158] on tissue-specific 
mtDNA knockout mice showed a large number of apoptotic cells in the myocardium. In 
addition, increased mtDNAcn can also protect cells from ROS-induced apoptosis. Mei 
and co-authors [26] found that mtDNAcn increased in apoptotic tumour cells. They also 
observed that reduced mtDNAcn inhibited antioxidant gene expression and resulted in 
elevated intracellular ROS levels, which made tumour cells more sensitive to 
chemotherapeutic agents.  
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1.3 Reactive oxygen species (ROS) 
ROS are described as chemically reactive molecules containing oxygen and by-products 
of normal cellular metabolism. The three major types of ROS are superoxide anion (O₂•ˉ), 
hydroxyl radicals (OH•) and hydrogen peroxide (H₂O₂) (reviewed in Ref. [159]) (Figure 
1.21). They can be also classified into two groups of compounds, namely radicals and 
non-radicals. Radicals such as hydroxyl radical (OH•) and superoxide anion (O₂•ˉ) contain 
one unpaired electron in the shell or outer orbit, making them unstable and highly 
reactive. These radicals tend to donate or obtain another electron to attain stability. The 
none-radical species such as hydrogen peroxide (H₂O₂) are not free radicals but can easily 
lead to free radical reaction in the living organism [159,160].  
 
Figure 1.21. Electron structures of common reactive oxygen species. The red • designates an unpaired 
electron [161].  
 
1.3.1 Source of ROS 
ROS can be generated from both endogenous sources (mitochondria, peroxisomes, 
endoplasmic reticulum where the oxygen consumption is high) and exogenous sources 
(pollution, alcohol, tobacco smoke, heavy metals such as iron and copper, certain drugs 
and radiation) [159,162]. However, mitochondria are considered a primary intracellular 
site of ROS generation. Some electrons in the mitochondrial electron transport chain 
escape from the mitochondrial respiratory complexes I/III and react with oxygen to 
generate superoxide radicals. This generation of superoxide is non-enzymatic and 
therefore higher metabolic rate results in greater production of ROS (reviewed in Ref. 
[163]). 
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Superoxide anion has a low reactivity with biomolecules but later can be converted to 
hydrogen peroxide via dismutation reaction catalysed by the superoxide dismutase 
enzymes (SOD). Hydrogen peroxide can easily penetrate the biological membranes with 
no direct effect on biomolecules. However, it can damage DNA by producing hydroxyl 
radical via Fenton reaction in the presence of metal ions (Fe2+ or Cu+). Hydroxyl radical 
is a highly reactive radical and can react with biomolecules including DNA, lipids and 
proteins causing severe damages to the cell more than any other ROS (reviewed in Ref. 
[159]) (Figure 1.22). 
 
Figure 1.22. Interaction between ROS and biomacromolecules [160].  
Peroxisome is also a major site of ROS production due to xanthine oxidase activity in the 
peroxisomal matrix and membranes. Endoplasmic reticulum also contribute to the 
production of ROS via the activity of cytochrome p-450 [164]. 
Membrane-bound enzymes such as NADPH oxidases (nicotinamide adenine dinucleotide 
phosphate oxidase; also known as NOXs) are also important contributors to the 
generation of ROS. The NOX genes produce the transmembrane proteins responsible for 
transporting electrons across biological membranes, which leads to the reduction of 
oxygen into superoxide [165]. 
Mammalian NOXs primarily localise on the cytoplasmic membrane, but they can also be 
found on other membranes, including those of mitochondria, nucleus, and endoplasmic 
reticulum [166]. 
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1.3.2 Oxidative stress 
In an organism, the redox balance depends on the production of ROS and their elimination 
via endogenous and exogenous antioxidants which act as “free radical scavengers” to 
prevent the damages caused by ROS (reviewed in Ref. [167]). In healthy tissues, 
intracellular ROS are preserved at a steady low level by the equilibrium between ROS 
generation and neutralisation via the activity of enzymatic antioxidants. The balance 
between ROS production and their elimination by endogenous mechanism is vital for 
preserving normal cell homeostasis since some types of ROS such as hydrogen peroxide 
and superoxide serve as important cell signalling molecules (reviewed in Ref. [168]). The 
shift in the balance between oxidant/antioxidant in favour of oxidants is termed “oxidative 
stress” [162].  
Generally, low levels of ROS act as mitogens and promotes cell survival and proliferation, 
whereas moderate levels cause a transient or permeant cell cycle arrest and induces cell 
differentiation. At higher levels, ROS can lead to oxidative damage to cell components 
such as proteins, lipids and mainly to DNA resulting in mutations that consequently lead 
to the development of various pathological conditions including cancer [169]. However, 
excessive production of ROS causes severe oxidative damage to biomacromolecules 
which consequently induces cell death [164] (Figure 1.23).  
 
Figure 1.23. Role of low and high levels of ROS on cell response: survival or cell death [168].  
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1.3.2.1 Effects of oxidative stress on DNA 
ROS can cause DNA alterations in various ways including bases degradation, single- or 
double-strand breaks, pyrimidine and purine modifications, deletions and cross-linking 
with proteins [170]. The majority of these alterations are highly associated with several 
diseases including cancer [162]. 8-Oxoguanine (8-oxoG) is the most remarkable 
mutagenic lesion generated by ROS and considered a potential biomarker for 
carcinogenesis [25,162] (Figure 1.24). 
 
Figure 1.24. A schematic representation of oxidative damage to mtDNA and its consequences. OH• can 
react with either bases or the sugar-phosphate backbone leading to DNA single-strand breaks, abasic sites, 
DNA–DNA intrastrand adducts, DNA–protein crosslinks and base damage. For example, the main products 
of guanosine base damage are oxazolone, FAPy-G and 8-oxo-dG, with the highest measured mutagenic 
potential for 8-oxo-dG being 10% [69].  
Promoter regions of genes harbour the binding sites for transcription factors. These 
binding sites contain GC-rich sequences that are susceptible to oxidant attacks. Formation 
of 8-oxoG in these sites can alter the binding of transcription factors, subsequently change 
the expression of the related genes [162]. 
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1.3.2.2 Effects of oxidative stress on lipids 
ROS can induce lipid peroxidation and alter the cell membrane lipid bilayer arrangement 
that may inactivate membrane-bound receptors and enzymes and increase tissue 
permeability [162]. Lipid peroxidation causes the production of lipoperoxyl radical 
(LOO·) which in turn reacts with a lipid to produce a lipid hydroperoxide (LOOH). These 
LOOHs are unstable products and can generate new peroxyl and alkoxy radicals. Free 
radicals generated during lipid peroxidation have a very local effect due to their short life 
cycles. However, 4-hydroxynonenal (HNE), aldehydes, hexanal and malondialdehyde, 
breakdown products of lipid peroxides, serve as “oxidative stress secondary messengers” 
due to their longer half-life and their ability to diffuse to other sites and hence interact 
with proteins and DNA resulting in covalent modifications on macromolecules [164]. 
1.3.2.3 Effects of oxidative stress on proteins 
ROS can result in peptide chain fragmentation, protein electrical charge alteration, 
protein-protein cross-links and oxidation of specific amino acids (reviewed in Ref. [171]). 
These modifications lead to increased susceptibility to proteolysis and degradation by 
specific proteases. Methionine and cysteine residues are predominantly more susceptible 
to oxidation. Oxidation of methionine or sulfhydryl group residues of proteins causes 
conformational changes, protein unfolding and degradation. In addition, oxidative 
modification of enzymes has been shown to inhibit their activities [162].  
Oxidative stress on protein can result in either reversible or irreversible oxidative 
modifications. One example of reversible oxidative modifications is the mechanism of 
redox signalling which involves the oxidation of cysteine residues in proteins. During 
redox signalling, ROS oxidises cysteine residues that exist as thiolate anions (Cys-S-) into 
the sulfenic form (Cys-SOH) causing allosteric changes within the protein that alter its 
function. The sulfenic form can be reduced to thiolate anions by antioxidant enzymes 
such as disulfide reductases, thioredoxin (Trx) and glutaredoxin (Grx) to restore the 
original state and function of the proteins. At higher levels of ROS, oxidised thiolate 
anions are oxidised into sulfinic (SO2H) or sulfonic (SO3H) species which, unlike sulfenic 
modifications, are irreversible and result in permanent oxidative damage of the protein 
[164] (Figure 1.25). 
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Figure 1.25. Oxidative modifications of the amino acid Cysteine. Reactive cysteine thiols (R-SH) can be 
oxidised by hydrogen peroxide to form sulfenic acids which can go on to form reversible disulfides (R-SS-
R') or irreversible oxidation products such as sulfinic acids or sulfonic acids [166].  
1.3.2.4 Effects of oxidative stress on signal transduction 
ROS can promote the expression of several genes implicated in signal transduction. 
Disruption of the redox balance causes the activation of redox sensitive transcription 
factors, such as NF-kB and activator protein 1 (AP-1) and HIF-1 that are involved in the 
inflammatory response [162]. 
Activation of transcription factors via ROS is achieved by signal transduction cascades 
that transfer the information from the outside to the inside of the cell. Receptor tyrosine 
kinases such as epidermal growth factor receptor (EGFR) and vascular endothelial growth 
factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are targets 
of ROS. Members of mitogen-activated protein kinase family (MAPKs) such as c-Jun N-
terminal kinases (JNKs) and p38 are implicated in various processes including 
proliferation, differentiation and apoptosis. They are also responsive to stress stimuli and 
can be regulated by oxidants [162].  
Under oxidative stress conditions, such as ROS, NF-kB can be activated allowing it to 
enter the nucleus to activate gene transcription [172]. NF-kB regulates the expression of 
several genes that participate in immune response such as interleukins 1 beta, 6 and 8  
(IL-1β, IL-6, IL-8) and several adhesion molecules such as Cadherins and Integrins.  
NF-kB also regulates cell proliferation and differentiation as well as angiogenesis [162].  
AP-1 is also regulated by redox state. It has been shown that hydrogen peroxide can 
enhance the activation of AP-1 and increase the binding to DNA by the reduction of a 
single conserved cysteine residue in the DNA-binding domain of each of protein of the 
heterodimer AP-1 [173]. The AP-1 transcription factor is involved in the regulation of a 
wide range of cellular processes including differentiation, proliferation and apoptosis via 
its gene expression modulation function (reviewed in Ref. [174]). 
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Therefore, it is not surprising that aberrant function and regulation of p38, NF-kB, MAPK 
and other ROS-related molecules have been correlated with both dysregulation of 
apoptosis and tumour initiation [53]. HIF-1 will be further discussed in section 1.3.5. 
 
1.3.3 Antioxidant defence mechanisms 
In order to protect biomolecules from oxidative damage by ROS, cells orchestrate a 
complex network of enzymatic and non-enzymatic endogenous antioxidants to preserve 
proper cellular functions. Enzymatically, superoxide dismutase (SOD) activity converts 
superoxide to hydrogen peroxide that will be converted later into water by catalase 
(CAT), peroxiredoxin (Prx) and glutathione peroxidase (GPx). On the other hand, free 
radical activity can be eliminated non-enzymatically through the interaction with 
substrates such as glutathione (GSH) [166,175]. Antioxidant mechanisms are summarised 
in Figure 1.26. 
1.3.3.1 Superoxide dismutase 
SOD is the first line of defence against free radicals and responsible for rapid conversion 
of superoxide anion into hydrogen peroxide to prevent O₂•ˉ -induced damage to proteins 
and other biomolecules. This enzyme has three isoforms, SOD1, SOD2 and SOD3, and 
is expressed in several cellular compartments: cytosolic Cu,Zn-SOD (SOD1), 
mitochondrial Mn-SOD (SOD2) and extracellular EC-SOD (SOD3) [166,175]. 
1.3.3.2 Catalase 
CAT exists as a tetramer composed of 4 identical monomers, each of which contains a 
heme group at the active site. It can be found abundantly in peroxisomes [162]. Catalase 
binds NADPH and functions as a reducing equivalent by decomposing hydrogen peroxide 
(H2O2) into water and oxygen. This process prevents H₂O₂ from entering the Fenton 
reaction if ions are available, and thus avoids the formation of highly toxic hydroxyl 
radicals that can damage various biomolecules [162,166]. 
1.3.3.3 Peroxiredoxins 
Prxs are ideal scavengers for H₂O₂ due to their abundant expression and wide distribution 
of their six isoforms across the cell inside mitochondria, cytosol, peroxisome and 
endoplasmic reticulum. Oxidised Prxs are reduced by thioredoxins (Trxs) which can be 
restored to their reduced state by thioredoxin reductase (TR) and the reducing equivalent, 
NADPH [162,166]. 
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1.3.3.4 Glutathione peroxidase 
GPx is one of the antioxidant enzymes that have several isoforms (GPx1-8). GPx can 
convert H₂O₂ to water and lipid peroxides to their corresponding alcohols in 
mitochondria and cytoplasm. During this process, GPxs eliminate H₂O₂ by using it to 
oxidise reduced glutathione (GSH) to oxidised glutathione (GSSG); glutathione reductase 
(GR) will regenerate GSH by reducing GSSG using NADPH as an electron donor 
[166,167]. 
1.3.3.5 Glutathione 
GSH is a non-enzymatic antioxidant that prevents the oxidative damage of protein, lipids 
and DNA. GSH is highly abundant in all cellular compartments and the major soluble 
antioxidant. It exists in two forms: the thiol reduced form (GSH) or the oxidised 
glutathione disulfide (GSSG) form. In healthy cells, the predominant form is the reduced 
form accounting for 99% of total GSH. GSH/GSSG ratio is a major determinant of 
oxidative stress. GSH functions as an antioxidant through scavenging hydrogen peroxide, 
with the help of glutathione peroxidase as mentioned earlier [162]. 
 
Figure 1.26. Antioxidant defence mechanisms. Superoxide generated during OXPHOS is converted to 
hydrogen peroxide by the activity of SOD1 and SOD2 in cytosol and mitochondria, respectively. Hydrogen 
peroxide is then converted to water by the activity of CAT and GPx, which prevents hydrogen peroxide 
from entering the Fenton reaction in the presence of iron and thus avoids the formation of hydroxyl radicals 
[160].  
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N-Acetyl-L-cysteine (NAC) is a remarkable antioxidant drug due to its role in enhancing 
the synthesis of glutathione (GSH), one of the substrates that eliminate free radical 
activity non-enzymatically [166,175]. It easily enters the cells and then is converted within 
the cytosol to L-cysteine which is a precursor to GSH. NAC is also a source of sulfhydryl 
groups inside the cell, and therefore a ROS scavenger in its own right because sulfhydryl 
groups can interact with hydroxyl radicals (OH•) and hydrogen peroxide (H₂O₂) [166]. 
1.3.4 Antioxidative role of transcriptional factors 
The production and activity of the enzymatic antioxidants and their reducing equivalents 
are regulated by different key transcription factors. Nuclear factor erythroid 2-related 
factor 2 (Nrf2) is a prime regulator of redox homeostasis in response to oxidative stress, 
and it is activated to upregulate the expression of genes implicated in protective activities. 
In normal conditions, Nrf2 remains in the cytoplasm bounded to its endogenous inhibitor 
Kelch-like ECH-associated protein 1 (Keap1). Keap1 supresses Nrf2 signalling by 
inducing Nrf2 degradation through proteasomal pathway. Once ROS react with redox 
reactive cysteines in Keap1, Nrf2 is released from Keap1 followed by its translocation to 
the nucleus [176].  
In the nucleus, Nrf2 forms a heterodimer with small musculoaponeurotic fibrosarcoma 
(Maf) protein and binds to the antioxidant responsive element (ARE) located in the 
promoter of the antioxidative genes. Nrf2-ARE binding regulates the expression of genes 
involved in the cellular antioxidant system (Figure 1.27) [164,166].  
The transcription factor p53 has also been presented to repress the accumulation of ROS 
by either upregulating the expression of several antioxidant genes or via the induction of 
the metabolic gene, TP53-inducible glycolysis and apoptosis regulator (TIGAR). TIGAR 
redirects glucose to the pentose phosphate pathway (PPP) resulting in increased 
generation of cytosolic NADPH and suppression of ROS accumulation within the cell 
[166]. 
Chapter 1 
 
49 
 
 
Figure 1.27. Nrf2-ARE activation pathway. In the cytoplasm, Nrf2 is bound to Keap1 in the form of dimer 
Nrf2-Keap1. During oxidative stress, Nrf2 is released from Keap1, which allows Nrf2 to translocate to the 
nucleus. Nrf2 forms a heterodimer with Maf which then binds to the ARE-regulated genes. This in turn 
upregulates the expression of antioxidant and therefore promotes cell survival [164].  
 
1.3.5 Mitochondrial ROS functions as second messenger molecules 
Although ROS have been described as by-products of oxidative phosphorylation for 
decades, it has been established that they function as second messenger under normal 
concentrations. ROS have been evidenced to regulate gene expression by controlling 
transcription factors; they also appear to influence protein activity by controlling 
phosphatases and kinases [177]. This regulatory function is exerted through ROS’s redox 
potential. For example, ROS-induced oxidation of cysteine-rich proteins will result in the 
formation of disulfide bonds in the same molecule or between two cysteine-rich 
molecules. This modification can therefore result in conformational changes of one 
molecule or dimerisation of two or more molecules, hence modulating the activity of 
those molecules (reviewed in Ref. [178]). More importantly, ROS-regulated molecules 
have been implicated in cell survival, cell cycle control, apoptosis, differentiation and 
several stress responses [53]. 
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Hypoxia-inducible factor 1 (HIF-1) activity has been demonstrated to be regulated by 
ROS. ROS stabilise HIF-1α allowing it to dimerise with HIF-1β and forming an active 
nuclear transcription factor. Active HIF-1 is well known to regulate the expression of 
glycolytic enzymes and VEGF, and to interfere with pro-apoptotic pathways [53].  
Mitogen-activated protein kinases (MAPK) are a superfamily of protein kinases that 
regulate several cell functions including gene expression, proliferation, cycle progression 
and apoptosis. Oxidative stress has been demonstrated to activate apoptosis signal 
regulated kinase 1 (ASK1) that regulates the c-Jun N-terminal kinase (JNK) and 
p38/MAPK pathways leading to apoptosis through phosphorylation of members of the 
MAPK cascades (reviewed in Ref. [167]). On the other hand, the ROS-activated 
MAPK/ERK (extracellular signal-regulated kinase) pathway can also lead to                   
non-apoptotic outcomes such as differentiation, proliferation and cell division, thus 
reinforcing the role of ROS signalling in cellular homeostasis [53,167]. 
Phosphoinositide 3-kinase (PI3K) and AKT pathway is another signalling pathway 
subjected to reversible redox regulation by ROS. It is regulated by ROS in a similar 
manner as the MAPK pathways at the oxidative interface where phosphatase and tensin 
homolog (PTEN), a natural inhibitor of the PI3K/AKT pathway, is directly oxidised by 
ROS. This renders inactivation of PTEN and consequently results in sustained activation 
of the PI3K/AKT and MAPK pathways that play critical roles in cell proliferation and 
survival [53,167]. 
 
1.3.6 ROS regulating apoptosis and cell cycle 
In the mitochondrial apoptotic process, initial damage induced by stress does not kill the 
cell immediately. Instead, it induces an apoptotic signalling program that cause cell death. 
At high levels, ROS appear to act as substantial regulatory signals in the apoptotic process 
through their interactions with essential signalling molecules [55]. 
ASK1 is an upstream MAPKKK that regulates the JNK pathways leading to apoptosis 
through phosphorylation of JNK. ASK1 kinase activity is shown to be directly inhibited 
by thioredoxin (Trx). However, ROS can oxidise Trx and cause the formation of a 
disulfide bond between Cys-32 and Cys-35 in Trx, leading to the release of ASK1 from 
Trx. This separation allows ASK1 to undergo complete homo-oligomerisation and 
subsequent autophosphorylation, resulting in its activation. Subsequently, ASK1-
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acitvated JNK can phosphorylate pro-apoptotic BH3-only proteins (BID and BMF). The 
phosphorylated BID and BMF further activate BAX and BAK to initiate apoptosis 
respectively [160]. 
ROS formation is also a key factor that facilitates MPTP opening and release of apoptosis-
inducing proteins [99]. In fact, it has been proposed that oxidation of adenine nucleotide 
translocase (ANT) by ROS is also linked to the regulation of the MPTP opening [160]. 
Moreover, ROS have been confirmed to regulate the activity of the BCL-2 family 
proteins, the dominant regulators of the mitochondrial apoptotic pathway. Elevated ROS 
have been shown to abate the anti-apoptotic activity of BCL-2 by directly oxidise it at 
Cys158 and Cys229. On the other hand, ROS can abrogate the ubiquination of BAX, 
whereas promote ubiquitination of BCL-2, thus allowing the activation and 
oligomerisation of BAX/BAK, resulting in the formation of a VDAC-containing pore and 
permeabilisation of mitochondrial membranes to facilitate cyt c release [160]. 
ROS were also proposed to mediate the death receptor dependent apoptosis (i.e. extrinsic 
apoptosis) [160]. Although ROS do not directly act via death receptors, it can influence 
the extrinsic pathway by modifying the intracellular milieu, hence allowing the 
environment to facilitate effective binding between death ligands and their receptors and 
the execution of the downstream cascades leading to apoptosis [179]. Moreover, ROS 
have been shown to supress the expression of cellular FLICE (FADD-like IL-1β-
converting enzyme)-inhibitory protein (c-FLIP), the endogenous inhibitor of TRAIL, and 
therefore promote extrinsic apoptosis [180]. In addition, several studies have suggested 
that ROS have a critical role in regulating the expression of functional FasL, a major death 
ligand in the extrinsic pathway [181] (Figure 1.28). 
Furthermore, ROS play an essential role in cell cycle blockade, which can result in cell 
cycle G2/M arrest [182] (Figure 1.28). The CDK1/Cyclin B1 complex is a fundamental 
regulator in cell cycle progression from G2 phase into M phase. During G2 phase, CDK1 
is activated by cell division cycle (CDC25C) through dephosphorylation and triggers the 
initiation of mitosis. However, activation of the ataxia telangiectasia mutated (ATM) 
protein triggered by ROS-induced DNA damage mediates activation of checkpoint kinase 
1 and 2 (CHK1, CHK2), which subsequently results in CDC25C inhibition and 
degradation. Deactivated CDC25C can no longer dephosphorylate CDK1, resulting in 
cell cycle arrest at G2/M phase [182,183].  
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Figure 1.28. Summary of the roles of ROS in apoptosis and cell cycle.  
 
Oxidative stress mainly induces programmed cell death. However, ROS can also trigger 
necrosis. As mentioned earlier, ROS modify lipids and result in lipid oxidation. This can 
lead to the loss of integrity of both plasma membrane and intracellular membranes, 
rendering the release of proteases and consequently necrosis. Another target of ROS is 
amino acid residues. ROS-mediated protein modification contributes to necrosis through 
the modification of Ca2+ channels. The resulting influx of Ca2+ into the cytoplasm from 
the extracellular environment and from the endoplasmic reticulum can trigger necrosis 
(reviewed in Ref. [184]). 
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1.3.7 Mitochondrial ROS (mROS) in cancer development 
Oxidative stress or overproduction of ROS has been associated with various disease 
processes including cancer, and unlimited growth of cancer cells in response to ROS 
accumulation has been the focus of interest in recent studies [175]. 
Generally, cancer cells have a constant metabolic oxidative stress compared to normal 
cells, and the elevated levels of ROS during cancer transformation are due to high 
mitochondrial metabolic rate that results in increased electron leakage and ROS 
generation [164]. However, it has also been established that beside their mitogenic effect 
in tumours, excessive levels of ROS can induce damage in cancer cells and trigger 
apoptosis if not counteracted by antioxidant systems. Therefore, cancer cells are required 
to achieve a delicate redox balance to ensure survival, growth and metastasis (Figure 
1.29). Mutations in mitochondrial DNA, deactivation of tumour suppressor genes and 
upregulation of oncogene expression are some mechanisms that are ROS-regulated and 
can in turn ensure an adequate tumorigenic ROS production [175]. 
 
Figure 1.29. Mitochondrial redox control in healthy and cancer cells. Balanced production and scavenging 
of mROS grant cell survival and induce more altered gene expression, and enhance cellular mitosis, 
angiogenesis and metastasis through mROS-mediated mechanisms. In contrast, when the oxidant 
scavenging system is overpowered by mROS production in cancer cells, an oxidative stress-induced 
apoptosis occurs [175].  
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Tumour suppressor genes that regulate vital cellular activities such as cell proliferation, 
differentiation and apoptosis respond to oxidative stress by regulating both antioxidant 
and pro-oxidant responses. For example, mROS-mediated upregulation of the P53 protein 
can enhance the expression of its downstream target genes, which subsequently limit or 
promote further ROS production to either restrict DNA damage or induce apoptosis 
through excessive DNA damage [185,186]. Oncogene expression can also promote the 
generation of mROS and tumour proliferation. For example, the Ras and Myc oncogenes 
can induce ROS production in mitochondria and modulate tumorigenic and migratory 
signalling. On the other hand, oncogene-driven ROS generation induces mutation within 
the mitochondrial genome leading to mitochondrial dysfunction and further production 
of ROS and eventually apoptosis [175]. 
Mitochondrial DNA instability is a main mechanism associated with tumorigenesis that 
involves increased mROS production and oxidative stress-induced mtDNA damage. Both 
mitochondrial superoxide and hydrogen peroxide have been shown to induce mutations 
in the ND6 subunit in the HepG2 cells (human liver carcinoma) [187]. This is consistent 
with the findings reported by Ishikawa and co-authors [77] that mutations in ND6 
enhanced the metastatic potential of tumour cell lines which was reversed by ROS 
scavengers. Moreover, another study on osteosarcoma cell lines by Sharma et al. [115] 
showed that inhibition of complex I resulted in overproduction of mROS and increased 
activation of AKT that promoted cell survival. 
Other ROS-mediated pathways are shared between cancer and healthy cells in terms of 
cellular proliferation. For instance, the mechanism of mROS-modulated angiogenesis 
under hypoxic conditions via mROS-induced HIF-1α stabilisation is also utilised by 
cancer cells to promote growth and proliferation. Indeed, HIF-1α has been associated with 
invasiveness of various types of cancer [188]. Matrix metalloproteinases (MMPs), a large 
family of proteases capable of degrading all kinds of extracellular matrix proteins, have 
also been associated with tumour progression [189]. ROS can indirectly modulate MMP 
gene expression by activating the MAPK family members ERK 1/2 which leads to the 
subsequent transcription of MMP genes such as MMP-1 [190].  
Since both HIF-1α and MMPs are highly regulated by mROS and play pivotal roles in 
metastatic disease progression, it is possible that their association with tumorigenesis is 
mediated by mitochondria through redox dependent programming [175]. 
Chapter 1 
 
55 
 
1.3.8 ROS as signalling molecules in cancer survival and metastasis 
ROS play a pivotal role at every stage of cancer development including initiation, 
progression and survival. Hydrogen peroxide reversibly causes the oxidation of cysteine 
thiol groups of phosphatases such as protein phosphatase 2 (PP2), protein tyrosine 
phosphatase 1B (PTP1B) and phosphatase and tensin homolog (PTEN). This 
modification results in the loss of their activity and activation of the PI3K/Akt/mTOR 
survival pathway (Figure 1.30). Several studies have shown that hydrogen peroxide can 
enhance growth factor signalling and Ras activation that result in promoting 
PI3K/Akt/mTOR and MAPK/ERK signalling cascades. In addition, oxidisation of prolyl 
hydroxylase domain-containing protein 2 (PHD2) by H2O2 results in stabilising HIF-1 
during hypoxia, hence promoting angiogenesis and metastasis by inducing the expression 
of pro-angiogenic genes [164].  
 
 
Figure 1.30. Role of ROS in signal transduction. High level of ROS in cancer cells activates survival 
pathway and inactivates PTEN pathway, which initiates apoptosis. ROS trigger activation of the 
PI3K/AKT/mTOR survival signalling resulting in metabolic modulation, cell survival and activation of 
Ras-MAPK pathway, leading to cell proliferation. Hypoxia causes activation of HIFα and HIFβ, which 
further activates VEGF, an angiogenic growth factor [164].  
It is well established now that metastasis requires a series of stages that leads to the 
formation of secondary tumours in distant organs, and ROS have been shown to regulate 
several signalling pathways (e.g. PI3K/AKT/mTOR and MAPK/ERK) and 
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transcriptional activities (e.g. HIF and Snail) that facilitate cancer cell migration and 
invasion. More importantly, elevated levels of ROS due to mutations in the mitochondrial 
genome have been shown to promote cancer metastasis [164]. 
ROS also seem to induce epithelial mesenchymal transition (EMT), a critical initial step 
of metastasis that allows cancer cells to avoid hostile environments. EMT is controlled 
by a network of signalling pathways involving growth factors (e.g. EGF, TGF-β) and 
their associated signalling proteins (e.g. NF-κB, ERK, PI3K/AKT) in response to stresses 
implicated in tumorigenesis, including oxidative stress. These signals promote 
transcription factors such as zinc finger protein SNAI1 (Snail) which regulates the 
expression of proteins engaged in cell-cell contact, cytoskeletal maintenance and 
extracellular matrix degradation. They also trigger loss of E-cadherin, an epithelium-
specific protein, which is considered as a key feature of EMT [191]. 
ROS have been shown to upregulate Snail expression by activating EGFR, ERK, and 
p38/MAPK cascades and subsequently deactivating the endogenous inhibitor of Snail, 
glycogen synthase kinase 3β (GSK3β) [192]. ROS also contribute to activation of the  
AP-1 transcription factor that directly induces Snail expression [191]. In addition, it has 
been reported that ROS increase the expression of distal-less homobox-2 (Dlx-2), an 
upstream regulator of Snail, thereby activating Snail [191]. Moreover, ROS have been 
shown to activate NF-κB signalling which is known to stabilise Snail by preventing its 
ubiquitination and degradation [193].  
When EGFR/PI3K/AKT pathway is activated by ROS, it subsequently inactivates 
GSK3β to increase the expression of activated Snail [194]. EGFR/PI3K/AKT pathway 
also activates signal transducer and activator of transcription 3 (STAT3) which is known 
to facilitate invasion by upregulating MMPs [191]. Recently, increased expression of 
MMP-2, MMP-3 and MMP-9 has been considered to be a significant factor in triggering 
EMT and predicative of tumour aggressiveness, invasion, metastasis and poor patient 
survival [164]. A recent study by Mori et al. [195] has shown that NOX4-mediated 
mitochondrial ROS signalling increases MMP9 mRNA stability and affects cancer 
invasiveness. The ROS-quenching agent N-acetyl cysteine (NAC) was shown to inhibit 
MMP-induced EMT, suggesting that ROS scavenging could be useful in the reversal of 
EMT leading to decreased tumour aggressiveness [164]. 
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1.3.9 Role of ROS in cancer therapies 
Emerging evidences have revealed that ROS act as a double-edged sword in cancer cells 
as they have quite opposite impacts on the cells according to their levels. Low to moderate 
levels of ROS play critical roles in promoting cell survival/proliferation and cancer 
progression. On the other hand, an excessive level of ROS is able to cause irreversible 
damage to DNA, lipids and proteins leading to cell death [196]. 
Generally, cancer cells exhibit elevated levels of ROS due to their genetic abnormalities, 
active energy metabolism and microenvironment associated instability. However, cancer 
cells can compensate for excessive levels of ROS and overcome oxidative stress in order 
to enhance survival and growth. This is achieved by increasing cellular antioxidant 
capacity and reprograming metabolic pathways [164]. Therefore, further increase of ROS 
levels using ROS-stimulating agents in cancer therapy has attracted more attention in the 
past decades, and various therapeutic strategies to utilise ROS have been developed [160]. 
1.3.9.1 Role of ROS in targeted molecular therapy 
Monoclonal antibodies and small-molecule inhibitors are the main biological agents 
targeting tyrosine kinases in cancer treatments. Several studies evidenced ROS-mediated 
anti-tumour effects of these drugs. Yang et al. [197] showed that Trastuzumab, a 
monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), 
promoted ROS generation which contributed to death of HER2-positive breast cancer 
cells. Other studies showed that Cetuximab, a monoclonal antibody which binds to and 
inhibits EGFR, increased intracellular ROS levels in laryngeal carcinoma cells by 
reducing the amount of glutathione, resulting in ROS-mediated apoptosis [198,199]. 
EGFR inhibitors (Erlotinib and Gefitinib), in combination with Vorinostat, a histone 
deacetylases inhibitor (HDACi), increased ROS levels in non-small cell lung carcinoma 
(NSCLC) cells and promoted caspase-dependent apoptosis [200]. Inhibition of EGFR by 
Echinatin has also been shown to induce the G2/M cell cycle arrest, and apoptosis via the 
intrinsic pathway of caspase-dependent activation due to ROS overproduction [201]. 
Bortezomib, a proteasome inhibitor and an approved drug for treating myelanoma, in 
combination with SAHA (an HDACi), was found to induce ROS generation to further 
promote mitochondria-dependent apoptosis in nasopharyngeal carcinoma cells [202]. 
Moreover, STAT3 inhibitors have been shown to promote ROS-dependent apoptosis in 
pancreatic cancer cells [203]. 
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1.3.9.2 Role of ROS in photodynamic therapy and radiotherapy 
Photodynamic therapy PDT is a method that requires a photosensitising agent, oxygen 
and light of a specific wavelength for the treatment of neoplastic diseases [204]. Once the 
agent enters cancer cells and the tumour is exposed to light, the agent changes from its 
ground state (i.e. the lowest energy state) to an excited state by absorbing the light. As it 
returns to the ground state, released energy is transferred to oxygen to generate ROS that 
destroy cancer cells via ROS-mediated apoptosis or necrosis [205]. 
Ionising radiation (IR) is a common therapeutic tool for the treatment of solid tumour. 
ROS have been evidenced to play a critical role in promoting the biological effect of IR 
[160]. IR can generate excessive ROS by water radiolysis during radiotherapy mainly 
hydroxyl radicals. High level of hydroxyl radicals induces cancer cell death by damaging 
the cellular DNA (reviewed in Ref. [206]). 
1.3.9.3 Role of ROS in cancer chemotherapy 
Regardless their strong side effects, chemotherapeutic drugs are still the most common 
treatment for cancer. Many of those drugs cause DNA damage leading to cell death. 
However, a large number of chemotherapeutic agents cause intracellular ROS 
accumulation either by accelerating ROS production or by supressing ROS clearance in 
tumour cells. Several studies evidenced the accumulation of ROS upon treatment with 
chemotherapeutic drugs. For example, cisplatin was reported to cause excessive 
accumulation resulting in cytotoxic effect in various types of cancer such as breast cancer 
[207], prostate cancer [208,209] and ovarian cancer [196]. However, drug resistance is 
still the main obstacle for efficient cancer treatment with chemotherapeutic drugs. 
Multidrug resistance protein 1 (MDR1) plays a critical role in drug efflux, hence 
decreasing the cytotoxicity of the drug [210]. Accumulating evidences have shown that 
ROS can downregulate MDR1 expression whereas other reports have suggested that ROS 
promote MDR1 expression in cancer cells instead [160,211]. This debate raises the 
possibility that ROS are involved in the regulation of MDR1. Indeed, Terada et al. [212] 
showed that low concentrations of ROS increase the expression of MDR1 whereas high 
concentrations of ROS decrease its expression in Caco-2, a human colon cancer cell line. 
Therefore, ROS not only induce chemo-resistance but also enhance chemo-sensitivity in 
tumour cells [160]. 
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1.4 Mitochondria as anticancer target 
The fact that mitochondria contribute to key cellular processes including ATP production, 
ROS generation for cell signalling, maintenance of intracellular homeostasis and 
regulation of apoptosis makes them an attractive target for cancer therapy [99]. 
Understanding different features of mitochondria in cancer cells compared to normal cells 
could help researchers exploit mitochondrial Vulnerabilities to Trigger Apoptosis 
Selectively in Cancer Cells [213]. Indeed, several therapeutic approaches have been 
proposed to target mitochondria as a tool for tumour elimination, as discussed below. 
 
1.4.1 Targeting the transition of cell metabolism 
Since cancer cells mostly rely on glycolysis for ATP generation compared to non-
malignant cells, drugs that disturb cellular metabolism mainly at the level of glycolysis 
can display effective anticancer effects. Indeed, inhibition of glycolysis in a variety of 
cancer cells by a non-metabolisable glucose analogue, 2-deoxyglucose (2-DG), resulted 
in significant ATP reduction. This ATP depletion also triggered dephosphorylation of 
BAD, translocation of BAX from cytosol to mitochondria and permeabilisation of OMM, 
leading to massive cell death [214]. However, one clinical trial for 2-DG as a glycolytic 
inhibitor for prostate cancer has been suspended, mainly due to the lack of cancer-specific 
targeting of the drug which caused severe damage to the normal tissue [215]. Lonidamine 
(LND), a derivative of indazole-3-carboxilic acid, is known for its ability to inhibit 
aerobic glycolysis in cancer cells. LND has shown synergistic effects when used in 
combination with chemotherapeutic agents such as cisplatin and doxorubicin [216]. 
Several phase III clinical trials of lonidamine have been carried out in breast cancer and 
NCLC (reviewed in Ref. [86]). 
 
1.4.2 Targeting the disabled apoptosis pathway 
Another approach to targeting mitochondria is the activation of the pro-apoptotic 
potential. The anti-apoptotic BCL-2 family proteins are well known to be overexpressed 
in many cancers and associated with cancer initiation and resistance to therapy by their 
attenuating the release of cytochrome c and inactivating other pro-apoptotic proteins. 
Therefore, researchers have focused on developing drugs that can neutralise the binding 
of anti-apoptotic proteins to BAK and BAX, hence allowing pore formation in the OMM.  
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ABT-199 (trade name Venetoclax), a selective small-molecular inhibitor of the anti-
apoptotic protein BCL-2, was found to disrupt the interaction between anti- and pro- 
apoptotic proteins. ABT-199 was approved by Food and Drug Administration (FDA) in 
2016 for its use in patients with chronic lymphocytic leukemia (CLL) [217]) 
 
1.4.3 Targeting cellular damage caused by abnormal ROS production 
Modulation of mitochondrial respiratory chain activity has been under investigation to 
stimulate cancer cell death. Indeed, inhibitors of mitochondrial respiratory chain 
including rotenone (complex I-specific inhibitor), antimycin (complex III-specific 
inhibitor) and oligomycin (inhibitor of mitochondrial ATP synthase) were shown to 
induce apoptosis in cultured human lymphoblastoid cells [218]. Cell death resulted from 
mitochondrial respiratory chain inhibition is predominantly mediated by overproduction 
of ROS [99]. Arsenic trioxide, a clinically used drug for treating acute myeloid leukaemia, 
can cause increased leakage of electrons by interfering with OXPHOS, hence promoting 
ROS generation and the subsequent apoptosis [219]. Other agents have been evidenced 
to exert their anticancer effects by supressing antioxidant enzymes leading to over-
accumulation of ROS [220]. For example, 2-methoxyoestradiol, an estrogen derivative, 
can selectively kill leukaemia cells (but not normal lymphocytes) by supressing 
superoxide dismutase. Phase I/II clinical studies have showed that 2-methoxyoestradiol 
causes disease stabilisation in patients with solid malignancies or multiple myeloma 
[221,222]. A recent study by Kim et al. [223] showed that oxalomalate, a well-known 
competitive inhibitor of isocitrate dehydrogenase (IDH) isoenzymes which serve as the 
major antioxidants and redox regulators in the mitochondria and cytosol, resulted in 
induction of ROS stress response, ultimately leading to apoptotic cell death and 
antiangiogenic effects in melanoma cells. 
 
1.4.4 Induction of mitochondrial permeability transition pore  
Induction of MPTP is another approach to overcoming the resistance to OMM 
permeabilisation as a result of overexpression of anti-apoptotic BCL-2 family proteins. 
Multiple conventional anticancer treatments (e.g ionising radiation) are exerting their 
anticancer effects by stimulating excessive ROS production that is a key factor in 
facilitating the induction of MPT. Anticancer drug-induced MPT may result from 
oxidative modification of the components of the MPT pore. For instance, due to its 
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mechanism of action as described above, arsenic trioxide was found to cause ROS-
mediated modification to thiol group in ANT thus resulting in cytochrome c release 
through MPT induction [99]. 
VDAC is another component of MPT. The interaction of VDAC with hexokinase II, a 
glycolytic enzyme usually over expressed in cancer cells, holds VDAC in the open state, 
which counteracts OMM permeabilisation to prevent apoptosis. Moreover, this 
interaction obstructs the binding of pro-apoptotic proteins to VDAC and subsequently 
supresses the induction of apoptosis (reviewed in Ref.  [224]). Several compounds trigger 
cell death through interacting with VDAC. For example, Avicins, a group of anti-
inflammatory-molecules with pro-apoptotic effects, target and close VDAC. Closure of 
VDAC leads to permeabilisation of the OMM and release of cytochrome c [225]. 
 
1.4.5 Targeting mutated mtDNA 
Several compounds that target the mitochondrial genome or the enzymes related to its 
replication process have potential clinical applications. For example, cisplatin, one of the 
most commonly used chemotherapeutic agents, is found to preferentially bind to the 
mitochondrial genome more than to nuclear DNA, which results in the formation of 
cisplatin–mtDNA adducts and subsequently inhibits OXPHOS and decreases ATP 
generation [226]. Ditercalinium, a bis-intercalating agent that accumulates specifically in 
mitochondria, can cause depletion of the mitochondrial genome and inhibit its replication. 
This agent exhibits in vivo anticancer effect in animal models, and several studies have 
shown a complete elimination of mtDNA upon treatment with ditercalinium [227]. 
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1.5 Cisplatin 
Cisplatin [cisplatinum or cisdiamminedichloroplatinum (II)] (CDDP; Figure 1.31) is one 
of the most commonly used chemotherapeutic agents to treat various cancers in both 
adults and children, including ovarian, cervical, testicular, bladder, head and neck, lung 
and colorectal cancers, either as a solo therapy or in combination with other anticancer 
drugs such as doxorubicin and paclitaxel  [228,229]. Cisplatin was approved by FDA in 
1978 for the treatment of bladder and testicular cancers. 
 
Figure 1.31. Chemical structure of cisplatin. Cisplatin loses chloride moieties in an aqueous medium and 
enters the cell. Once inside the cell, the positively charged platinum (Pt) reacts with DNA and forms cross-
links and adducts. 
CDDP can enter cells through passive diffusion, and recent studies have suggested an 
active uptake of CDDP facilitated by the copper transport proteins (CTR1 and CTR2) as 
another major mechanism for cisplatin uptake (reviewed in Ref. [230]). 
Previous studies have shown that once inside the cells, cisplatin is a highly reactive 
molecule which forms various types of adducts by binding to DNA, RNA and sulfudryl 
groups of proteins, and the cytotoxic effect of cisplatin is mainly due to the lesions formed 
within the nuclear DNA [231,232]. The platinum atom of cisplatin forms hydrogen and 
covalent bonds with purine bases producing intrastrand and interstrand crosslinks [233]. 
These CDDP-nDNA adducts interfere with DNA transcription and/or replication and 
subsequently trigger apoptosis [234–237].  
However, more recent studies from the last decade have challenged the previous 
observations by stating that very low percentage of cisplatin interacts with the nuclear 
genome. Those studies have found that the largest amount of cisplatin accumulates inside 
mitochondria and interacts with mitochondrial DNA and proteins causing significant 
changes in mitochondrial structure and metabolic function. This leads to significant 
modifications in metabolites levels associated with the TCA cycle and glycolysis pathway 
[238,239].  
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Recent reports evinced that cisplatin-induced apoptosis could be inhibited by compounds 
that interfere with ROS generation (Figure 1.32). These observations elucidate that the 
killing effect is correlated to activation of oxidative stress pathways [240].  
 
Figure 1.32. Model for major components of cisplatin-induced cytotoxicity. Cisplatin causes direct damage 
to mtDNA leading to reduction of mitochondrial protein synthesis, impairment of electron transport chain 
function, hence increasing intracellular ROS levels. ROS ultimately promote cell death and therefore 
significantly enhance the cytotoxic effect exerted by cisplatin-induced nDNA damage. Mitochondrial 
dysfunction, increased mROS scavenging and glycolytic metabolism can reduce cellular sensitivity to the 
mROS-mediated component of cisplatin toxicity. Cells can also become more resistant to cisplatin through 
increased DNA repair capacity [209].  
Despite its effectiveness, cisplatin is non cancer specific and the clinical use of cisplatin 
is limited because of its severe irreversible side effects including neurotoxicity, 
ototoxicity and nephrotoxicity which has been reported as the main limitation of cisplatin  
[241–243]. In addition, many cancer patients exhibit an intrinsic resistance to cisplatin or 
develop resistance during the treatment course resulting in therapy failure (reviewed in 
Ref. [244]). More specifically, colorectal and prostate cancers are intrinsically resistant 
to cisplatin whereas acquired resistance is commonly observed in ovarian cancer patients 
[245–247].  
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Researches [248–251] have proposed reasons for cisplatin resistance such as decreased 
drug uptake, increased drug efflux, elevated detoxification system achieved by high levels 
of scavengers, enhanced tolerance to DNA damage and highly efficient DNA repair 
mechanisms. These mechanisms are specific to individual cancer cases where each single 
cancer cell may possess one or more or even the whole resistance mechanisms.  
In addition, a number of studies have highlighted the potential involvement of the 
mitochondrial genome in cisplatin resistance. Qian et al. [252] showed that the Rho0 cells 
(i.e. cells depleted of mtDNA) generated from a normal intestinal epithelial cell line, IEC-
6, demonstrated a significantly increased resistance to cisplatin compared to their parental 
counterparts. Similar results were observed by Park and co-authors in hepatocarcinoma 
cells [253]. This suggests that the mitochondrial genome is a target of cisplatin and 
mitochondria are pivotal in the apoptotic process. On the other hand, several studies have 
indicated that mtDNA copy number reduction, unlike complete mtDNA depletion, may 
contribute to enhanced cisplatin sensitivity. Mei et al. [174] showed that decreasing 
mtDNA copy number sensitised tumour cells to cisplatin. In their study, they observed 
that reducing mtDNAcn by treatment with ethidium bromide or transfection with shRNA-
TFAM significantly elevated ROS levels and subsequently enhanced tumour cells’ 
sensitivity to cisplatin. Therefore they proposed that altering mDNAcn could be a new 
approach to improved cancer treatment [26]. 
According to the aforementioned results, the mitochondrial genome appears to have a 
significant impact on drug efficacy in terms of cisplatin. Therefore, mtDNA could be a 
promising target for treating otherwise cisplatin-resistant cancers, and selective delivery 
of cisplatin to cancer cells can further enhance the efficacy.  
In a study conducted by Marrache et al., an engineered hydrophobic cisplatin prodrug, 
Platin-M, was efficiently delivered inside the mitochondria of neuroblastoma cells, 
facilitated by a positively charged mitochondria-targeting nanoparticle. The authors 
observed a much greater activity level of Platin-M compared to unmodified cisplatin (17 
times more active) [254]. 
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1.6 Delocalised lipophilic cations 
Traditional chemotherapeutic drugs have achieved limited success in cancer treatment 
due to their marked side effects as a result of their lacking specificity for cells of 
tumorigenic origin. Therefore, developing new strategies to provide selective cancer cell 
killing which depends on novel cellular targets sufficiently different between cancer and 
normal cells is crucial [255]. Delocalised lipophilic cations (DLCs) comprise a potential 
new class of anticancer agents that accumulate in mitochondria, driven by the negative 
electric potential across the mitochondrial membrane. It has been reported that DLCs are 
selectively more toxic to cancer cells than to normal ones [255,256]. 
 
1.6.1 Accumulation of delocalised lipophilic cations in mitochondria 
Translocation of protons across the inner mitochondrial membrane from the matrix to the 
intermembrane space by the mitochondrial proton pumps (complexes I, III and IV) during 
the oxidative phosphorylation results in the generation of mitochondrial transmembrane 
potential (ΔΨm). In response to the negative inside transmembrane potential, lipophilic 
cations possessing a delocalised positive charge can penetrate the lipid membranes and 
accumulate in the mitochondrial matrix. It has been reported that ΔΨm is approximately 
60 mV higher in carcinoma cells than that of normal epithelial cells [257]. According to 
the Nernst equation (ΔΨ (mV) = 61.5 log10{[cation]in/[cation]out}), a 61.5 mV difference 
in mitochondrial transmembrane potential between normal and cancer cells results in a          
ten-fold increase in DLC accumulation in carcinoma mitochondria (reviewed in Ref. 
[258]), making the selective accumulation of DLCs in the mitochondria of cancer cells 
an attractive approach to cancer-specific therapy. The difference in ΔΨm between 
carcinoma and normal epithelial cells may be attributed to differences in the structure and 
function of the mitochondrial components that serve to create and maintain the electrical 
gradient such as mitochondrial complexes, electron carriers, ATP syntheses and 
membrane lipid structure (reviewed in Ref. [255]). 
 
1.6.2 Selective mitochondrial toxicity of delocalised lipophilic cations 
All DLCs share a common mechanism for mitochondrial accumulation due to their 
lipophilic nature and response to the negative inside transmembrane potential. However, 
their mechanisms of toxicity to mitochondria at high concentrations are very different. 
For example, rhodamine 123 (Rh123) inhibits F0F1-ATPase resulting in compromised 
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mitochondrial bioenergetic function [259]. In contrast, dequalinium chloride (DQA) 
damages mtDNA and inhibits NADH ubiquinone reductase activity in complex I 
resulting in disruption in mitochondrial respiration [260]. Another DCL, rhodacyanine 
(MKT-077), causes a general disturbance of mitochondrial membrane leading to 
nonspecific inhibition of mitochondrial respiratory enzymes [261]. In addition, MKT-077 
was also shown to have a degradative effect on mtDNA [262]. 
 
1.6.3 Delocalised lipophilic cations as chemotherapeutic agents 
The selective accumulation of DLCs in cancer cells due to the increased ΔΨm and their 
mitochondrial toxicity suggest a rationale for utilising DLCs to achieve cancer-specific 
therapy. Different DLCs have already demonstrated various degrees of cancer cell killing 
in vitro and/or in vivo [255]. Rh123 was the first DLC to show anticancer activity. In a 
study published in 1982 by Bernal et al., Rh123 noticeably supressed the clonal growth 
of carcinoma cells in vitro [263]. In a follow-on study conducted by the same research 
group, Rh123 was also found to prolong the survival of mice implanted with the MB49 
cells (mouse bladder cancer) [264]. DQA showed a 100-fold greater level of clonal 
growth suppression of carcinoma cells in vitro compared to control epithelial cells [265]. 
The same study also demonstrated DQA’s anticancer efficacy in nude mice implanted 
with human colon adenocarcinoma cells [265]. Several studies showed that MKT-077 
significantly inhibited growth in various human cancer cell lines in vitro [266], and it had 
marked anticancer efficacy in nude mice implanted with human melanoma (LOX) and 
prostate carcinoma (DU-145) cells [255]. MKT-077 was the first DLC to be approved for 
clinical trial by FDA for the treatment of cancer. However, the trials were stopped in 
phase II since the efficacy in cancer cell killing was not observed at the approved dose 
and drug regimen [255]. Recently, D112, a photosensitiser developed by Eastman Kodak 
Company, was shown to induce intrinsic apoptosis. D112 was found to bind to mtDNA 
and inhibit electron flow through ETC resulting in ROS production, mtDNA damage, 
activation of pro-apoptotic proteins and eventually apoptosis [267]. 
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1.6.4 Dequalinium chloride 
Dequalinium is a quaternary ammonium cation that contains two quaternary quinolinium 
units linked by an N-decylene chain (Figure 1.33). It is most commonly available as a 
dichloride salt and used as an active ingredient in antibiotics for treating vaginal bacterial 
infections. Dequalinium chloride (DQA) has been reported to demonstrate potent 
anticancer activity in vitro and in vivo in different malignancies [268]. Several studies 
have suggested that the cytotoxicity mechanism of DQA is related to mitochondrial 
dysfunction due to the damage to mitochondrial DNA and the inhibition of mitochondrial 
complex I [267]. It has also been reported that DQA triggers cell death in the HeLa cells 
by selective depletion of mtDNA [269]. Moreover, it has been postulated that DQA 
causes human cancer cell death by affecting the redox balance [270–272]. 
Sancho et al. [270] observed in human leukaemia cells that DQA-induced apoptosis was 
mediated via the intrinsic mitochondrial pathway triggered by mitochondrial DQA 
accumulation which subsequently led to loss of ΔΨm, cytochrome c release and ROS 
overproduction. They also showed that elevated ROS caused apoptotic cell death in the 
early phase of DQA exposure when sufficient levels of intracellular ATP were detected, 
whereas necrosis was the main cell death mechanism in the later phases when ATP 
became significantly reduced. Similar results were observed in a study conducted with 
the PC-3 cells (human prostate cancer) in which DQA induced oxidative stress and 
apoptosis, followed by necrosis secondary to apoptosis [272]. Another study by Sancho 
et al. [271] showed that DQA rendered the cell cycle arrest in G2/M phase in the NB4 
cells (human leukaemia) before the cells underwent apoptosis and necrosis. 
 
Figure 1.33. Chemical structure of Dequalinium Chloride. Dequalinium is a delocalised lipophilic cation 
that is able to enter mitochondrial membranes, and preferentially into those of cancer cells due to their more 
negative mitochondrial transmembrane potential (governed by the Nernst equation). Since DLCs are toxic 
at high concentration, the accumulation of such molecules in cancer cells leads to targeted cell death [255].  
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1.7 Need for efficient predictive biomarkers in cancer therapy 
Cancer biomarkers can be classified into three categories according to their usage: 
predictive biomarkers which can predict the response to specific therapeutic 
interventions; prognostic biomarkers which aim to give the physicians indication of 
clinical outcomes such as disease progression or cancer recurrence in the future; 
diagnostic biomarkers which are used to identify a specific disease condition (reviewed 
in Ref. [273]). 
Several predictive biomarkers for human cancers are currently in clinical use.  For 
example, overexpression of HER2, a member of the EGFR family, is predictive of a 
patient’s response to the HER2 monoclonal antibodies such as pertuzumab and 
trastuzumab in breast cancer therapy. Phase III trials have confirmed that breast cancer 
patients with HER2 overexpression show improved disease-free and overall survival rates 
when anti-HER2 therapy is administrated [274,275]. Overexpression of HER2 is also 
predictive of response to trastuzumab in patients with advanced gastric or gastro-
oesophageal junction cancer [276]. In terms of the anti-EGFR therapy for treating 
colorectal cancer, the mutation status of KRAS is a predictive biomarker of patients’ 
response, because KRAS-activating mutations are associated with resistance to EGFR 
inhibitors such as cetuximab [277,278]. In breast cancer, overexpression of oestrogen 
receptor (ER) is tested in order to predict response to anti-endocrine therapies such as 
tamoxifen [279]. Other major predictive biomarkers as well as those described above are 
listed in Table 1.1. 
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Table 1.1. Predictive biomarkers in clinical use. HER2: Human epidermal growth factor receptor 2; ER: 
Oestrogen receptor; GIST: Gastrointestinal stromal tumour; CML: Chronic myeloid leukaemia; NSCLC: 
Non-small cell lung cancer; EGFR: Epidermal growth factor receptor.  
 
Currently, numerous predictive biomarkers based on single genes are in phase II or III 
trials (Table 1.2). In light of the increasing clinical significance of efficient predictive 
biomarkers, identifying novel biomarkers to help develop enhanced therapeutic strategies 
is becoming a trend.  
 
 
 
  
Organ Cancer Biomarker 
Associated Target and 
Drug 
Ref. 
Breast 
Breast Cancer 
  
HER2: Overexpression 
 HER2: Trastuzumab, 
Pertuzumab, Ado- 
trastuzumab emtansine 
[274,275]  
ER: Overexpression 
ER: Endocrine therapy 
(Tamoxifen, Aromatase 
inhibitors) 
[280]  
Gastrointestinal 
Colorectal 
Cancer 
KRAS: Mutations 
EGFR: Cetuximab, 
Panitumumab 
 [277,281] 
GIST KIT: Mutation BCR-ABL: Imatinib [282]  
Esophago-gastric 
adenocarcinoma 
HER2: Overexpression HER2: Trastuzumab  [276] 
Haematological CML BCR-ABL 
BCR-ABL: Imatinib, 
Dasatinib, Nilotinib 
[283]  
Lung 
NSCLC EGFR (HER1): Mutations 
EGFR: Erlotinib, 
Gefitinib, Afatinib 
[284]  
Lung 
adenocarcinoma 
EGFR (HER1): Mutations 
EGFR: Erlotinib, 
Gefitinib, Afatinib, 
Cetuximab 
[285]  
HER2: Overexpression 
HER2: Neratinib, 
Lapatinib, Trastuzumab 
 [285] 
KRAS: Mutations 
KRAS: Erlotinib, 
Tivantinib, Everolimus, 
Ridaforalimus, 
Selumetinib 
 [285] 
Skin Melanoma BRAF: Mutations 
BRAF: Vemurafenib, 
Dabrafenib 
 [286] 
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Table 1.2. Predictive biomarkers currently under clinical evaluation with their companion therapeutic 
agents and registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home).  
Organ Cancer Biomarker 
Associated 
Drug 
Phase 
Clinicaltrials.gov 
identifier  
Breast Breast cancer 
BRCA1/2 Olaparib III NCT02000622 
HER2 
(negative in 
tumour but 
positive 
in circulating 
tumour cells) 
Lapatinib III  NCT01619111 
Gastrointestinal 
Colorectal RAS 
FOLFOXIRI,
Bevacizumab 
II  NCT02350530 
Esophagogastric HER2 
Afatinib, 
Trastuzumab 
II NCT01522768 
Head and Neck 
Squamous cell 
carcinoma 
HER and 
KRAS 
Poziotinib II  NCT02216916 
Lung NSCLC 
ROS1 Crizotinib II NCT02183870 
BRAF 
Dabrafenib, 
Trametinib 
II NCT01336634  
Skin Melanoma BRAF 
Trametinib, 
Binimetinib 
II  NCT02196181 
 
Mitochondria are well known to play a fundamental role in various physiological aspects 
of cells. Besides being the major source of ATP generation, they are also involved in 
numerous metabolic reactions and play a pivotal role in apoptosis. Therefore, it is not 
surprising that mitochondrial dysfunction has been associated with a wide range of human 
diseases including cancer. Nevertheless, specific mutations within the mitochondrial 
genome might provide significant and important biomarkers in the detection of cancer, 
cancer classification and prediction of cancer recurrence. MtDNA mutations could also 
be used as efficient markers in personalised readjustment of chemotherapy, since the 
currently accepted markers for clinical use (e.g. nodal status, size of tumour and 
histological grade) are unable to adequately indicate patients’ outcome and/or assess their 
risk levels of recurrence. Therefore, correlations between mitochondrial genetic 
abnormalities and clinicopathological classification of the tumours should be further 
established (reviewed in Ref. [66]). 
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Despite its strong side effects and high incidence of resistance, conventional 
chemotherapy is still widely used in clinical practice. Therefore, developing novel 
pharmacological approaches and targets in the treatment of cancer becomes a high 
priority in chemotherapy to overcome its existing issues.  
Currently, increased information obtained at the level of mitochondria aims to broaden 
the knowledge of cisplatin resistance and optimistically lead to the identification of 
predicative biomarkers that might be utilised as an early indicator of cisplatin therapy 
response. Once the specific mechanisms associated with cisplatin activity have been 
elucidated, new regimen could be developed for a synergic combination with cisplatin 
(reviewed in Ref. [17]). 
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1.8 Project significance, hypotheses, aims and objectives 
One of the biggest challenges in treating cancer is to avoid drug resistance and minimise 
the side effects of chemotherapy by delivering the minimal dosage of drugs required to 
achieve an adequate cancer cell death. Although the mitochondrial genome mutation 
spectra are highly variable between different cancer types, impact of mtDNA mutations 
on the diverse mitochondrial activities and cellular behaviours including response to 
anticancer treatment is not well investigated. The results of this PhD project provide a 
better understanding as to how we can utilise intracellular ROS and mitochondrial genetic 
abnormalities as novel biomarkers to predict drug efficacy. 
Hypothesis 
ROS-mediating agents that target mitochondria can enhance therapeutic efficacy and 
intracellular ROS level as well as certain mitochondrial genetic abnormalities (mtDNA 
mutation and mtDNAcn change) are effective biomarkers to predict drug sensitivity in 
cancer cells. 
Aims  
1. Investigate the impact of intracellular ROS on drug response and the underlying 
molecular mechanisms. 
2. Investigate the link between mitochondrial genetic abnormalities and intracellular 
ROS level. 
3. Evaluate ROS-mediating agents as potential synergistic anti-cancer drugs in 
combination with conventional chemotherapy. 
Objectives 
1. Measure the baseline intracellular ROS and mitochondrial superoxide levels in a 
number of cancer and non-cancerous cell lines 
2. Measure the cytotoxicity effect of the conventional chemotherapy (cisplatin, CDDP) 
and mitochondria-targeting compound (dequalinium chloride hydrate, DQA) on the 
cell lines 
3. Measure the relative mitochondrial DNA (mtDNA) copy number in the cell lines 
4. Identify mutations in the whole mtDNA genome in the cell lines  
5. Predict functional mutations within the mtDNA-encoded OXPHOS subunits by 3D 
protein modelling 
6. Evaluate mitochondrial genetic alternations as biomarkers to predict drug response
 
73 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
Chapter 2 
 
74 
 
2.1 Cell culture and drug treatment 
2.1.1 Human cell lines 
The human cell lines used in this study were obtained from the departmental cell bank at 
the University of Portsmouth; five cancer cell lines including Ishikawa/endometrium, 
MDA-MB-231/breast, Caco-2/colon, PC-3/prostate, Caki-2/kidney and two non-
cancerous cell lines including PNT-2/prostate and HEK-293/kidney were enrolled in the 
study. All cell lines were originally purchased from the European Collection of 
Authenticated Cell Cultures (Ishikawa, MDA-MB-231, Caco-2, PNT-2 and Caki-2) or 
the American Type Culture Collection (PC-3 and HEK-293). All cell lines were 
authenticated using PowerPlex 16 HS System (Promega, Southampton, UK) for short 
tandem repeat (STR) profiling and screened for mycoplasma contamination using the 
PCR Mycoplasma Test Kit (PromoCell, Heidelberg, Germany), over the period of the 
investigation. 
 
2.1.2 Maintenance of cell lines 
The Caco-2, MDA-MB-231 and HEK-293 cells were grown in DMEM (Gibco, Fisher 
Scientific, Loughborough, UK) supplemented with 10% fetal bovine serum (FBS, Merck, 
Dorset, UK). The Ishikawa cells were grown in DMEM supplemented with 5% FBS. 
Caki-2 cells were grown in McCoy's 5A (Gibco) supplemented with 10% fetal bovine 
serum. The PC-3 and PNT-2 cells were grown in a mixture (1:1) of RPMI 1640 and Ham's 
F-12 (Gibco) supplemented with 10% FBS. Culture media are summarised in Table 2.1. 
All media contained 1% Amphotericin B/Penicillin/Streptomycin (Fisher Scientific). 
Table 2.1. Cell lines and their culture media employed in the study.  
Cell line Origin Culture media 
Ishikawa Endometrium DMEM + FBS 5% 
MDA-MB-231 Breast DMEM + FBS 10% 
Caco-2 Colon DMEM + FBS 10% 
Caki-2 Kidney McCoy's 5A + FBS 10% 
HEK-293 Kidney DMEM + FBS 10% 
PC-3 Prostate RPMI 45% + HAM'S F12 45% + FBS 10% 
PNT-2 Prostate RPMI 45% + HAM'S F12 45% + FBS 10% 
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All cells were grown in humidified incubator at 37°C under 5% CO2, and culture medium 
was changed twice per week. At 90% confluence, the culture medium was removed and 
the cells were washed with 5 mL of phosphate buffered saline (PBS, Gibco). The cells 
were detached following the incubation with 3 mL of the TrypLE Express solution 
(Gibco) for 5 min at 37°C. The trypsin enzymatic reaction was terminated by adding 7 
mL of complete medium to the cell culture flask, then the cell solution was collected in a 
centrifuge tube and centrifuged at 1,150 rpm for 5 min. The supernatant was decanted 
and the cell pellet was re-suspended in 8 mL of fresh complete medium to be used for all 
the downstream procedures. 
 
2.1.3 Cell counting 
Cells were counted using an automated cell counting device, Moxi™ Z (ORFLO 
Technologies, Idaho, USA). For each counting, 75 µL of cell suspension was loaded into 
the designated cassette and the cell concentration (cell number/mL) was automatically 
calculated and displayed on the screen of the device. 
 
2.1.4 Population doubling time 
Population doubling time (PDT) was measured for all cell lines by plating an equal 
number of cells (50,000 cells/well) and then counting them using the automated cell 
counter at 24, 48 and 72 hours post seeding. The values of 3 separate experiments were 
plotted and the average population doubling time for each cell line was calculated using 
the Graphpad Prism version 8.0 software. 
 
2.1.5 Drug treatment 
Stock solutions of cisplatin (CDDP, Merck) and dequalinium chloride hydrate (DQA, 
Merck) were prepared at 100 mM in DMSO and 2 mM in distilled water respectively. 
Both drugs were added to the cells (separately or jointly) at various working 
concentrations, and the cells were incubated for specific durations according to the nature 
of the experiments (described in the relevant subsections below). The IC50s (IC50: the 
half maximal inhibitory concentration) of CDDP and DQA were determined following 
the drug treatment for 24 hours. Concentrations of CDDP and DQA used to determine 
the IC50 of each drug and the new IC50 of CDDP in combination with DQA at half of its 
IC50, are summarised in Table 2.2. 
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After the CDDP and DQA IC50s were determined, cells were treated with either CDDP 
IC50, DQA IC50 or combined treatment of CDDP and DQA at half of their IC50 
concentrations for different incubation times up to 24 hours in all subsequent 
experiments. 
Table 2.2. Concentrations of CDDP and DQA used to determine IC50s.  
CDDP (µM) DQA (µM) CDDP (µM) + ½ DQA IC50 (µM)* 
5 1 5 + ½ DQA IC50 
10 5 10 + ½ DQA IC50 
50 10 50 + ½ DQA IC50 
100 25 100 + ½ DQA IC50 
250 50 250 + ½ DQA IC50 
500 75 500 + ½ DQA IC50 
750 100 750 + ½ DQA IC50 
1000 200 1000 + ½ DQA IC50 
 * The ½ DQA IC50 was 89.6 μM for Caco-2 and 7.2 μM for Ishikawa respectively.  
N-Acetyl-L-cysteine (NAC, Merck), a powerful antioxidant, was dissolved in distilled 
water at the concentration of 100 mM shortly before each experiment and the pH was 
adjusted to 7.4 using sodium hydroxide before diluting the solution to the working 
concentration (10 mM) with complete cell culture medium. Cells were pre-incubated with 
NAC (10 mM) for 1 hour before the CDDP and DQA treatments were applied. All 
experiments related to NAC followed the same procedure as described in the sections 
below. 
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2.2 Functional assays 
2.2.1 Cell viability assay (MTS assay) 
Cell viability was measured colorimetrically using the [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) solution 
(CellTiter 96 Aqueous) (Promega) in the presence of phenazine methosulfate (PMS, 
Merck). The MTS assay assesses the metabolic activity by detecting the mitochondrial 
dehydrogenase activity (Figure 2.1). Viable cells are able to reduce tetrazolium salt to a 
blue formazan whereas dead cells are unable to. The generated signal is proportional to 
the number of viable cells (reviewed in Ref. [287]). 
 
Figure 2.1. The MTS assay is based on the conversion of yellow MTS tetrazolium compound into blue 
formazan by living cells, which determines mitochondrial activity and reflects the number of viable cells 
present [288]. 
For the MTS assay, 90 µL of cell suspension containing 10,000 cells was added in each 
well of the 96-well plate (VWR, Pennsylvania, USA), and the plate was incubated for 24 
hours at 37°C with 5% CO2 in a fully humid environment. Cells were treated with 10 µL 
of the 10 × drug (working solution) for the desired amount of time (24 hours to determine 
the IC50 of the drugs and 1, 3, 5 and 24 hours for time course experiments). At the end 
of the experiment, the medium was replaced with 100 µL of fresh medium containing 
MTS and PMS (final concentrations: 0.4 μM and 0.3 nM respectively), and the 96-well 
plate was incubated for 90-180 minutes at 37°C with 5% CO2 according to the cell type. 
Absorbance was measured using the microplate reader (Multiskan® GO, ThermoFisher 
Scientific, Loughborough, UK) at 490 nm. Viability changes upon treatments were 
determined as percentage of untreated wells after background subtraction. 
IC50 was calculated as the concentration of the drug that caused a 50% loss of metabolic 
activity using the Graphpad Prism version 8.0 software. 
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2.2.1.1 Combination Index for synergism assessment 
Analysis of drug synergy was performed by calculating the Combination Index (CI) to 
assess how drug combination might have influenced the therapeutic efficacy (CI > 1 – 
Antagonistic; CI = 1 – Additive; CI < 1 – Synergistic) at different combinations according 
to the median-effect principle of the Chou and Talalay method, using the CompuSyn 
software 1.4 [289]. 
 
2.2.2 Cell viability/cytotoxicity assay (ApoTox-Glo™ Triplex) 
The ApoTox-Glo™ Triplex Assay Kit (Promega) was used to assess the viability and 
cytotoxicity events by measuring two protease activities; one is a marker for cell viability 
and the other is a marker for cytotoxicity. The activity of live-cell protease is restricted to 
the intact viable cells and measured using a cell permeant fluorogenic substrate (GF-
AFC/glycylphenylalanyl-aminofluoroumarin). The substrate enters intact cells where it 
is cleaved by the activity of live-cell protease to release AFC and generates a fluorescent 
signal proportional to the number of living cells. This live-cell protease becomes inactive 
upon loss of cell membrane integrity and leakage into the surrounding culture medium. 
A second fluorogenic yet cell impermeant substrate (bis-AAF-R110/bis-alanyl-alanyl 
phenylalanyl-rhodamine 110) is used to measure the activity of dead-cell protease which 
is released from cells that have lost membrane integrity (Figure 2.2). Because bis-AAF-
R110 is not cell-permeant, subsequently no signal from this substrate is generated by 
intact, viable cells. The live- and dead-cell proteases produce different products, AFC and 
R110, which have different excitation and emission spectra, allowing them to be detected 
simultaneously [290]. 
 
Figure 2.2. The biology of the viability/cytotoxicity assay (diagram taken from the manufacturer’s 
protocol: https://www.promega.co.uk/products/cell-health-assays/apoptosis-assays/apotox_glo-triplex-
assay/?catNum=G6320#protocols).  
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According to the manufacturer’s protocol, 90 µL of cell suspension containing 10,000 
cells was added in each well of the 96-well black-wall plate (Corning, NY, USA), and the 
plate was incubated overnight. Cells were treated with 10 µL of the 10 × drug (working 
solution) for 24 hours. At the end of the experiment, the freshly prepared 
viability/cytotoxicity reagent (a mixture of GF-AFC and bis-AAF-R110 in the assay 
buffer) (20 µL) was added to each well, and the plate was shaken at 400 rpm for 30 
seconds and incubated for 60 minutes at 37°C. Fluorescence was then measured at two 
wavelength sets using the microplate reader (POLARstar Omega, BMG LABTECH Ltd., 
Ortenberg, Germany): 380 nm (excitation) / 510 nm (emission) for viability and 485 nm 
(excitation) / 520 nm (emission) for cytotoxicity. Viability and cytotoxicity changes upon 
treatments were determined as percentage of untreated wells after background 
subtraction. 
 
2.2.3 Intracellular ROS assays 
Baseline intracellular ROS levels were measured in a 96-well-plate format using the 
Cellular Reactive Oxygen Species Detection Assay Kit (Abcam, Cambridge, UK) based 
on the fluorogenic dye 2’,7’-dichlorofluorescin (DCFDA). After diffusion into the cells, 
DCFDA is deacetylated by cellular esterases to a non-fluorescent compound which is 
later oxidised by ROS into dichlorofluorescein (DCF), a highly fluorescent compound 
which can be detected by fluorescence spectroscopy [291].  
According to the manufacturer’s protocol (https://www.abcam.com/dcfda--h2dcfda-
cellular-ros-assay-kit-ab113851-protocols.html#top-500), 25,000 cells were seeded in 
each well of the 96-well black-wall plate overnight prior to the experiments. After 24 
hours, the cells were washed with 150 µL of HBSS (Gibco), then 100 µL of the staining 
buffer (20 μM of DCFDA in HBSS) was added to each well, and the plate was incubated 
for 40 minutes at 37 °C. The cells were then washed twice with 150 µL of HBSS, and 
100 μL of HBSS was added to each well following the second wash. Fluorescence was 
measured using the microplate reader (POLARstar Omega) at 485 nm (excitation) and 
535 nm (emission).  
For determining intracellular ROS levels upon drug treatments, the staining buffer was 
added for 40 min at 37 °C. The cells were then washed twice with 150 µL of HBSS and 
treated with 100 μL of phenol red-free media containing the therapeutic compound(s) of 
interest.  
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The plate was then incubated for 1, 3, 5, 7, 16, 20 and 24 hours before fluorescence was 
measured. ROS changes upon treatments were determined as percentage of untreated 
wells after background subtraction. 
The tert-Butyl hydrogen peroxide (TBHP) solution (provided in the Kit) was used as a 
positive control in each experiment. Four hours prior to the completion of the drug 
treatment, fresh TBHP (500 µM) was prepared in the phenol red-free media and added to 
the designated positive control wells to achieve the final concentration of 50 µM. 
 
2.2.4 Mitochondrial superoxide assay 
2.2.4.1 Plate reader based assay 
To measure mitochondrial superoxide, the same procedure was conducted as described 
above using a mitochondrial ROS-specific dye, MitoSOX™ (Life Technologies, Fisher 
Scientific), instead of DCFDA. MitoSOX™ permeates live cells where it selectively 
targets mitochondria. It is rapidly oxidised by superoxide but not by other reactive oxygen 
species. The cells were incubated with 5 µM of MitoSOX in HBSS for 30 minutes. 
Fluorescence was measured using the same microplate reader at 510 nm (excitation) and 
580 nm (emission). Mitochondrial superoxide changes upon treatments were determined 
as percentage of untreated wells after background subtraction. 
2.2.4.2 Fluorescence microscopy based assay 
The presence of mitochondrial superoxide was visualised with a confocal laser-scanning 
microscope (LSM710; Zeiss, Oberkochen, Germany) using a Plan Apochromatic 20 × 
DIC objective (NA0.8) (pixel size 0.42 µm). For the sample preparation, 15,000 cells 
were seeded in each well of an 8-well chamber slide (Nunc™ Lab-Tek™ II Chamber 
Slide™, ThermoFisher Scientific) overnight prior to the experiments. In the following 
day, the cells were washed with 300 µL of HBSS, then 200 µL of the staining buffer (5 
µM of MitoSOX™ in HBSS) was added to each well, and the slide was incubated for 30 
minutes at 37 °C. The cells were then washed twice with 300 µL of HBSS and incubated 
with the drug treatments for 6 hours before imaging. All images presented represent a 
single optical section. These images were acquired using sequential acquisition of the 
different channels to avoid cross-talk between fluorophores, with the pinholes adjusted to 
one airy unit. Images were processed with the software Zen2009 Light Edition and 
exported into Adobe Photoshop. Only brightness and contrast were adjusted for the whole 
frame, and no part of a frame was enhanced or modified in any way. 
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2.2.5 Mitochondria quantification by fluorescent staining 
The level of mitochondria was measured in a 96-well plate format using MitoTracker™ 
Red CMXRos (Invitrogen, ThermoFisher Scientific). MitoTracker™ is a red fluorescent 
dye that passively diffuses across the plasma membrane and accumulates in active 
mitochondria.  
According to the manufacturer’s protocol (https://www.thermofisher.com/order/catalog/ 
product/M7512#/M7512), 25,000 cells were seeded in each well of the 96-well black-
wall plate overnight prior to the experiments. In the following day, the cells were washed 
with 150 µL of HBSS, then 100 µL of the staining buffer (0.1 µM of MitoTracker™ in 
HBSS) was added to each well, and the plate was incubated for 40 minutes at 37 °C. The 
cells were then washed twice with 150 µL of HBSS, and 100 μL of HBSS was added to 
each well following the second wash. Fluorescence was measured using the microplate 
reader (POLARstar Omega) at 584 nm (excitation) and 620 nm (emission). 
 
2.2.6 Mitochondrial transmembrane potential assay 
MMP was measured by staining the cells with the JC-10 fluorescent dye (Enzo Life 
Sciences, Exeter, UK). In healthy cells, JC-10 concentrates in the mitochondrial matrix 
where it forms red fluorescent aggregates. However, in apoptotic and necrotic cells,       
JC-10 diffuses out of mitochondria where it changes to monomeric form and stains cells 
in green fluorescence. The ratio of red to green fluorescence intensity depends on the 
transmembrane potential and can reflect the maintenance of cellular health and viability. 
For example, a decrease in the red/green ratio indicates reduced transmembrane potential 
as seen in apoptotic and necrotic cells when mitochondrial membrane disintegrates.  
Based on the manufacturer’s protocol (https://www.enzolifesciences.com/ENZ-52305/jc-
10-ultra-pure/), 90 µL of the cell suspension containing 25,000 cells was added in each 
well of the 96-well black-wall plate, and the plate was incubated overnight at 37°C with 
5% CO2. In the next day, the cells were treated with 10 µL of the 10 × drug solution for 
1, 3, 5 and 24 hours. At the end of the experiment, the cells were washed with 150 µL of 
HBSS, then 100 µL of the staining buffer (20 µM of JC-10 in HBSS) was added to each 
well and the plate was incubated for 40 min at 37°C. The cells were then washed twice 
with 150 µL of HBSS and 100 µL of HBSS was added to each well following the second 
wash.  
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Red and green fluorescent signals were measured using the microplate reader 
(POLARstar Omega) at 540 nm (excitation) / 590 nm (emission) and 490 nm (excitation) 
/ 525 nm (emission) respectively. MMP was calculated as ratio of red/green, and MMP 
changes upon treatments were determined as percentage of untreated wells. 
 
2.2.7 Caspase activity assay 
Caspase-3/7 activity was measured using the Caspase-Glo® 3/7 Reagent (a mixture of the 
Caspase-Glo 3/7 lysis buffer and a luminogenic substrate) from the ApoTox-Glo™ 
Triplex Assay Kit (Promega). The Caspase-Glo® 3/7 Reagent causes cell lysis, followed 
by caspase cleavage of the substrate and generation of a luminescent signal. 
Luminescence is proportional to the amount of caspase activity present. 
According to the manufacturer’s protocol, 90 µL of cell suspension containing 10,000 
cells was added in each well of the 96-well black-wall plate, and the plate was incubated 
at 37°C overnight. The next day, the cells were treated with 10 µL of the 10 × drug 
solution for 24 hours. At the end of the experiment, the freshly prepared Caspase-Glo 
3/7® Reagent (100 µL) was added to each well, and the plate was shaked at 400 rpm for 
30 seconds and incubated for 60 minutes at room temperature. Luminescence was then 
measured using the microplate reader (POLARstar Omega). Caspase activities upon 
treatments were determined as percentage of untreated wells after background 
subtraction. 
 
2.2.8 Apoptotic or necrotic cell death evaluation 
Apoptosis was also analysed by studying the translocation of the membrane 
phosphatidylserine (PS) from the inner face of the plasma membrane to the cell surface. 
For this purpose, cells were double stained with fluorescent conjugate of Annexin V 
(Annexin V-FITC) and propidium iodide (PI) using the Annexin V-FITC Apoptosis 
Staining / Detection Kit (Abcam).  
Live cells correspond to Annexin V-FITC negative and PI negative (A-/PI-). Cells with 
intact cell membrane integrity do not uptake PI which is impermeable to such cells, and 
therefore cells stained with Annexin V-FITC only (A+/PI-) are considered to be in an early 
stage of apoptosis. In late apoptosis or necrosis secondary to apoptosis, cell membrane 
loses its integrity hence cells will be stained with both Annexin V-FITC and PI (A+/PI+). 
Cells with PI staining alone (A-/PI+) are considered necrotic. 
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According to the manufacturer’s protocol (https://www.abcam.com/annexin-v-fitc-
apoptosis-staining--detection-kit-ab14085.html), 300,000 cells were plated in each well 
of a standard 6-well cell culture plate (VWR). The plate was incubated overnight and then 
exposed to drug treatments for 24 hours. At the end of the experiment, the cells were 
washed with PBS, trypsinised, collected by centrifugation and re-suspended in 500 µL of 
the binding buffer provided in the Kit. The cells were double stained by adding 5 µL of 
Annexin V-FITC and 5 µL of propidium iodide and incubated at room temperature for 
10 minutes in the dark. The samples were then analysed by flow cytometry using BD 
FACSCalibur™ (BD Biosciences, New Jersey, USA) according to the standard procedure 
(PI: 493 nm (excitation) / 636 nm (emission), Annexin V-FITC: 488 nm (excitation) / 530 
nm (emission)), and the generated data were analysed using the FlowJo-V10 software. 
 
2.2.9 Lactate assay 
Baseline lactate concentrations were measured in a 96-well-plate format using the Lactate 
Colorimetric Assay Kit (Abcam) where lactate is oxidised by LDH to generate pyruvate 
that interacts with the water-soluble tetrazolium salts probe (WST) and produces a colour 
change. 
According to the manufacturer’s protocol (https://www.abcam.com/l-lactate-assay-kit-
colorimetric-ab65331-protocols.html#top-0), 2 × 106 cells were harvested, washed with 
cold PBS (4°C) and re-suspended in 200 µL of the lactate assay buffer. The tubes 
containing the cell suspension were vortexed on the highest setting for 15 seconds to fully 
re-suspend the cells and then centrifuged at 14,000 × g for 5 minutes at 4°C. The soluble 
supernatants were transferred into new Eppendorf tubes and kept on ice. Endogenous 
LDH was removed from the samples to avoid the degradation of lactate by using the 
Deproteinizing Sample Preparation Kit – TCA (Abcam). Basically, 15 µL of ice-cold 
trichloroacetic acid (TCA) was added to the sample and left on ice for 15 minutes. The 
tubes were later vortexed at 12,000 × g for 5 minutes at 4°C and the soluble supernatants 
were transferred into new Eppendorf tubes and kept on ice. Then 10 µL of ice-cold 
Neutralization Solution (provided in the Kit) was added to neutralise excess 
trichloroacetic acid in the samples, and the tubes were left on ice for 5 min. 
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To determine the lactate concentrations of the samples, a standard curve was prepared by 
measuring a series of diluted Lactate Standard solutions at 20, 40, 60, 80 and 100 µM. 
The test samples were diluted 1:1 in the provided assay buffer, and 50 µL of each test 
sample as well as each of the standard solutions was loaded in the same 96-well plate (all 
samples were loaded in duplicate). Then 50 µL of the reaction mix (46:2:2, Assay buffer: 
lactate substrate: lactate enzyme) was added to the standard and the test samples. The 
plate was incubated at room temperature for 30 minutes before absorbance was measured 
using the microplate reader (Multiskan® GO) at 450 nm. The absorbance readings of the 
Lactate Standards were utilised to generate a standard curve to determine the lactate 
concentration of each test sample. 
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2.3 Molecular biology techniques 
2.3.1 DNA extraction 
Total DNA was isolated from 300,000 cells (either untreated or treated for 24 hours) using 
the QIAmp DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s 
protocol (https://www.qiagen.com/gb/resources/resourcedetail?id=566f1cb1-4ffe-4225-
a6de-6bd3261dc920&lang=en) . In the last step, DNA was eluted with 100 μL of the AE 
buffer. The purity and concentration of isolated DNA were assessed using an automated 
spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE, USA). Based 
on the spectrophotometry results, DNA samples were diluted accordingly in order to 
achieve an equal concentration of all the DNA samples used in the SYBR Green qPCR 
experiments (i.e. 14 ng/μL; Table 2.3). 
 
2.3.2 Measurement of mtDNA copy number by SYBR Green real-time PCR 
Relative quantification of mtDNAcn was performed using the QuantiTect SYBR Green 
PCR Kit (QIAGEN), and the qPCR was run on the LightCycler® 96 System (Roche, 
Basel, Switzerland). According to the manufacturer’s protocol (https://www.qiagen.com 
/dk/shop/new-products/quantitect-sybr-green-pcr-kits/), two 70-µL reaction mixes were 
prepared for each test sample, one containing D-loop primers and the other β-actin 
primers (Table 2.3), then 20 µL of each reaction mix was added to the 96-well qPCR plate 
in triplicate for each test sample. 
Table 2.3. Reaction setup for SYBR Green real-time PCR.  
Component Volume (μL) Volume (μL) 
Nuclease-free water 19.4 19.4 
2 × QuantiTect SYBR Green PCR 
Master Mix 
35 35 
Primers set 1 (D-loop primers, 5 μM) 5.6 - 
Primers set 2 (β-actin primers, 5 μM) - 5.6 
DNA (14 ng/μL) 10 10 
Total volume per reaction 70 μL 70 μL 
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The amplification procedure entailed 95°C for 10 seconds, followed by 30 cycles of 95°C 
for 30 seconds, 58°C for 30 seconds and 72°C for 90 seconds. Two sets of primers were 
used based on a previous study [292], one to amplify the D-loop region (1232 bp) within 
the mitochondrial genome and the other to amplify the housekeeping gene, β-actin (318 
bp) (Table 2.4). 
Table 2.4. SYBR Green qPCR primers to amplify the D-loop and β-actin fragments [292].  
Primers set 1 D-loop (forward) 5′ CTCCACCATTAGCACCCAAAG 3′ 
D-loop (reverse) 5′ GTGATGTGAGCCCGTCTAAAC 3′ 
Primers set 2 β-actin (forward) 5′ ATCATGTTTGAGACCTTCAACA 3′ 
β-actin (reverse) 5′ CATCTCTTGCTCGAAGTCCA 3′ 
The relative quantity of mtDNA content in each sample was calculated by normalising 
the copy number of mtDNA against that of β-actin. The data from qPCR were analysed 
based on the 2-ΔΔCT method (CT: cycle threshold).  ΔCT was first calculated as the average 
D-loop CT value deducted by the average β-actin CT value of the same sample. The 
relative mtDNAcn fold change in the drug-treated samples was calculated by normalising 
against the untreated samples in which ΔΔCT was the ΔCT value of the treated sample 
deducted by the ΔCT value of the untreated sample. Three independent experiments were 
carried out and all the samples were run in triplicates in each experiment. 
 
2.3.3 RNA extraction 
Total RNA was isolated from 300,000 cells (either untreated or treated for 24 hours) using 
the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s protocol 
(https://www.qiagen.com/gb/resources/resourcedetail?id=0e32fbb1-c307-4603-ac81-
a5e98490ed23&lang=en). In the last step, RNA was eluted with 40 μL of RNA–free 
sterile water. The purity and concentration of isolated RNA were assessed using an 
automated spectrophotometer (ND-1000; NanoDrop Technologies). Based on the 
spectrophotometry results, RNA samples were diluted accordingly in order to provide an 
equal concentration of all the RNA samples in the complementary DNA synthesis 
experiments (i.e. 0.1 μg/μL; Table 2.5). 
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2.3.4 Synthesis of complementary DNA 
Complementary DNA (cDNA) was synthesised using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, California, USA). Based on the manufacturer’s 
protocol (https://www.thermofisher.com/order/catalog/product/4368813#/4368813), a 
20-µL reaction mix was prepared for each RNA sample (Table 2.5).  
Table 2.5. Reaction setup for cDNA synthesis.  
Component Volume (μL) 
10 × RT Buffer 2 
25 × dNTP Mix (100 mM) 0.8 
10 × RT Random Primers 2 
MultiScribe™ Reverse Transcriptase 1 
Nuclease-free water 4.2 
RNA sample (0.1 μg/μL) 10 
Total volume per reaction 20 μL 
The cDNA synthesis reaction was carried out on the T100™ Thermal Cycler (Bio-Rad, 
Watford, UK). Conditions for the thermal cycling were: 25°C for 10 min, 37°C for 120 
min, 85°C for 5 min then 4°C infinitely. Synthesised cDNA samples were used directly 
in TaqMan qPCR assays or stored at -20°C for later use. 
 
2.3.5 TaqMan real-time quantitative polymerase chain reaction  
TaqMan real-time qPCR (RT-qPCR) was performed using the FastStart Essential DNA 
Probes Master reagents (Roche) in 96-well plates, and the assays were run on the 
LightCycler® 96 System (Roche). The pre-designed primer/probe mixes for all the target 
genes (i.e. genes of interest) were purchased from Integrated DNA Technologies (IDT, 
Leuven, Belgium), whereas the primer/probe mix for the endogenous control gene (i.e. 
housekeeping gene) was obtained from Life Technologies (Table 2.6). 
The primer/probe mixes of the target and housekeeping genes were labelled with FAM 
and VIC fluorophores respectively, which enabled a duplex reaction for simultaneous 
determination of the expression levels of both genes.  
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 Table 2.6. The pre-designed primer/probe mixes for all the target genes.  
Gene Ref Sequence Source 
SOD1 NM_000454(1) IDT 
SOD2 NM_001024466(3) IDT 
CAT NM_001752(1) IDT 
GPX1 NM_000581(2) IDT 
Nrf2 NM_006164(1) IDT 
NOX1 NM_001271815(3) IDT 
NOX2 NM_000397(1) IDT 
NOX3 NM_015718(1) IDT 
NOX4 NM_016931 IDT 
NOX5 NM_001184779(5) IDT 
DUOX1 NM_175940(1) IDT 
OPA1 NM_130835(2) IDT 
PINK1 NM_032409(1) IDT 
BCL-XL NM_001191(2) IDT 
BAX NM_138764(1) IDT 
APAF1 NM_181868(5) IDT 
Cyt C NM_018947(1) IDT 
MDR1 NM_000927(1) IDT 
OGG1 NM_002542(8) IDT 
RRM2B NM_015713(1) IDT 
ENDOG NM_004435(1) IDT 
PDK1 NM_002610(1) IDT 
GAPDH NM_001686.3 Life Technologies 
According to the manufacturer’s protocol (https://lifescience.roche.com/en_gb/products 
/faststart-essential-dna-probes-master.html#documents), a 20-µL reaction mix was 
prepared for each TaqMan qPCR reaction (Table 2.7), then 10 µL of the reaction mix was 
added to the 96-well qPCR plate in duplicate for each test sample. 
Table 2.7. Reaction setup for TaqMan qPCR.  
Component Volume (μL) 
Nuclease-free water 3 
10 × Primer-probe mix (gene of interest) 1 
10 × Primer-probe mix (housekeeping gene) 1 
2 × Master Mix 10 
cDNA sample 5 
Total per reaction 20 μL 
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The amplification procedure entailed a pre-incubation step at 95°C for 10 minutes and 45 
cycles of 95 °C for 10 seconds followed by 60 °C for 30 seconds. For each TaqMan qPCR 
reaction, GAPDH was utilised as the endogenous control gene. Three independent 
experiments were carried out and all the samples were run in duplicates in each 
experiment. The TaqMan qPCR data were analysed based on the same 2-ΔΔCT principle as 
described above in Section 2.3.2. 
 
2.3.6 Western blotting 
2.3.6.1 Cell lysis and protein extraction 
Based on the standard protocol, 300,000 cells (either untreated or treated for 24 hours) 
were washed twice with ice-cold PBS and lysed in ice-cold RIPA lysis buffer (pH 8.0) 
(150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate/SDS and 50 mM Tris) supplemented with the Protease Inhibitor Cocktail solution 
(Fisher scientific). The cells were incubated at 4°C on a shaker for 60 minutes then the 
cell lysates were collected and transferred into labelled tubes. The tubes were vortexed 
on the highest setting for 3 minutes and incubated on ice for 40 minutes. Another round 
of vortex was carried out and the lysates were centrifuged at 14,000 × g for 10 minutes at 
4°C. The soluble supernatants which contained the total cellular proteins were transferred 
into new Eppendorf tubes and stored at -20°C until required. 
To study the release of cytochrome c from mitochondria, cytoplasmic protein extract was 
prepared using the NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Fisher 
Scientific). According to the manufacturer’s protocols (https://www.thermofisher.com 
/order/catalog/product/78833#/78833), 300,000 cells (either untreated or treated for 24 
hours) were harvested and transferred to labelled tubes, and the pellets were washed twice 
with ice-cold PBS. The cells were then lysed using 200 µL of ice-cold Cytoplasmic 
Extraction Reagent I (CER I) supplemented with the Protease Inhibitor Cocktail solution 
(Fisher scientific). The tubes were vortexed on the highest setting for 15 seconds to fully 
re-suspend the cells and incubated on ice for 10 minutes. Then 11 µL of Cytoplasmic 
Extraction Reagent II (CER II) was added to the tubes that were later vortexed for 15 
seconds on the highest setting and incubated on ice for 1 minute. Another round of vortex 
was carried out and the lysates were centrifuged at 14,000 × g for 10 minutes at 4°C. The 
soluble supernatants that contained the cytoplasmic proteins were transferred into new 
Eppendorf tubes and stored at -20°C until required. 
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2.3.6.2 Protein quantification 
Protein concentrations were determined using the BCA (bicinchoninic acid) protein 
assay. Bovine serum albumin (BSA) (1 mg/mL stock; Merck) was diluted with distilled 
water to achieve protein standard concentrations of 10, 20, 30, 40 and 50 μg/mL. Later, 
25 μl of each standard solution was loaded into a 96-well plate in duplicate.  
For each protein sample, the whole cell lysate was diluted 1:10 with distilled water and 
25 μl of the diluted sample was loaded into the same 96-well plate in duplicate. Then 200 
μl of the BCA working reagent {50:1, reagent A (bicinchoninic acid solution): reagent B 
(copper sulfate solution)} was added to the standard and sample wells. The plate was 
incubated at 37°C for 30 minutes before absorbance was measured using the microplate 
reader (Multiskan® GO) at 562 nm. The absorbance readings of the BSA standards were 
utilised to generate a standard curve to determine the protein concentration of each test 
sample. 
Based on the BCA assay results, protein samples were diluted accordingly in order to 
result in an equal concentration for all samples. 
2.3.6.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
A 10% SDS-PAGE gel solution was prepared according to the established protocol (Table 
2.8) and poured into the designated glass plates. Once the gel was set, the comb was 
removed and the electrophoresis reservoir was filled with 1 × running buffer (pH 8.3) (25 
mM Tris base, 190 mM glycine and 0.1% SDS). Each cell lysate was mixed with 4 × 
loading buffer [0.3 M Tris-HCl (pH 6.8), 50% glycerol, 10% SDS and 0.05% 
bromophenol blue] supplemented with 5 mM Dithiothreitol (DTT), and the samples were 
heated for 5 minutes at 95°C. Then 25 μL of the heated sample was loaded into each lane; 
10 μL of PageRuler™ Plus Prestained 10-250 kDa Protein Ladder (Fisher Scientific) was 
loaded on the same gel as size standards. The samples were run on 100 volts through the 
stacking gel then the voltage was increased to 200 V through the resolving gel. 
All chemicals in the running and loading buffers were purchased from Fisher scientific. 
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Table 2.8. Western blot gels preparation.  
Volume (mL) required for   
Source 
Running gel (10%) Stacking gel (4%) 
Protogel 3.3 Protogel 1.2 Fisher Scientific 
2M Tris PH 8.8 2 0.5M Tris PH 6 1.4 Fisher Scientific 
60% Sucrose 2 60% Sucrose 2 Fisher Scientific 
20% SDS 0.025 20% SDS 0.025 Fisher Scientific 
TEMED 0.005 TEMED 0.01 Merck 
Distilled water 2.64 Distilled water 5.33 In house 
10% APS 0.03 10% APS 0.03 Fisher Scientific 
Total volume 10 mL Total volume 10 mL  
SDS: Sodium dodecyl sulfate. TEMED: Tetramethylethylenediamine; APS: Ammonium 
persulfate 
2.3.6.4 Protein transfer 
The separated proteins were transferred onto an activated polyvinylidene fluoride 
membrane (PVDF; Millipore, Nottingham, UK) using a wet transfer method. Prior to 
transferring, the membrane and the gel and the blotting paper pads were soaked with the 
transfer buffer (25 mM Tris base, 200 mM Glycine, 0.04% SDS and 0.005% Tween-20). 
Transfer occurred by applying 300 mA for 2.5 hours at 4°C. Following the transfer, non–
specific protein binding was blocked by incubating the PVDF blots for 1 hour in 3% fat-
free milk/TBST (tris-buffered saline and Tween 20) when blotting for total proteins and 
in 3% BSA/TBST when blotting for phospho–proteins. The membranes were incubated 
overnight at 4°C with the primary antibody diluted in appropriate blocking buffer (Table 
2.9) then incubated with the corresponding secondary antibody (Table 2.10) for 2 hours 
at room temperature. Between each step, the membranes were washed three times with 
TBST buffer. 
The immunoreactive proteins were detected by incubating the membrane with the 
Immobilon Forte Western HRP substrate (Millipore) for three minutes with no direct light 
and visualised with a high sensitivity CCD (charge-coupled device) camera imaging 
platform, i.e. the ChemiDoc™MP Gel Imaging System (Bio-Rad). The ImageJ software 
was used for the densitometric quantification of the western blot bands [293]. 
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Table 2.9. List of primary antibodies used in western blotting.  
Protein Antibody Code Species Dilution Source 
SOD1 SC-101523 Mouse 
monoclonal 
1:500 Santa Cruz, USA 
SOD2 SC-130345 Mouse 
monoclonal 
1:500 Santa Cruz 
CAT SC-271803 Mouse 
monoclonal 
1:250 Santa Cruz 
BCL-XL MAB894 Rabbit 
monoclonal 
1:500 R&D systems, USA 
BAX SC-20067 Mouse 
monoclonal 
1:250 Santa Cruz 
OGG1 SC-376935 Mouse 
monoclonal 
1:250 Santa Cruz 
ATR SC-515173 Mouse 
monoclonal 
1:500 Santa Cruz 
pATR D5K8W Rabbit 
monoclonal 
1:1000 Cell Signalling, USA 
Chk1 SC-8408 Mouse 
monoclonal 
1:500 Santa Cruz 
pChk1 D12H3 Rabbit 
monoclonal 
1:1000 Cell Signalling 
Cytochrome c MA5-11674 Mouse 
monoclonal 
1:500 ThermoFisher 
VDAC1 SC-390996 Mouse 
monoclonal 
1:500 Santa Cruz 
β-Actin MAB8929 Mouse 
monoclonal 
1: 2000 R&D systems 
Table 2.10. List of secondary antibodies used in western blotting.  
Antibody Dilution Source 
Anti-rabbit HRP 
 
1:2000 Dako, Denmark 
 
Anti-mouse HRP 
 
1:5000 Dako 
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2.4 MtDNA mutation analysis 
2.4.1 Polymerase chain reaction 
To assess the mtDNA mutations of the cell lines enrolled in our study, sufficient mtDNA 
templates were required for the sequencing analysis. Therefore, seventeen primer pairs 
were designed using Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi) to amplify the entire mitochondrial genome in overlapping fragments of 
~ 1.1 kb (Table 2.11).  
Table 2.11. List of the primers designed to amplify 17 overlapping mtDNA fragments.  
Primer 
ID 
Sequence Length Start End 
Size 
(bp) 
F1 CCCTATTAACCACTCACGGG 20 17 36 
1139 
R1 CTGTGGCTCGTAGTGTTCTG 20 1155 1136 
F2 GATACCCCACTATGCTTAGCC 21 1079 1099 
1114 
R2 TTGGTGGCTGCTTTTAGGC 19 2192 2174 
F3 CTGGTGATAGCTGGTTGTCC 20 2006 2025 
1131 
R3 CTTGTCCTTTCGTACAGGGAG 21 3137 3117 
F4 GATCTGAGTTCAGACCGGAG 20 3063 3082 
1103 
R4 GTATGAGTTGGTCGTAGCGG 20 4165 4146 
F5 AACATATGACGCACTCTCCC 20 4041 4060 
1108 
R5 TCGTGGTGCTGGAGTTTAAG 20 5148 5129 
F6 ACCGTACAACCCTAACATAACC 22 5051 5072 
1150 
R6 GTTGTTTATGCGGGGAAACG 20 6200 6181 
F7 CCAGGCAACCTTCTAGGTAAC 21 6033 6053 
1099 
R7 CGTAGGTTTGGTCTAGGGTG 20 7131 7112 
F8 TGTAGCCCACTTCCACTATG 20 7022 7041 
1109 
R8 GTTTGGTTTAGACGTCCGGG 20 8130 8111 
F9 GTAGTACTCCCGATTGAAGCC 21 8009 8029 
1153 
R9 TAGGCTTGGATTAAGGCGAC 20 9161 9142 
F10 CATTACTGCAGGCCACCTAC 20 9015 9034 
1136 
R10 ATGTAGCCGTTGAGTTGTGG 20 10150 10131 
F11 ATAATCAACACCCTCCTAGCC 21 10080 10100 
1070 
R11 CAAGGTGGGGATAAGTGTGG 20 11149 11130 
F12 TCCAGTGAACCACTATCACG 20 11012 11031 
1114 
R12 CGGTAATGATGTCGGGGTTG 20 12125 12106 
F13 ACACCTATCCCCCATTCTCC 20 12076 12095 
1072 
R13 GGCTATTTTCTGCTAGGGGG 20 13147 13128 
F14 CAGCCCAATTAGGTCTCCAC 20 13007 13026 
1168 
R14 TAATTGAGATTGCTCGGGGG 20 14174 14155 
F15 TCCATCATCACCTCAACCCA 20 14056 14075 
1081 
R15 GCCTATGAAGGCTGTTGCTA 20 15136 15117 
F16 CAGAAACCTGAAACATCGGC 20 15075 15094 
1112 
R16 GGGTTTTGATGTGGATTGGG 20 16186 16167 
F17 GACTCACCCATCAACAACCG 20 16065 16084 
1150 
R17 TTTATGGGGTGATGTGAGCC 20 645 626 
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All PCR amplifications were performed using GoTaq® G2 Hot Start Polymerase 
(Promega). Briefly, a 50-µL reaction mix was prepared for each set of primers (Table 
2.12). A negative control was included in every PCR experiment where water was used 
to replace the template DNA.  
Table 2.12. Reaction setup for PCR amplifications.  
Component Volume (μL) 
5 × PCR buffer 10 
MgCl2 (25 mM) 3 
dNTPs (5 mM) 2 
Primers set (5 μM) 2 
GoTaq® G2 Hot Start Polymerase (5 U/μL) 0.25 
Nuclease-free water 22.75 
DNA (20 ng/μL) 10 
Total volume per reaction 50 μL 
The PCR tubes were vortexed, followed by a pulse spin and placed on ice until ready to 
load onto the T100™ Thermal Cycler (Bio-Rad). The amplification procedure entailed 
95°C for 15 min, followed by 35 cycles of 95°C for 40 seconds, 60°C for 40 seconds and 
72°C for 2 min with a final elongation step for 10 min at 72°C. 
 
2.4.2 Agarose gel electrophoresis 
To check whether the amplification of the 17 amplicons was successful, PCR products 
were run using agarose gel electrophoresis to confirm the bands before the products being 
sequenced. A 1.2% gel solution was prepared by dissolving 1.2 g of agarose in 100 mL 
of 1 × TBE buffer (Fisher Scientific). The gel solution was heated by microwave to fully 
dissolve the agarose and left to cool down before adding 10 µL of the DNA stain, 
SafeView (NBS Biologicals, Huntingdon, UK). The gel solution was then poured into the 
gel tank. Once the gel was set, the comb was removed and the electrophoresis reservoir 
was filled with 1 × TBE buffer.   
After 20 μL of the PCR product was mixed with 5 μL of 5 × DNA Gel Loading Buffer 
(Eppendorf, Stevenage, UK), the sample was loaded into the gel. In addition, 10 μL of 
exACTGene™ DNA Ladders (Fisher Scientific) was used as size standards. 
The gel was run on 125 V for 50 minutes. Once the electrophoresis was completed, the 
gel was viewed with the Gel Doc™ EZ System (Bio-Rad). 
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2.4.3 Sanger sequencing 
Sanger sequencing for the PCR products was performed by Eurofins Genomics 
(Ebersberg, Germany). 
 
2.4.4 Mutation analysis 
Mutations in the mitochondrial genome were identified by comparing the obtained 
sequences with the NCBI Human Mitochondrial Reference Sequence (NC_012920.1; 
https://www.ncbi.nlm.nih.gov/nuccore/251831106/) using the Nucleotide BLAST 
software (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Identified mtDNA mutations were 
annotated and their disease association was analysed using online tools and databases 
including MitoWheel (http://mitowheel.org/mitowheel.htmL), MitoMAP 
(https://www.mitomap.org/MITOMAP) and Human Mitochondrial DataBase (HmtDB; 
http://www.hmtdb.uniba.it/hmdb/index.jsp). 
2.4.4.1 MitoWheel 
MitoWheel displays a circular graphical representation of the human mitochondrial 
genome. The entire genome is displayed as a wheel that can be viewed by spinning the 
wheel allowing users to scan through and browse different regions of the genome. The 
sequence used is the NCBI Human Mitochondrial Reference Sequence (NC_012920.1). 
The MitoWheel tool was used to identify the location of the mutation on the 
mitochondrial genome and whether the regions containing variants were protein or non-
protein coding. If the mutations were identified as protein coding, the amino acid changes 
(if applicable) were recorded (Figure 2.3). 
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Figure 2.3. A screenshot of the MitoWheel search tool using the T14798C mutation as an example.  
2.4.4.2 MitoMap 
MitoMap is a human mitochondrial genome database containing a compendium of 
polymorphisms and mutations in the human mitochondrial genome. MitoMap reports 
published data on human mitochondrial variants and mutations [294]. 
The Allele Search tool in MitoMap was used to record any diseases previously associated 
with the observed mutations along with their specific references (Figure 2.4). 
 
Figure 2.4. The screenshot of the MitoMap’s Allele Search tool showing reported variants and mutations 
at the 14798 bp position of mtDNA.  
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2.4.4.3 Human Mitochondrial DataBase 
Human Mitochondrial DataBase (HmtDB) is a human mitochondrial genome database 
hosting human mitochondrial genome sequences annotated with population and 
variability data (Figure 2.5). HmtDB was also used to record any diseases previously 
associated with the observed mutations along with their specific references. 
 
2.4.5 In silico protein structure mapping and analysis 
A three-dimensional (3D) protein structure mapping and analysis tool (developed and 
validated by Lloyd and McGeehan) [45] was used to predict the functional impact of all 
non-synonymous mitochondrial DNA mutations identified in protein coding regions. The 
3D structure modelling provides a powerful tool for assessing the impact of mtDNA 
mutations on protein structure and therefore its function by allowing the amino acid 
changes to be visualised [45]. 
2.4.5.1 Selection of OXPHOS structures 
Because of their complex nature and location within the inner mitochondrial membrane, 
the respiratory chain proteins were difficult to be crystallised. Since not all structures of 
human respiratory chain complexes are well defined, some homologous structures have 
been used in parallel with the human ones for the purpose of analysing human mtDNA 
mutations. 
In this PhD project, the human mitochondrial protein sequences were used to choose the 
best quality, latest and most similar OXPHOS complex structures for complexes I, III, IV 
and V available from the Research Collaboratory for Structural Bioinformatics Protein 
Data Bank (RCSB PDB, http://www.rcsb.org/).  
The RCSB PDB (or it’s short form, the PDB) is a global archive for experimentally 
determined, atomic level 3D structures of biological macromolecules (DNA, RNA and 
proteins) [295]. 
Homologous structures were selected if they had a good atomic resolution and were in an 
organism whose protein sequence had a high level of identity to the human one. 
FASTA sequences of the potential homologous respiratory chain complexes (downloaded 
from the PDB) were aligned with their respective human sequences (NC_012920.1) using 
Clustal Omega, a multiple sequence alignment program that generates alignments 
between several sequences (https://www.ebi.ac.uk/Tools/msa/clustalo/).  
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Sequences with the level of structure identity greater than 60% were considered suitable 
for the 3D structural analysis (Table 2.13). 
Table 2.13. List of the complex structures obtained from the RCSB PDB.  
Complex PDB 
accession 
code 
Organism Subunit Sequence 
identity 
(%) 
Ref. 
Complex I 
 
5XTD Homo sapiens ND1 99.37 [46] 
ND2 99.71 
ND3 98.26 
ND4 99.56 
ND4L 97.94 
ND5 99.50 
ND6 99.43 
5LC5 Bos taurus ND1 77.96 [38] 
ND2 63.37 
ND3 72.97 
ND4 73.96 
ND4L 72.63 
ND5 69.77 
ND6 61.40 
Complex III 5XTE Homo sapiens MT-CYB 100 [46] 
1NTZ Bos taurus MT-CYB 78.89 [44] 
Complex IV 5Z62 Homo sapiens COI 100 [47] 
COII 100 
COIII 100 
Complex V 5ARA Bos taurus ATP 6 77.42 [51] 
All the alignments of the reference protein sequences used in the 3D modelling analyses 
are listed in Appendix Figures 1-7, with the identified mutation positions marked in 
rectangular boxes. 
2.4.5.2 Creating structural files for mutation analysis 
The atomic co-ordinates of each respiratory chain complex were downloaded from the 
PDB and opened using PyMol (the PyMOL Molecular Graphics System/Version 1.8, 
distributed by Schrödinger, LLC, NY, USA). The PDB files were also opened using the 
COOT software (Crystallographic Object-Oriented Toolkit), a program used to display 
and manipulate atomic models of macromolecules, typically proteins or nucleic acids 
[296]. COOT was used in our project to create PDB files containing all non-synonymous 
mutations identified by Sanger sequencing. Each residue in the non-human structures was 
carefully checked before mutating it to make sure that it was homologous with the human 
protein sequence. A new PDB file was generated for each mutation as well as for each 
complex containing all mutations. 
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2.4.5.3 Mapping and analysis of non-synonymous mutations 
All identified non-synonymous mutations were mapped to their locations on the protein 
structures using PyMol. PDB files including the mutations (created by COOT) were also 
opened with PyMol. The whole structure was displayed in a cartoon style, and each 
mutation was identified and displayed in the stick and sphere format. 
Detailed analysis of the effect of each mutation on protein structure was performed by 
examining the location of the amino acid change within the protein. Proximity to 
important catalytic regions, such as active sites, binding pockets and subunit interfaces, 
as well as whether the amino acid substitution could be accommodated or not at a specific 
position were analysed using PyMol. Such information and the type of amino acid change 
(Figure 2.6) were then used to predict the functionality of the associated mutations. Each 
of the mutations was also classified into one of the five structural classes previously 
defined by Lloyd and McGeehan: 1) Frameshift; 2) Active site; 3) Binding pocket; 4) 
Protein interaction region; 5) Non-functional [45]. 
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Figure 2.5. The structures of the 21 amino acids. Amino acids are grouped in A) amino acids with 
electrically charged side chains, B) amino acids with polar uncharged side chains, C) amino acids with 
different side chains and D) amino acids with hydrophobic side chains. Figure created by Dr Dan Cojocari, 
University of Toronto and taken from https://commons.wikimedia.org/wiki/File:Molecular 
_structures_of_the_21_proteinogenic_amino_acids.svg.  
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2.5 Statistical Analysis 
Data were analysed with the GraphPad Prism version 8.0 (Graphpad Software, CA, USA) 
and presented as the mean ± SEM of at least two independent experiments. Specific 
statistical tests used to analyse various data sets are described in the associated figure 
legends in the following chapters. Differences between groups were considered 
statistically significant based on the following criteria: *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001.  
Potential linear correlation between two variables was assessed by Pearson correlation 
coefficient method using SPSS (2015) software. Pearson's r has a value between +1 and 
−1, where +1 indicates a total positive linear correlation, 0 indicates a non-linear 
correlation, and -1 indicates a total negative linear correlation. 
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Chapter 3 
Mitochondria-targeting/ROS-
mediating agents as novel 
synergistic drugs for improved 
cancer-specific therapy 
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3.1 Introduction 
Mitochondria are the primary source of intracellular ROS as side-products of the 
mitochondrial electron transport chain reaction during cellular respiration [160]. ROS 
play important roles in cell signalling pathways such as growth, differentiation, 
metabolism and apoptosis [160,297]. They are also regarded as a double-edged sword in 
cancer cells since low doses of ROS can promote cell proliferation and invasion, whereas 
excessive levels of ROS cause oxidative damage to biomolecules which consequently 
induce cell death [168,196]. Therefore, a slight increase of ROS is associated with the 
initiation and progression of cancer [144,160], but high levels of ROS can induce cell 
death by activating several signalling pathways resulting in cell apoptosis [168,196]. 
Despite its strong side effects, chemotherapy is still widely used in clinical practice. Many 
chemotherapy drugs cause cell death by a direct damage to the nucleic acids while others 
disrupt the redox balance within the cell. Some chemotherapeutic agents can cause an 
excessive accumulation of ROS either via an overproduction of ROS or by supressing 
their elimination in tumour cells by the antioxidant systems (reviewed in Ref. [175]). 
Cisplatin (CDDP) is one of the most commonly used chemotherapeutic agents employed 
in the treatment of various human cancers. It is a highly reactive molecule which forms 
various types of adducts by binding to DNA, RNA and proteins [209]. Moreover, 
previous studies have demonstrated that cisplatin accumulates in mitochondria and causes 
significant changes in mitochondrial structure and metabolic function [209,240]. Recent 
reports evinced that cisplatin-induced apoptosis could be inhibited by compounds that 
interfere with ROS generation. These observations elucidate that the killing effect is 
correlated to increased ROS generation [240]. However, the clinical use of cisplatin is 
limited because of its severe irreversible side effects including neurotoxicity, ototoxicity 
and nephrotoxicity which has been reported as the main limitation of cisplatin [298]. 
Recently, due to their critical role in metabolism, ATP synthesis and redox status, and 
because of their involvements in many pathways related to the cell death, mitochondria 
have become one of the main interests in developing cancer treatments. Since cancer cells 
generally have higher levels of ROS compared to normal cells, and because of the 
differences in the mitochondrial transmembrane potential between cancer and normal 
cells, a direct targeting on mitochondrial functions could be an effective approach to 
triggering cancer-specific cell death.  
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Delocalised lipophilic cations (DLCs), a group of small membrane permeable agents 
driven by negative potential across the mitochondrial membrane, accumulate in 
mitochondria and are more toxic to cancer cells compared to normal cells (reviewed in 
Ref. [255]). This characteristic attracts researchers to evaluate DLCs for selective cancer 
cell elimination [299]. Within a wide range of DLCs, dequalinium (DQA) has been 
reported to demonstrate a potent anticancer activity in vitro and in vivo in different 
malignancies [270]. Several studies have suggested that the cytotoxicity mechanism of 
DQA is related to mitochondrial dysfunction due to the damage of mitochondrial DNA 
and the inhibition of mitochondrial complex I [267]. 
Given the merit of mitochondria-targeting therapy, the combination of conventional 
chemotherapy drugs such as cisplatin with mitochondria-targeting agents (e.g. DQA) may 
offer a promising strategy for enhanced anticancer therapy [300]. 
In this chapter, we report our investigation on how baseline ROS level might influence 
cells’ response to ROS-stimulating therapy. The potential synergistic effect of cisplatin 
and dequalinium chloride in killing cancer cells was also assessed. 
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3.2 Results 
3.2.1 Overproduction of intracellular ROS and mitochondrial superoxide in 
cancer cells 
Initially, in advance of the first ROS experiments, a population-doubling-time (PDT) 
analysis was performed for all the cell lines enrolled in the study so that cell lines with 
comparable PDT values could be selected to avoid potential interference of disparate 
proliferation rates with the downstream work.  
Results in Figure 3.1 show that the average doubling times were 27.2, 34.7, 34.3, 33.2, 
32.1, 35.9 and 40.2 hours for Caki-2, Ishikawa, Caco-2, PC-3, MDA-MB-231, PNT-2 
and HEK-293 cells, respectively. According to these results, Ishikawa, Caco-2, PC-3, 
MDA-MB-231 and PNT-2 cells were selected due to their comparable doubling times.  
 
Figure 3.1. Cell line doubling times illustrated by graphs with cell number plotted against culture time.  
 
Chapter 3 
 
106 
 
After establishing this phenotypic characteristic of the cells, comparative analyses of the 
baseline intracellular ROS level and mitochondrial superoxide across the various cell 
types were performed. As shown by DCFDA and MitoSOX assays in Figure 3.2 a & b, 
all cancer cell lines had increased baseline intracellular ROS and mitochondrial 
superoxide levels compared to the non-cancerous cells (PNT-2). Amongst the cancer cell 
lines, Caco-2 had the highest baseline intracellular ROS and mitochondrial superoxide 
levels whereas Ishikawa had the lowest. Moreover, the baseline mitochondrial superoxide 
and the overall intracellular ROS levels were positively correlated in all the cell lines 
(Figure 3.2 c). 
 
Figure 3.2. Correlation between the baseline mitochondrial superoxide and intracellular ROS levels. 
Intracellular ROS (a) and mitochondrial superoxide (b) levels of the PNT-2, Ishikawa, MDA-MB-231, PC-
3 and Caco-2 cell lines are represented by the fluorescence intensity of DCFDA and MitoSOX respectively. 
Data are mean ± SEM (N=3 separate experiments); p values were calculated using one-way ANOVA with 
Tukey multiple comparison post-hoc analysis; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. (c) 
Positive correlation between the baseline mitochondrial superoxide and intracellular ROS levels. Data 
points representing the cell lines are in the same sequence as the columns in panels a and b. r and p values 
were calculated using the Pearson correlation coefficient method; **p<0.01.  
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3.2.2 Increased drug resistance in cancer cells 
To evaluate the drug sensitivity of all the cell lines towards cisplatin (CDDP) and 
dequalinium chloride hydrate (DQA), cells were treated with various concentrations of 
CDDP and DQA for 24 hours (described in Chapter 2, 2.1.5). 
The MTS assay results showed that the PNT-2 cells were more sensitive to both drugs 
compared to the cancer cells with Caco-2 being the most resistant whereas Ishikawa the 
most sensitive amongst the cancer cells (Figure 3.3 a & b). The IC50s of CDDP were 
34.31±2.5, 84.96±3, 158.9±8.2, 372.7±17.5 and 499.5±15.1 μM for PNT-2, Ishikawa, 
MDA-MB-231, PC-3 and Caco-2 respectively, whereas the IC50s of DQA were 
9.07±0.66, 14.24±0.59, 57.85±3.59, 93.31±3.21 and 179.2±5.2 μM respectively for the 
above cell lines.  
Interestingly, the increased IC50s of both CDDP and DQA among the cell lines followed 
the same trend as that of the baseline intracellular ROS levels. This indicates that the 
baseline intracellular ROS levels were positively correlated with the resistance levels to 
both drugs in the cell lines (Figure 3.3 c & d).  
 
Figure 3.3. Comparison of the CDDP IC50s and the DQA IC50s amongst the 5 cell lines. The columns 
represent the CDDP IC50s (a) and the DQA IC50s (b) in the all cell lines. Data are mean ± SEM (N=3 
separate experiments); p values were calculated using one-way ANOVA with Tukey multiple comparison 
post-hoc analysis; ns, not significant, **p<0.01, ***p<0.001 and ****p<0.0001. Positive correlation 
between the baseline intracellular ROS levels and drug resistance levels against CDDP (c) and DQA (d). 
Data points representing the cell lines are in the same sequence as the columns in panels a and b. r and p 
values were calculated using the Pearson correlation method; **p<0.01.  
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Based on these observations, Caco-2 and Ishikawa were chosen to represent the most 
resistant and sensitive cell lines respectively in the downstream experiments to investigate 
the synergistic effect of CDDP and DQA as well as the underlying killing mechanisms 
that might be influenced by baseline intracellular ROS levels, since Caco-2 and Ishikawa 
also represented cancer cells with the highest and the lowest ROS levels in this study. 
 
3.2.3 Synergistic effect of cisplatin and dequalinium chloride observed in Ishikawa 
and Caco-2 
In order to study the synergistic effect of cisplatin and dequalinium chloride hydrate, the 
Caco-2 and Ishikawa cells were incubated with a combined treatment of CDDP and DQA 
at half of their IC50 concentrations for 24 hours. Such treatments resulted in a marked 
reduction of cell viability in both Caco-2 and Ishikawa cells, compared to the cells treated 
with a single drug (either CDDP or DQA) at its IC50 (Figure 3.4 a & b).  
Moreover, treating cells with various concentrations of CDDP (5, 10, 50, 100, 250, 500, 
750 and 1000 µM) in combination with DQA at half of its IC50 (i.e. 89.6 μM for Caco-2 
and 7.2 μM for Ishikawa) resulted in a significant decrease of CDDP IC50 for the       
Caco-2 (384±8.3 μM) and Ishikawa (21.8±.91 μM) cells (Figure 3.4 c & d). 
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Figure 3.4. Comparison of Caco-2 (a) and Ishikawa (b) cell viability upon treatments with CDDP and 
DQA at their IC50 concentrations, and a combination of ½ IC50 of both drugs at 24 hours. The columns 
represent cell viability under various treatment conditions normalised against the untreated controls. Data 
are mean ± SEM (N=3 separate experiments); p values comparing single and combined treatments were 
calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; *p<0.05, **p<0.01. 
(c) Comparison between the CDDP IC50 (499.5 µM) in single drug treatment and the new CDDP IC50 
(384 µM) in combination with ½ DQA IC50 in the Caco-2 cells. (d) Comparison between the CDDP IC50 
(84.9 µM) in single drug treatment and the new CDDP IC50 (21.8 µM) in combination with ½ DQA IC50 
in the Ishikawa cells. Data are mean ± SEM (N=3 separate experiments); p values comparing single and 
combined treatments were calculated using a two-tailed t-test; **p<0.01 and ****p<0.0001.  
 
Furthermore, to elucidate the influence of drug combination on therapeutic efficacy (i.e. 
Antagonistic, Additive or Synergistic), the Combination Index (CI) was calculated at 
different combinations according to the median-effect principle of the Chou and Talalay 
method, using the CompuSyn software.  
Data from the CompuSyn analysis (Table 3.1) indicate synergistic effects of the 
compounds in both cell lines. However, the Ishikawa cells demonstrated higher 
synergistic effects within the whole concentration range for CDDP in combination with 
DQA at half of its IC50 (7.2 μM), whereas the Caco-2 cells demonstrated lower 
synergistic effects of the compounds and only within the concentration range of 5–250 
Chapter 3 
 
110 
 
μM for CDDP in combination with DQA at half of its IC50 (89.6 μM). Antagonistic 
effects of the compounds were observed only in the Caco-2 cells treated with 500–1000 
μM of CDDP in combination with DQA. No additive effects were observed in either 
Ishikawa or Caco-2 with the concentrations of the compounds used in the study. 
Table 3.1. The Measurement of Combination Index (CI).  
Caco-2 
Dose CDDP / µM Dose DQA / µM Effect CI 
5 89.6 0.66 0.99136 
10 89.6 0.64 0.92967 
50 89.6 0.60 0.94462 
100 89.6 0.55 0.92323 
250 89.6 0.45 0.90660 
500 89.6 0.39 1.07629 
1000 89.6 0.33 1.37327 
Ishikawa 
Dose CDDP / µM Dose DQA / µM Effect CI 
5 7.2 0.66 0.72731 
10 7.2 0.59 0.63296 
42.5 7.2 0.38 0.57506 
50 7.2 0.34 0.55585 
85 7.2 0.28 0.65842 
100 7.2 0.25 0.66588 
500 7.2 0.01 0.21071 
1000 7.2 0.01 0.41721 
 
3.2.4 Intracellular ROS and mitochondrial superoxide levels increased upon 
treatments 
To evaluate the impact of the compounds on ROS production upon treatment, the       
Caco-2 and Ishikawa cells were continuously exposed to CDDP and DQA at their IC50 
concentrations and to the combination of both drugs at half of their IC50 concentrations 
for 24 hours. Such treatments resulted in significant increases of intracellular ROS and 
mitochondrial superoxide levels in both Caco-2 and Ishikawa cells in a time-dependent 
manner (Figure 3.5). Significant increases in intracellular ROS were observed in the 
Caco-2 cells at 5 hours following initial exposures to CDDP and the combined therapy 
(Figure 3.5 a & c), and at 7 hours following DQA treatment (Figure 3.5 b).  
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ROS levels increased continuously up to 24 hours in the Caco-2 cells under all treatments. 
Earlier increases of intracellular ROS were observed in the Ishikawa cells, i.e. at 3 hours 
following initial exposures to CDDP and DQA (Figure 3.5 d & e), and at 1 hour with the 
combined therapy (Figure 3.5 f). Parallel increases in mitochondrial superoxide were 
observed in both cell lines (Figure 3.5 a-f).  
 
Figure 3.5. Increases in the intracellular ROS and mitochondrial superoxide levels in the Caco-2 and 
Ishikawa cells upon treatments during a 24-hour period. The columns represent the fold changes of 
intracellular ROS (DCFDA) and mitochondrial superoxide (MitoSOX) respectively normalised against the 
untreated controls. Data are mean ± SEM (N=3 separate experiments); p values comparing treated and 
untreated cells were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.  
Furthermore, greater increases in intracellular ROS and mitochondrial superoxide were 
observed with the combined therapy compared to single treatment of CDDP or DQA in 
the Caco-2 cells at 24 hours (Figure 3.6 a & b). On the contrary, ROS and mitochondrial 
superoxide productions were equally elevated in the Ishikawa cells under all treatment 
conditions (Figure 3.6 c & d). However, the Ishikawa cells showed markedly higher 
increases in intracellular ROS and mitochondrial superoxide upon treatments compared 
to Caco-2 (Figure 3.6 e & f). 
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Figure 3.6. Increases of intracellular ROS and mitochondrial superoxide levels in the Caco-2 (a & b) and 
Ishikawa (c & d) cells upon treatments at 24 hours. The columns represent the fold changes of ROS and 
mitochondrial superoxide normalised against the untreated controls. Data are mean ± SEM (N=3 separate 
experiments); p values comparing treated and untreated cells were calculated using one-way ANOVA with 
Tukey multiple comparison post-hoc analysis; ns, not significant, *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. (e) Comparison of intracellular ROS level changes upon treatments between the Caco-2 
and Ishikawa cells at 24 hours. (f) Comparison of mitochondrial superoxide changes upon treatments 
between the Caco-2 and Ishikawa cells at 24 hours. Data are mean ± SEM (N=3 separate experiments); p 
values comparing the Caco-2 and Ishikawa cells were calculated using a two-tailed t-test; *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001.  
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The presence and production of mitochondrial superoxide upon treatments were also 
confirmed using fluorescence microscopy. Fluorescence staining with MitoSOX showed 
significantly increased production of mitochondrial superoxide in the Caco-2 and 
Ishikawa cells upon treatments with CDDP and DQA at their IC50 concentrations and 
with the combination of both drugs at half of their IC50 concentrations (Figure 3.7). The 
highest levels of mitochondrial superoxide were observed following the combined drug 
treatment in Caco-2 whereas comparable mitochondrial superoxide productions were 
observed under all treatment conditions in Ishikawa (Figure 3.7 b & c). 
 
Figure 3.7. (a) Visualisation of mitochondrial superoxide stained by the MitoSOX probe upon treatments 
at 6 hours using confocal laser-scanning microscopy. Magnification of these images was ×20 and the scale 
bar represents 20 µm. (b & c) Quantification of the increased MitoSOX staining in treated cells. The 
columns represent the fold changes of mitochondrial superoxide normalised against the untreated controls. 
Data are mean ± SEM (N=3 separate experiments); p values comparing treated and untreated cells were 
calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; ns, not significant, 
*p<0.05, **p<0.01 and ***p<0.0001. Fluorescence intensity was normalised to the number of cells per 
field of view in order to account for variations in the number of cells in each image.  
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3.2.5 Cell viability and mitochondrial transmembrane potential reduction along 
the same timeline as increased ROS generation 
Continuous exposure to CDDP and DQA at their IC50 concentrations and to the 
combination of both drugs at half of their IC50 concentrations for 24 hours resulted in 
significant reduction of cell viability in both Caco-2 and Ishikawa cells in a time-
dependent manner (Figure 3.8). MTS assay showed marked reductions of cell viability at 
3 hours for CDDP and the combined therapy in both cell lines with cell viability 
continuously decreasing up to 24 hours, whereas marked reductions of cell viability were 
observed at 5 hours for DQA in both cell lines. 
 
Figure 3.8. Effects of CDDP and DQA at their IC50 concentrations and a combination of both drugs at 1/2 
IC50 concentrations, on cell viability in the Caco-2 (a, b, c) and Ishikawa (d, e, f) cells over a 24-hour 
treatment period. The columns represent the fold changes of cell viability normalised against the untreated 
controls. Data are mean ± SEM (N=3 separate experiments); p values comparing treated and untreated cells 
were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001.  
MMP was evaluated using the JC-10 fluorescence dye whose red/green fluorescence ratio 
depends only on the transmembrane potential (described in Chapter 2, 2.2.6). It was 
observed that the fluorescence changed from red to green following the treatments in both 
cell lines in a time-dependent manner. Data in Figure 3.9 show that CDDP noticeably 
depolarised mitochondrial potential at 1 and 3 hours in Ishikawa and Caco-2 respectively, 
and MMP continued to reduce up to 24 hours in both cell lines. Interestingly, cells treated 
with DQA and the combined therapy showed significantly greater mitochondrial 
depolarisation at the 1-hour time point compared to the CDDP treatment in both cell lines, 
predominantly in Ishikawa. 
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Figure 3.9. Effects of CDDP and DQA at their IC50 concentrations, and a combination of both drugs at 
1/2 IC50 concentrations, on mitochondrial membrane potential in the Caco-2 (a, b, c) and Ishikawa (d, e, 
f) cells over a 24-hour treatment period. The columns represent the fold changes of MMP normalised 
against the untreated controls. Data are mean ± SEM (N=3 separate experiments); p values comparing 
treated and untreated cells were calculated using one-way ANOVA with Tukey multiple comparison post-
hoc analysis; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.  
It is worth noting that the aforementioned changes in cell viability, MMP and ROS (both 
intracellular and mitochondria-specific) levels showed good correlations in the same 
time-dependent manner over the 24-hour treatment period (Figures 3.5, 3.8 and 3.9). 
 
3.2.6 MtDNAcn decreased upon treatments 
Using SYBR Green real-time PCR, the relative content of mtDNA in respect of the β-
actin gene was determined in Caco-2 and Ishikawa upon the treatments. As shown in 
Figure 3.10, incubation with CDDP, DQA and their combination for 24 hours resulted in 
a marked reduction of mtDNAcn in both cell lines. The SYBR Green qPCR results 
showed that the mtDNAcn in both cell lines decreased significantly upon the treatments 
and reached its lowest value in the combined therapy at 24 hours, especially in Caco-2 
(Figure 3.10 a). 
The mtDNAcn data of all the cell lines are presented and discussed in Chapter 6 (6.2.1). 
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Figure 3.10. Decreases of mtDNAcn of the Caco-2 (a) and Ishikawa (b) cells upon treatments at 24 hours. 
The columns represent the fold changes of mtDNAcn that were normalised against the untreated controls. 
Data are mean ± SEM (N=3 separate experiments); p values comparing treated and untreated cells were 
calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; **p<0.01, 
***p<0.001 and ****p<0.0001.  
 
3.2.7 Cancer-preferential uptake of dequalinium chloride 
To elucidate the impact of higher MMP in cancer cells on DQA uptake, and how this can 
provide a window opportunity to achieve cancer-specific targeting by using delocalised 
lipophilic cations such as DQA, one pair of normal-cancer cell lines of prostate origin 
(PNT-2 and PC-3) was used in the cancer-preferential uptake experiments. The JC-10 
assay results indicated that the PC-3 cell line (prostate cancer) had indeed significantly 
higher MMP compared to PNT-2 (non-cancerous counterpart) (Figure 3.11 a). Applying 
10 µM of DQA to both cell lines resulted in far more rapid mitochondrial depolarisations 
in the PC-3 cells compared to the PNT-2 cells within the 3-hour incubation period (Figure 
3.11 b). 
 
Figure 3.11. (a) Mitochondrial membrane potential of the PNT-2 and PC-3 cells. The columns represent 
the red/green ratio of fluorescence intensity. Data are mean ± SEM (N=3 separate experiments); p values 
comparing PNT-2 and PC-3 was calculated using a two-tailed t-test; **p<0.01. (b) Effects of DQA (10 
µM) on mitochondrial membrane potential in the PNT-2 and PC-3 cells. The columns represent the fold 
changes of MMP normalised against the untreated controls. Data are mean ± SEM (N=3 separate 
experiments); p values comparing the PNT-2 and PC-3 cells were calculated using a two-tailed t-test; 
*p<0.05 and ****p<0.0001.  
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3.3 Discussion 
Elevated level of ROS has been associated with various disease processes including 
cancer, and the unlimited growth of cancer cells in response to accumulation of ROS has 
been the focus of interest in recent studies. However, it has also been established that 
beside their mitogenic effect on tumorigenesis, excessive levels of ROS can induce 
damage in cancer cells and trigger apoptosis if not counteracted by antioxidant systems 
(reviewed in Ref. [175]). 
Therefore, further increase of ROS levels using ROS stimulators in cancer therapy has 
attracted more attention in the past decades and various strategies of utilising ROS in the 
treatments of cancer have been developed [160]. 
This PhD project investigated the role of baseline intracellular ROS level in modulating 
the effect of anticancer drug treatment in various human cancer cell lines. In this Chapter, 
the initial screening of ROS levels among the cancer cell lines and their responses to 
ROS-stimulating agents are presented and discussed. 
3.3.1 Correlation between baseline ROS levels and drug resistance 
Several previous studies have demonstrated that various types of cancer cell lines have 
elevated levels of ROS compared to non-cancerous cell lines [301–303]. Our own 
intracellular ROS and mitochondrial superoxide assays were conducted with one pair of 
non-cancerous - cancer cell lines (PNT-2 and PC-3) of the same origin to verify this 
previous observation. Indeed, our results confirmed it to be the case and also 
demonstrated that all cancer cell lines involved in this study showed higher ROS levels 
compared to the non-cancerous cell line (PNT-2). Interestingly, results from the DCFDA 
and MitoSOX assays showed the same trend of both intracellular ROS and mitochondrial 
superoxide levels among the cell lines. This observation confirmed that mitochondria are 
the main source of ROS production in the cells employed in the study. 
It has been postulated that cisplatin increases the generation of intracellular ROS which 
may cause damage to DNA, proteins and lipids leading to apoptosis [209]. Several 
previous studies also related the mechanism of the anti-tumour effect of dequalinium to 
an impairment of mitochondrial function and the associated ROS generation 
[270,271,304]. Therefore, the potential link between the baseline ROS levels in cancer 
cells and their drug response towards cisplatin and dequalinium was investigated in the 
present study.  
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Population doubling time results showed that all cell lines enrolled in this study had 
comparable doubling times (≈ 34 hours). Therefore, the 24-hour drug incubation period  
was considered appropriate in the toxicity experiments conducted to measure the IC50s 
because the same number of cells of each cell line had been seeded in the beginning of 
the experiments and the populations remained comparable among the cell lines during the 
24-hour incubation period which was significantly shorter than the doubling times.  
Our results showed that the IC50s of both CDDP and DQA at 24 hours were significantly 
greater in cancer cells with higher baseline intracellular ROS levels. On the contrary, 
cancer cells with the lowest baseline ROS level (i.e. Ishikawa) required the lowest doses 
of both treatments to achieve 50% of cell death. Consequently, our data suggested that 
the drug resistance levels of those cancer cells were correlated with their baseline ROS 
levels, and that cancer cells with a low intracellular ROS level were more sensitive to 
both cisplatin and dequalinium, whereas cancer cells with high baseline ROS levels were 
significantly more resistant. These results were in agreement with a study conducted by 
Yang et al. [267] who observed a positive correlation between baseline levels of ROS and 
drug resistance to photo activation of the delocalised lipophilic cation D112. Therefore, 
baseline ROS levels could be utilised to predict drug response of cancer cells. 
Based on the above findings, the Ishikawa and Caco-2 cell lines were employed as in 
vitro models in the downstream investigations to represent cancer cells with the lowest 
and highest baseline intracellular ROS levels respectively. 
3.3.2 Synergistic effect of cisplatin and dequalinium chloride 
Neurotoxicity, ototoxicity and nephrotoxicity have been previously reported as the main 
limitations in the use of cisplatin (reviewed in Ref. [305]). Therefore, it is plausible to 
apply a lower dose of cisplatin in combination with another anticancer agent in order to 
reduce the side effects of cisplatin while enhancing the therapeutic efficacy. In this study, 
the effect of combining CDDP and DQA was evaluated by applying a combined treatment 
of both drugs at half of their IC50 concentrations to the Ishikawa and Caco-2 cell lines.  
Our data showed that the combined therapy significantly caused a further reduction in the 
cell viability compared to the single treatment with CDDP and DQA at their IC50 
concentrations. Moreover, incubating cells with various concentrations of CDDP in 
combination with DQA at half of its IC50 resulted in a significant decrease of CDDP 
IC50 in both Caco-2 and Ishikawa cells. 
Chapter 3 
 
119 
 
It is noteworthy that the extent of reduction in the CDDP IC50 under the combined 
treatment was far more obvious in Ishikawa (75%) than that in Caco-2 (25%). This 
correlates with the observation that the Caco-2 cells were most resistant to the drugs 
whereas the Ishikawa cells were most sensitive amongst the 4 cancer lines that we initially 
screened for drug response. In other words, the Ishikawa cells showed a much greater 
level of sensitivity towards the combined treatment compared to Caco-2. 
In this study, significant synergistic effects of CDDP and DQA were also observed in 
both Caco-2 and Ishikawa cells when the cytotoxicity data were analysed using the 
CompuSyn software. We did not observe any additive or antagonistic effects in Ishikawa 
within the dose range of 5-1000 µM (as indicated by the CI values of Ishikawa in Table 
3.1 which are all <1). This further confirms high sensitivity of Ishikawa to the treatments. 
Interestingly, an antagonistic effect was observed in Caco-2 within the dose range of 500-
1000 µM. This antagonistic effect could explain the much greater resistant levels of Caco-
2 towards both DQA and CDDP compared to Ishikawa, and it might be a result of 
competition between the two compounds over the cell membrane influx system at higher 
drug concentrations. Furthermore, our CompuSyn data from Caco-2 suggest that an 
additive effect may well occur if the Caco-2 cells are exposed to CDDP at a concentration 
between 250 µM and 500 µM in combination with 90 µM of DQA. (As indicated by the 
CI values of Caco-2 in Table 3.1; i.e. CI=0.90660 at 250 µM and CI=1.07629 at 500 µM). 
Our observations were in alignment with previous findings that mitochondria are a 
promising target for anticancer therapy [52], and our data clearly suggest that combining 
mitochondria-targeting agents could provide improved efficacy while reducing side 
effects of conventional therapy in treating cancer. 
3.3.3 Cell viability and mitochondrial transmembrane potential reduction along 
the same timeline as increased ROS generation 
Cancer cells are highly sensitive to ROS-stimulating agents due to an elevated oxidative 
stress environment. To investigate treatment-induced ROS production in our study and 
its contribution to cell killing, the intracellular ROS and mitochondrial superoxide levels 
in the Ishikawa and Caco-2 cells were measured upon the treatments with CDDP, DQA 
and their combination. Interestingly, the present study revealed a significant difference 
between the Caco-2 and Ishikawa cells in terms of their response and behaviour to the 
treatments at cellular and molecular levels.  
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Our data showed significant increases in the intracellular ROS and mitochondrial 
superoxide levels in a time-dependent manner up to 24 hours following the continuous 
exposure to the treatments in both cell lines. However, ROS production upon drug 
exposure was significantly elevated in Ishikawa compared to Caco-2, and the onset of 
ROS production was far more rapid in Ishikawa than that in Caco-2. In addition, the  
Caco-2 cells responded most significantly to the combined therapy, whereas similar levels 
of increased ROS generation were observed in the Ishikawa cells across all treatments.  
These results suggested that CDDP, DQA and their combination could stimulate greater 
ROS production in cells with relatively low baseline levels of intracellular ROS. As 
elevated ROS can trigger cell death, this explains the significantly higher sensitivity of 
the Ishikawa cells towards those treatments compared to the Caco-2 cells.  
For cells with relatively high baseline ROS levels, the combined treatment of CDDP and 
DQA could have a greater impact on ROS production compared to the single treatment 
of the same compounds. This is in line with our aforementioned observation that 
combining CDDP with DQA had a synergistic effect in killing cancer cells. Since cancer 
cells with higher baseline ROS levels could be more resistant to CDDP, combining CDDP 
and DQA might warrant a new strategy to tackle such resistance issues in the future. 
It is worth mentioning that DQA caused morphological changes to the cells such as 
irregular cell shape and reduced cell size. These changes were predominantly observed in 
the Caco-2 cells but not Ishikawa, and might be attributed to the increased cell membrane 
permeability due to the severe damages of the cell membrane components by excessive 
ROS in Caco-2. However further investigation is needed to elucidate the actual causes of 
this phenomenon. 
Since mitochondrial membrane depolarisation is an early key feature of cell death and 
also could affect respiration and increase ROS generation (reviewed in Ref. [24]), 
changes in mitochondrial transmembrane potential due to the treatments were examined 
in the present study. Indeed, depolarisations occurred in both cell lines upon treatments 
in a time-dependent manner, which indicated that both CDDP and DQA affected the 
mitochondrial transmembrane potential and interfered with ROS generation.  
A far more rapid and overwhelming depolarisation upon DQA treatment and its 
combination with CDDP was observed in both cell lines compared to the MMP changes 
observed in cells treated with CDDP alone. It should be noted that unlike the synergistic 
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effects on ROS production and cytotoxicity, the combined treatment did not have a 
synergistic effect on mitochondrial depolarisation in both cell lines. In fact, although the 
combined treatment had a profound impact on mitochondrial transmembrane potential, 
cells treated with DQA alone showed the most rapid and significant depolarisation upon 
the treatment. This could be attributed to the positive charge of DQA which led to its 
prompt and excessive accumulation within mitochondria, consequently neutralising the 
negative electric potential on the inner mitochondrial membrane at a speedy pace. Such 
swift changes in MMP were observed in our time course experiments. The impact on 
MMP was less severe from the combined treatment compared to that from DQA alone 
during the early phase of the time course particularly at the 1-hour and 3-hour time points. 
This could be due to the fact that only half of the DQA dosage was administrated to the 
cells in the combined treatment, which affected the speed and extent of depolarisation in 
those cells.  
Furthermore, changes in cell viability upon the treatments were examined in the present 
study. Interestingly, the time-dependent changes in ROS and MMP matched the time 
course of cell death as shown by the relevant time course data. Indeed, decrease in cell 
viability occurred in both cell lines in a time-dependent manner and followed the same 
time points for ROS overproduction upon the treatments, which indicated that both cell 
death and ROS generation are linked.  
A previous study showed that dequalinium induced a selective depletion of mitochondrial 
DNA in carcinoma cells [269]. Other reports also demonstrated that cisplatin accumulated 
in mitochondria formed adducts in mtDNA that interfered with mtDNA transcription and 
replication, and caused ATP deficiency which then led to cell death [209,307,308]. Our 
results showed significant decreases of mtDNAcn in both cancer cell lines upon the 
treatments and the relative mtDNAcn value reached the lowest in samples that had 
undergone the combined therapy. Such mtDNA depletion would reduce the expression 
levels of mtDNA-encoded complex subunits of the electron transport chain (ETC) and 
cause more leakage of electrons during OXPHOS, consequently leading to an excessive 
generation of ROS. 
All together, these data indicate that CDDP and DQA and their combination exert cancer 
cell killing via mitochondrial dysfunction and ROS-induced cell death.  
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It should be emphasised that another advantage of using mitochondria-targeting cations 
in anticancer therapy, apart from the synergistic killing effect, is that those compounds 
preferentially enter mitochondria in cancer cells which generally have higher 
transmembrane potential compared to that of mitochondria in normal cells. This allows 
cations to selectively target cancer cells and accumulate more rapidly in their 
mitochondria (reviewed in Ref. [255]). Our data comparing the prostate cancer (PC-3) 
and non-cancerous (PNT-2) cell lines confirmed the preferential targeting of cancer cells 
by DQA. This in vitro phenomenon needs to be investigated in vivo to evaluate the 
potential of DLCs in clinical practice. If proven, DLCs could offer cancer-specific therapy 
with significantly reduced side effects. MKT-077 was the first DLC to be tested in clinical 
trials which were terminated due to renal toxicity [255,267]. Therefore, more suitable 
DLCs still need to be trialled.  
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3.4 Summary 
The intracellular redox imbalance and the abnormal levels of ROS within the cell may 
lead to damages to macromolecules cell dysfunction, activation of protein kinases and 
inhibition of protein phosphatases resulting in malignant transformation and cancer 
development and progression. These events are accompanied by activation of 
transcription factors, accumulation of defective proteins, and adaptation to high levels of 
ROS and resistance to ROS-dependent apoptosis. Moreover, prolonged operation of cells 
at abnormal steady-state levels of ROS provokes genetic mutations, which makes the cells 
well adapted to oxidative stress by mobilising a set of adaptive mechanisms such as 
activating anti-oxidant systems to counteract the oxidative stress and inhibiting apoptosis. 
Recent evidences suggest that such adaptation contributes to malignant transformation, 
metastasis and resistance to anticancer drugs (reviewed in Ref. [168]). The 
aforementioned data might explain the increased resistance observed in cancer cells with 
higher baseline intracellular ROS levels. 
This chapter focused on the different baseline intracellular ROS levels among the cancer 
cells and their impact on the cytotoxic efficacy of cisplatin and dequalinium. It was 
concluded that cancer cells with lower baseline ROS levels are more sensitive to ROS-
stimulating agents whereas cells with higher baseline ROS levels are more resistant. 
Moreover, it was suggested that a robust increase in ROS production might explain the 
remarkable sensitivity of the Ishikawa cells to CDDP and DQA compared to other cancer 
cells. It is also possible that the Ishikawa cells are ill adapted to dealing with rapidly 
elevated oxidative stress upon ROS-stimulating therapy due to their relatively low 
baseline ROS level. In comparison, the Caco-2 cells are able to survive excess ROS 
production much better because those cells have already adapted to living under a 
relatively high level of ROS. 
In summary, the present study suggests that baseline ROS level in cancer cells could be 
an efficient predictive biomarker for drug response. Since measuring ROS in tissues is 
technically challenging, a more efficient biomarker linked to ROS to indicate the response 
to ROS-stimulating agents is still needed (please see further results and discussion in 
Chapter 6). This study also supports the theory that combining conventional 
chemotherapy with mitochondria-targeting therapy enhances cell death and allows 
reduced doses of the conventional drug.
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Chapter 4 
Understanding the implication of 
cellular redox and apoptosis status 
in ROS-mediated cell death using 
Ishikawa and Caco-2 as in vitro 
models 
Chapter 4 
 
125 
 
4.1 Introduction 
In healthy tissues, the intracellular ROS are preserved at a steady and low level by the 
equilibrium between ROS production and enzymatic elimination by antioxidants such as 
cytoplasmic superoxide (SOD1), mitochondrial superoxide (SOD2), catalase (CAT), 
peroxiredoxins (PRxs) and glutathione peroxidases (GPxs). Free radical activity can also 
be eliminated non-enzymatically through the interaction between ROS and their 
substrates such as glutathione (GSH) (reviewed in Ref.s [65,166,175]). 
Generally, cancer cells have a constant metabolic oxidative stress compared to normal 
cells, and the elevated levels of ROS during cell transformation are due to high metabolic 
rate in mitochondria resulting in increased electron leakage and ROS generation [164]. 
Furthermore, cancer cells express relatively low levels of antioxidants  compared to non-
cancerous cells, which renders higher ROS levels in cancer cells (reviewed in Ref. [65]). 
However, cancer cells are capable of compensating the excessive levels of ROS by 
increasing the antioxidant capacity and reprograming the metabolic pathways to 
overcome oxidative stress and enhance tumour survival/growth [164]. Therefore, 
inducing further increase of intracellular ROS levels by ROS stimulators as a novel 
approach to cancer therapy has attracted more attention in the past decades, and various 
strategies for ROS-stimulating therapy have been developed (reviewed in Ref.s 
[144,160]). 
Although cancer cells generally have higher ROS levels compared to their normal 
counterparts, they exhibit various levels of intracellular ROS due to differences in their 
tissue origin, genetic background, energy metabolic activity and microenvironment. 
Moreover, different capacity of the antioxidant system among cancer cells may also 
render their different levels of ROS. 
On the other hand, cancer cells exhibit different levels of sensitivity to ROS-stimulating 
agents. Variations in the efficiency of the mitochondrial apoptosis signalling pathways 
among the cancer cells may also explain their different responses to the drugs. 
The Ishikawa and Caco-2 cell lines were employed as in vitro models in the downstream 
investigations to represent cancer cells with the lowest and highest baseline intracellular 
ROS levels respectively, with the aim of understanding why cancer cells with different 
baseline ROS levels also respond differently to ROS-induced cell death. 
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In this chapter, we report our investigation on the link between the relative expression 
levels of the antioxidant enzymes and the baseline intracellular ROS level in both cell 
lines. Implications of the key genes associated with the mitochondrial apoptosis pathway 
and drug resistance were also assessed. 
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4.2 Results 
4.2.1 Comparable mitochondrial organelle content levels in Ishikawa and Caco-2 
with higher mitochondrial DNAcn in Caco-2 
To correlate the differences in the baseline intracellular ROS level between the Ishikawa 
and Caco-2 cells to the mitochondrial function of each cell line, the baseline physical 
mitochondrial content level and mitochondrial DNA copy number in both cell lines were 
measured. MitoTracker™ Red CMXRos, a red-fluorescent dye that passively diffuses 
across the plasma membrane and accumulates in active mitochondria was used to 
determine mitochondrial content level. 
As shown in Figure 4.1, comparable mitochondrial content levels were detected in the 
Ishikawa and Caco-2 cells with higher mtDNAcn observed in the Caco-2 cells.  
 
Figure 4.1. Mitochondrial content level and mitochondrial DNA copy number in Ishikawa and Caco-2. (a) 
Mitochondrial content levels of the Ishikawa and Caco-2 cells measured by MitoTracker. (b) Relative copy 
numbers of mtDNA in Ishikawa and Caco-2 normalised against the house keeping gene (β-actin). Data are 
mean ± SEM (N=3); p value comparing Caco-2 and Ishikawa was calculated using a two-tailed t-test; ns, 
not significant and ***p<0.001. 
 
4.2.2 Higher NADPH oxidases expression in Ishikawa 
The membrane-bound enzyme family of NADPH oxidases (NOXs) is an important group 
of signalling mediators associated with the generation of ROS. To elucidate their 
influence on the baseline intracellular ROS levels between the Ishikawa and Caco-2 cells, 
the relative baseline expression levels of the NOX isoforms were investigated by 
quantitative reverse transcription polymerase chain reaction (TaqMan qPCR) in both cell 
lines.  
As shown in Figure 4.2, the relative baseline expression levels of NOX1, 2, 5 and DUOX1 
were significantly higher in the Ishikawa cells compared to the Caco-2 cells with NOX1 
being the most expressed isoform. NOX3 and NOX4 were not detected in either of the 
two cell lines. 
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Figure 4.2. Comparison of the relative expression levels of NOX family between the untreated Ishikawa 
and Caco-2 cells. The columns represent the relative gene expression levels of the NOX1 (a), NOX2 (b), 
NOX5 (c) and DUOX1 (d) using TaqMan qPCR. Data are mean ± SEM (N=3 separate experiments); p 
values comparing Ishikawa and Caco-2 were calculated using two-tailed t-test; ns, not significant, *p<0.05 
and ***p<0.001.  
 
4.2.3 Higher anti-oxidants expression observed in Ishikawa 
To demonstrate the influence of the antioxidant system on the differences in the redox 
status between the Ishikawa and Caco-2 cells, the antioxidant profiles of the two cell lines 
were compared.  
The TaqMan qPCR results showed that the relative baseline gene expression levels of the 
four antioxidant genes, SOD1, SOD2, CAT and GPx, were significantly higher in the 
Ishikawa cells compared to the Caco-2 cells. Moreover, the relative baseline expression 
level of the nuclear factor erythroid 2-related factor 2 (Nrf2), a prime regulator of redox 
homeostasis in response to oxidative stress, was also significantly higher in the Ishikawa 
cells (Figure 4.3 a-e). The mRNA expression patterns of SOD1, SOD2 and CAT genes in 
the Ishikawa and Caco-2 cells were largely mirrored at the protein expression level as 
observed by western blot (Figure 4.3 f-h). However, the protein expression of GPx and 
Nrf2 were not analysed in this study due to technical issues with the antibodies. 
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Figure 4.3. Comparison of the relative expression levels of antioxidants between the untreated Ishikawa 
and Caco-2 cells. The columns represent the relative gene expression levels of the SOD1 (a), SOD2 (b), 
CAT (c), GPx (d) and Nrf2 (e) using TaqMan qPCR. Western blots showing the protein levels of SOD1 (f), 
SOD2 (g) and CAT (h) in the Ishikawa and Caco-2 cells. The columns represent the protein levels 
normalised against the loading control protein β-actin. Data are mean ± SEM (N=3 separate experiments); 
p values comparing Ishikawa and Caco-2 were calculated using two-tailed t-test; *p<0.05 and **p<0.01.  
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4.2.4 Upregulation of mitochondria-related survival genes in Caco-2 
To elucidate the impact of the variations in baseline ROS level on the mitochondrial 
dynamics, some key mitochondrial adaptation mechanisms were studied in Ishikawa and 
Caco-2. 
The relative baseline expression levels of genes related to mitochondria conservation and 
protection of cells from stress-induced mitochondrial dysfunction such as optic atrophy 1 
(OPA1) and PTEN-induced kinase 1 (PINK1) were evaluated using TaqMan qPCR. The 
results showed that the expression levels of both OPA1 and PINK1 genes were 
significantly higher in the Caco-2 cells compared to the Ishikawa cells (Figure 4.4). 
 
Figure 4.4. Comparison of the relative expression levels of the OPA1 (a) and PINK1 (b) genes between 
the untreated Ishikawa and Caco-2 cells. The columns represent the relative expression levels of the genes 
using TaqMan qPCR. Data are mean ± SEM (N=3 separate experiments); p values comparing Ishikawa and 
Caco-2 were calculated using two-tailed t-test; *p<0.05 and **p<0.01.  
 
4.2.5 Higher levels of pro-apoptotic proteins and drug resistance gene expression 
in Ishikawa 
To gain further insights into the reasons for different sensitivity levels between the 
Ishikawa and Caco-2 cells towards the treatments, the relative baseline expression levels 
of some key genes involved in the intrinsic apoptosis pathway were investigated.  
The TaqMan qPCR results showed that the relative baseline expression level of the anti-
apoptotic gene BCL-XL was significantly higher in the Caco-2 cells (Figure 4.5 a) 
whereas all pro-apoptotic genes, BAX, APAF-1 and cytochrome c, were significantly 
higher in the Ishikawa cells (Figure 4.5 b-d). The mRNA expression patterns of the     
BCL-XL and BAX genes in the Ishikawa and Caco-2 cells were largely mirrored at the 
protein expression level as observed by western blot (Figure 4.5 e-f). However, the 
protein expression of APAF-1 and cytochrome c were not analysed in this study due to 
technical issues. 
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Figure 4.5. Comparison of the relative expression levels of apoptosis-associated genes between the 
untreated Ishikawa and Caco-2 cells. The columns represent the relative gene expression levels of the    
BCL-XL (a), BAX (b), APAF-1 (c) and Cyt C (d) using TaqMan qPCR. Western blots showing the protein 
levels of BCL-XL (e) and BAX (f) in the Ishikawa and Caco-2 cells. The columns represent the protein 
levels normalised against the loading control protein β-actin. Data are mean ± SEM (N=3 separate 
experiments); p values comparing Ishikawa and Caco-2 were calculated using two-tailed t-test; *p<0.05 
and **p<0.01.  
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The multi-drug resistance protein 1 (MDR1) is an important protein of the cell membrane 
that acts as an efflux pump for many foreign substrates. Therefore, the expression level 
of MDR1 was investigated to elucidate its impact on the differences in drug sensitivity 
between the Ishikawa and Caco-2 cells towards the treatments. The TaqMan qPCR results 
showed that the relative baseline expression level of the MDR1 gene was significantly 
higher in the Ishikawa cells compared to the Caco-2 cells (Figure 4.6). 
 
Figure 4.6. Comparison of the relative gene expression levels of the MDR1 gene between the untreated 
Ishikawa and Caco-2 cells. The columns represent the relative expression levels of the gene using TaqMan 
qPCR. Data are mean ± SEM (N=3 separate experiments); p values comparing Ishikawa and Caco-2 were 
calculated using two-tailed t-test; ****p<0.0001.  
 
4.2.6 Enhanced DNA repair in Caco-2 
Cells with higher baseline ROS levels are expected to have higher potential for DNA 
damage, and therefore cells enhance their DNA repair systems to avoid the accumulation 
of DNA damage and grant cell survival. To elucidate the impact of the variations in 
baseline ROS level on cell’s response to DNA damage, the activation of the ATR-Chk1 
pathway and expression levels of a key player engaged in other DNA repair mechanisms 
(OGG1) were analysed and compared in the Ishikawa and Caco-2 cells. 
The TaqMan qPCR and western blotting results showed that the relative baseline 
expression levels of the OGG1 gene and protein were significantly higher in the Caco-2 
cells compared to the Ishikawa cells (Figure 4.7 a & b).  
Western blotting results showed that the phosphorylated proteins of Chk1 at Ser-317 and 
ATR at The-1989 were significantly higher in the Caco-2 cells (Figure 4.7 c & d) 
indicating that the ATR-Chk1 pathway was markedly over activated in the Caco-2 cells 
compare to the Ishikawa cells. 
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Figure 4.7. Comparison of the relative expression levels of OGG1 and the activation of the ATR-Chk1 
pathway between the untreated Ishikawa and Caco-2 cells. (a) Comparison of the relative gene expression 
levels of the OGG1 gene between untreated Ishikawa and Caco-2. The columns represent the relative gene 
expression levels of the OGG1 using TaqMan qPCR. Western blots showing the protein levels of OGG1 
(b) and phosphorylated ATR (pATR) (c) and phosphorylated Chk1 (pChk1) (d) in Ishikawa and Caco-2. 
The columns represent the protein levels normalised against the loading control protein β-actin for OGG1, 
and total ATR and Chk1 for pATR and pChk1, respectively. Data are mean ± SEM (N=3 separate 
experiments); p values comparing Ishikawa and Caco-2 were calculated using two-tailed t-test; *p<0.05, 
**p<0.01 and ***p<0.001.  
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4.3 Discussion 
Among the cancer cell lines enrolled in our study, Ishikawa (endometrium) and Caco-2 
(colon) were employed as in vitro models in the downstream investigations to represent 
cancer cells with the lowest and highest baseline intracellular ROS levels respectively. 
Given that both cell lines belong to different tissue origins, certain cellular and molecular 
factors might have led to the variations in the baseline intracellular ROS level as well as 
the sensitivity towards ROS-stimulating agents between these two cell lines.  
In this chapter, such differences between the Caco-2 and Ishikawa cells are explained 
based on some of the key molecular mechanisms for ROS-related drug resistance. 
4.3.1 Higher intracellular ROS level linked to higher mtDNAcn 
Mitochondria are well known to be the powerhouse of the cell, and the amount of ATP 
produced in mitochondria is influenced by the abundance of the organelles and the 
number of mtDNA copies according to the cell type and the physiological conditions 
[105].  
Since mitochondria are the primary source of intracellular ROS as side-products of the 
mitochondrial electron transport chain reaction during cellular respiration (reviewed in 
Ref. [65]), it was necessary to compare the mitochondrial content levels between 
Ishikawa and Caco-2 in order to evaluate the impact of mitochondrion quantity on their 
ROS levels. Interestingly, comparable mitochondrial content levels were detected in the 
Ishikawa and Caco-2 cells using the MitoTracker™ Red CMXRos staining in our study. 
This result indicates that the difference in the baseline ROS level between Ishikawa and 
Caco-2 may be independent of the abundance of mitochondria within the cells. This 
finding also suggests that the baseline ROS level (either intracellular or mitochondrial 
superoxide) might be more indicative of drug response compared to the abundance of the 
organelles in the cells. 
Generally, cancer cells with a higher demand for ATP can increase their mtDNAcn in 
each mitochondrion to produce more subunits for the OXPHOS or upregulate  
mitochondrial fission to produce additional copies of the existing organelles; either of the 
two mechanisms helps the cell achieve the required energy. Therefore, it appears that the 
Caco-2 cells require a higher level of cellular energy compared to the Ishikawa cells, and 
this is achieved by increasing the mtDNAcn only without the need for mitochondrial 
replication. 
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It is widely acknowledged that each mitochondrion can contain 2-10 copies of the 
mitochondrial genome [87], and its copy number is preserved within a stable range to 
achieve the required energy of the cell and hence to ensure normal physiological functions 
[146]. Therefore, since the Caco-2 cells had higher mtDNAcn compared to the Ishikawa 
cells, we speculate that the average copy number of mtDNA per mitochondrion must be 
far greater in a single Caco-2 cell than that in a single Ishikawa cell. In addition, our data 
suggest that the copy number of the cell’s mtDNA, rather than its mitochondrion quantity, 
may have a more influential role in mitochondrial superoxide production. 
 
4.3.2 Different redox statuses between Caco-2 and Ishikawa 
The NADPH oxidases (NOXs) are important sources of cellular reactive oxygen species. 
Seven NOX homologues are present in the human genome: NOX1-5, DUOX1 and 
DUOX2 which differ in their expression level and type of ROS release (reviewed in Ref. 
[309]). It has been reported that ROS generated by the NOXs are essential for cell growth 
in prostate cancer cells [208]. Therefore, the relationship between the baseline ROS levels 
and the mRNA expression levels of the NOX isoforms in Ishikawa and Caco-2 was 
determined. 
Interestingly, our results showed that NOX1, NOX2, NOX5 and DUOX1 were 
significantly overexpressed in the Ishikawa cells compared to the Caco-2 cells whereas 
NOX3 and NOX4 were not expressed in either of the cell lines. This observation could 
have been translated into the outcome that Ishikawa should be the cell line with the higher 
ROS level, which was not the case in our study (our DCFDA and MitSOX results showed 
that Caco-2 had the highest ROS level among the 4 cancer cell lines). This finding 
suggests that the overexpression of NOXs in the Ishikawa cells has not resulted in an 
overall high level of intracellular ROS in Ishikawa. It also indicates that mitochondria are 
the main source of ROS generation in the cells investigated in our study. Collectively, the 
above observations strongly indicate that mitochondrial genetic abnormalities would have 
been the main influencer in ROS production (further discussion will be covered in 
Chapter 6).  
To gain further insight into the reason behind the different baseline ROS levels between 
the Ishikawa and Caco-2 cells, the expression levels of four antioxidant enzymes, SOD1, 
SOD2, CAT and GPx, and the expression level of the transcription factors Nrf2 which 
regulates the expression of genes involved in the cellular antioxidant system were 
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analysed. Our data showed that the expression levels of these antioxidant genes were 
significantly lower in the naïve Caco-2 cells compared to Ishikawa. This could explain 
the differences in the baseline ROS level between the two cell lines, since cells producing 
less antioxidants are expected to have an inefficient ROS scavenging system, resulting in 
higher baseline ROS level in those cells. 
All the aforementioned data elucidate that different ROS levels in the two cell lines are 
related to the variations in their mitochondrial function and antioxidant systems, making 
them good candidates for our in vitro study. 
 
4.3.3 Greater adaptability of Caco-2 to oxidative stress 
To test our theory that the different ROS-associated drug sensitivity levels seen in 
Ishikawa and Caco-2 were affected by the variations in their mitochondrial abnormalities, 
the expression levels of genes related to mitochondrial function were evaluated by 
TaqMan qRT-PCR.  
The optic atrophy 1 (OPA1) is a nuclear-encoded mitochondrial protein. It localises on 
the inner mitochondrial membrane and helps regulate mitochondrial stability and energy 
output. It also mediates the fusion of inner membranes to facilitate the union of two 
mitochondria into one mitochondrion. This fusion phenomenon helps cells moderate 
stress by sharing multiple elements that sustain mitochondrial biology [9].  Moreover, 
stabilisation of mitochondrial cristae by OPA1 protects cells from mitochondrial 
dysfunction, cytochrome c release and ROS-induced damage, thus preventing cell death 
[310]. 
Indeed, our results showed that the OPA1 gene was overexpressed in the Caco-2 cells 
compared to the Ishikawa cells confirming the adaption of the Caco-2 cells to the 
escalated oxidative stress condition, which may result in their enhanced resistance to 
ROS-stimulating agents.  
Our result was in agreement with that reported by Fang et al. [311] who showed that lung 
cancer cells with higher OPA1 expression were more resistant to cisplatin. Moreover, a 
study conducted by Santin el al. demonstrated that OPA1-mediated mitochondrial fusion 
was responsible for cisplatin resistance in the neuroblastoma B50 rat cells, and silencing 
the expression of OPA1 mitigated the cisplatin resistance [312]. 
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Mitophagy is a fundamental process which contributes to mitochondrial quality control 
and exploits the same core machinery of autophagy through the formation of 
autophagosomes and autolysosomes (reviewed in Ref. [313]). However, several 
mitophagy effectors have been identified including the mitophagy receptors such as NIX, 
BNIP3 and FUDNC1 and several mediators in the PINK1/Parkin pathway [15,314]. 
PTEN-induced kinase 1 (PINK1) is a mitochondrial serine/threonine-protein kinase 
encoded by the PINK1 gene that plays a role in protecting cells from stress-induced 
mitochondrial dysfunction. PINK1 is involved with mitochondrial quality control by 
identifying damaged mitochondria and targeting specific mitochondria for degradation. 
Its activity causes the parkin protein (a ubiquitin ligase that plays a critical role in 
ubiquitination) to bind to depolarised mitochondria and subsequently induce selective 
autophagy of those mitochondria (mitophagy) [315,316]. PINK1 has also been shown to 
facilitate the generation of mitochondria-derived vesicles which can shuttle ROS toward 
lysosomes for degradation [317]. 
Indeed, our results showed that PINK1 gene was overexpressed in the Caco-2 cells 
compared to the Ishikawa cells, indicating the greater capability of Caco-2 to adapt to the 
increased oxidative stress condition. This was achieved by upregulating the pro-survival 
mechanism through the elimination of the dysfunctional mitochondria, and as a result of 
it, the Caco-2 cells also became more resistant to ROS-stimulating agents.  
Our observation was echoed by Su et al. [318] who demonstrated that triggering 
mitophagy by overexpression of galactin-1 (Gal-1, a protein encoded by the LGALS1 gene 
and involved in many biological processes such as cell proliferation, differentiation and 
tumour progression) resulted in cisplatin resistance in hepatocellular carcinoma. This 
study showed that Gal-1 was capable of reducing the loss of mitochondrial potential and 
apoptosis induced by cisplatin treatment by inducing mitophagy via BNIP3 upregulation 
[318]. Moreover, other studies demonstrated that inhibition of the mitophagy pathways 
and downregulation of the mitophagy receptors such as  BNIP3 and FUDNC1 
chemosensitised cancer cells [319,320]. A study by Datta et al. [321] has also shown that 
inhibition of autophagy with chloroquine prevented the development of paclitaxel 
resistance and potentiated the effect of paclitaxel by increased accumulation of 
superoxide-producing damaged mitochondria. 
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A recent study by Green et al. [322] has shown that telomerase, beside its role in telomere 
stabilisation, seems to play a role in the response to oxidative stress. Results suggest that 
the cells expressing the mutant telomerase had significant increases in autophagy markers 
as a response to H₂O₂ challenge. These results suggest that the loss of hTERT in 
mitochondria initiates a signalling cascade that allows for cells to adapt to and cope with 
the lack of mitochondrial telomerase. Such effects also influence the cellular response to 
oxidative damage. 
Given that both OPA1 and PINK1 are overexpressed in the Caco-2 cells compared to the 
Ishikawa cells, it is speculated that the Caco-2 cells have greater potential to cope with 
severe oxidative stress induced by the treatments and therefore are more resistant than 
Ishikawa. 
 
4.3.4 Higher resistance in Caco-2 
Many mechanisms may contribute to cisplatin resistance including the inhibition of 
apoptosis, increased drug efflux, upregulation of DNA repair and other survival 
mechanisms (reviewed in Ref. [323]). However, different cancer cells display various 
levels of resistance according to the efficiency of their mechanisms. Therefore, how 
Ishikawa and Caco-2 responded to ROS-induced apoptosis was investigated with a focus 
on the pro- and anti-apoptotic pathways.  
Beside their vital role in biosynthetic processes such as ATP generation, mitochondria 
play a central role in apoptotic cell death (reviewed in Ref. [52]). The mitochondrial 
intrinsic pathway is highly regulated by certain members of the BCL-2 protein family 
which control the release of pro-apoptotic proteins that facilitate the activation of caspase 
9, such as cytochrome c, leading to apoptosis [26].  
Given the importance of the role of mitochondria in apoptosis, it is not surprising that 
downregulation of pro-apoptotic BCL-2 family proteins as well as overexpression of anti-
apoptotic BCL-2 family proteins have the propensity to allow cells to acquire resistance 
to apoptosis [35]. Several studies have shown that cancer cells overexpress anti-apoptotic 
proteins (e.g. BCL-XL) that inhibit the function of the key apoptotic effectors BAX or 
BAK and consequently prevent the formation of permeable pores and the release of pro-
apoptotic molecules such as cytochrome c (reviewed in Ref. [52]). 
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To correlate the drug sensitivity level to the apoptosis condition in the Ishikawa and  
Caco-2 cells, the relative mRNA and protein levels of the key apoptosis mediators were 
analysed. Our data showed that the expression level of the anti-apoptotic protein         
BCL-XL was significantly lower in the naïve Ishikawa cells whereas all pro-apoptotic 
proteins BAX, APAF-1 and cytochrome c were significantly lower in the Caco-2 cells. 
Taken together, these results may explain the different drug responses of the two cell 
lines, Ishikawa being more vulnerable to oxidative stress due to higher pro-apoptotic 
activities and low levels of anti-apoptotic proteins whereas Caco-2 being more resistant 
thanks to the more powerful anti-apoptotic mechanisms. 
The correlation between inhibition of apoptosis and drug resistance does not only apply 
to cisplatin but also extends to ROS-stimulating agents generally. As mentioned earlier 
(Section 1.3.6), excessive ROS level is a key factor in facilitating MPTP opening by 
promoting the ubiquitination of the anti-apoptotic protein BCL-2, thus allowing the 
activation and oligomerisation of BAX and BAK resulting in permeabilisation of 
mitochondrial membranes and the release of apoptosis-inducing proteins such as 
cytochrome c (reviewed in Refs. [99,160]). Therefore, it is not surprising that cells with 
higher expression of BCL-XL require more drug to produce sufficient ROS level to abate 
its anti-apoptotic activity. 
On the other hand, enhanced drug efflux can also contribute to the drug-resistance 
phenotype by affecting a net decrease in drug intake. The ABC superfamily is the most 
abundant trans-membrane protein family that plays essential roles in pumping chemo 
drugs out of the cells, leading to reduced drug concentrations in the cells and thus 
resulting in the failure of chemotherapy (reviewed in Ref. [324]). So far, 49 members of 
the ABC superfamily have been discovered and ABCB1, also known as multidrug 
resistance protein 1 (MDR1), is considered as the predominant member because of its 
special role in chemo resistance (reviewed in Refs. [325,326]). MDR1 is a 170 kDa ATP-
dependent membrane transporter that is widely distributed throughout the body and 
pumps many foreign substances out of the cells (reviewed in Ref. [327]). Overexpression 
of MDR1 has been associated with various types of cancers, and several previous studies 
have revealed that cisplatin resistance is correlated with increased expression of MDR1 
and downregulation of MDR1 attenuates cisplatin resistance [328,329]. 
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In our study, since the Caco-2 cells were more resistant to cisplatin compared to the 
Ishikawa cells, we speculated that the Caco-2 cells would have a higher expression level 
of MDR1. Surprisingly, our results showed that the expression level of MDR1 was 
significantly higher in the Ishikawa cells. This observation indicates that the enhanced 
drug efflux in the Ishikawa cell line could not account for its greater cisplatin sensitivity 
compared to Caco-2. It also further confirms that cellular redox status is the main 
regulator of drug response between the two cell lines. However, since only 1 out of 49 of 
the ABC superfamily members was investigated in this study,  it is possible that other 
ABC proteins might be overexpressed in the Caco-2 cells rendering their higher resistance 
to the treatments. Further investigation into the expression levels of other key  members 
of the ABC superfamily would shed some light on this theory. 
The increased rate of repair of cisplatin-induced DNA damages constituting an essential 
mechanism of cisplatin resistance and the consequential decrease in cisplatin-mediated 
cell death has been demonstrated in several human tumour cell lines (reviewed in Ref. 
[330]). Generally, once cisplatin-induced DNA lesions occur, cells must remove them 
otherwise those DNA damages will lead to massive cell death. Several DNA repair 
systems are involved in removing cisplatin-induced DNA damage including nucleotide 
excision repair (NER), mismatch repair (MMR) and base excision repair (BER) [331]. 
Since cells have different baseline ROS levels, it is speculated that those with higher ROS 
levels are more vulnerable to oxidative DNA damage and therefore require an enhanced 
correction mechanism to avoid the accumulation of DNA lesions and to evade cell death. 
Indeed, our results showed that the Caco-2 cells had higher expression level of OGG1 
which mainly removes 8oxoG adducts (the most dominant mutagenic lesions generated 
by ROS) [73]. As mentioned earlier, it has been postulated that the anti-tumour effect of 
cisplatin and dequalinium is associated to ROS generation [270,271,304,332]. Therefore, 
the efficiency of the mechanism responsible for correcting DNA lesions generated by 
ROS could contribute to drug resistance. Having a higher baseline expression level of 
OGG1 might have rendered the higher resistance to ROS-stimulating agents in the Caco-
2 cells compared to the Ishikawa cells. 
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DNA lesions alter the transcription and synthesis of DNA, which in turn triggers an 
orchestrated signal transduction cascade to clear the lesions. Once the cell cycle is 
arrested, adequate time for DNA repair is provided to remove the lesions through various 
mechanisms, or cell death occurs if DNA damage is irreversible (reviewed in Ref. [249]). 
ATR (ataxia telangiectasia and Rad3-related) is essential for sensing DNA damage and 
activating the DNA damage checkpoint, resulting in cell cycle arrest [333]. Once ATR is 
activated in the cell due to DNA damage, it phosphorylates checkpoint kinase 1 (Chk1) 
which facilitates DNA damage repair by activating several repair factors such as PCNA, 
Rad51 and FANCE [196]. ROS-stimulating agents are well known to cause DNA 
damages, and therefore the efficiency of the ATR-Chk1 pathway is highly susceptible to 
influence the level of response to the treatments. The best way to evaluate the correlation 
of the cisplatin / dequalinium resistance with the ATR-Chk1 pathway is to examine and 
compare the activation state of ATR-Chk1 in both Ishikawa and Caco-2 cells.  
Our results showed that the phosphorylation of ATR and Chk1 was significantly higher 
in the naïve Caco-2 cells compared to the Ishikawa cells. Knowing that the Caco-2 cells 
have a higher baseline ROS level which might result in a higher rate of DNA damage, it 
would be well acceptable to conclude that the elevated ROS production has reinforced 
the active status of the ATR-Chk1 pathway in the Caco-2 cells for them to survive high 
frequency of DNA damage compared to Ishikawa. 
Taking all together, higher baseline ROS levels act as a driving force to promote 
resistance to ROS-stimulating agents by activating the ATR-Chk1 pathway. 
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4.4 Summary 
This chapter focused on the differential cellular and molecular profiles of the Ishikawa 
and Caco-2 cells and their impact on baseline intracellular ROS levels as well as drug 
sensitivity observed in both cell lines.  
It was concluded that the variable ROS levels were mainly due to specific mitochondrial 
abnormalities and antioxidant system capacity of the cells.  
Moreover, it was suggested that higher adaptability for oxidative stress via enhanced 
DNA repair mechanisms and upregulated anti-apoptotic pathways might explain 
increased resistance to ROS-stimulating agents, as observed in the Caco-2 cells in 
comparison with the Ishikawa cells. 
Therefore, although the Ishikawa and Caco-2 cells belong to different tissue origins, 
which may cause some limitations to our study, the aforementioned data assert that the 
Ishikawa and Caco-2 cells are good in vitro models to investigate the possible underlying 
mechanisms of differential response to ROS-stimulating therapy.
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5.1 Introduction 
Playing a critical role in the regulation of apoptosis pathways makes mitochondria an 
attractive target for cancer therapy. Therefore, several therapeutic approaches have been 
proposed to target mitochondria for tumour elimination (reviewed in Ref. [99]). 
The anti-apoptotic BCL-2 family proteins are well known to be overexpressed in many 
cancers and associated with cancer initiation and resistance to therapy by their attenuating 
the release of cytochrome c and inactivating other pro-apoptotic proteins. Therefore, 
preventing the interaction between the anti-apoptotic proteins (e.g. BCL-XL) and the 
apoptosis effectors (such as BAK and BAX) to allow pore formation in outer 
mitochondrial membrane (OMM) is one of the main strategies in cancer treatments 
(reviewed in Ref. [217]). 
In this respect, elevated ROS levels have been shown to abate the anti-apoptotic activity 
of BCL-2 and to abrogate the ubiquination of BAX and BAD, thus allowing the activation 
and oligomerisation of BAX and BAK that result in the formation of a VDAC (voltage-
dependent anion channel)-containing pore and permeabilisation of mitochondrial 
membranes to facilitate cytochrome c release (reviewed in Ref. [160]). Moreover, 
excessive ROS production has been shown to be a key factor in facilitating the induction 
of mitochondrial permeability transition (MPT) following oxidative modification of ANT 
(adenine nucleotide translocase), a major component of the MPT pore, thus resulting in 
cytochrome c release (reviewed in Ref. [99]). 
Modulating the mitochondrial respiratory chain activity is another approach to cancer 
treatment (reviewed in Ref. [99]). Inhibition of OXPHOS by several inhibitors or by 
targeting the mitochondrial genome to form drug-mtDNA adducts has been shown to 
induce apoptosis mediated by ROS overproduction [86,99]. 
In this chapter, we report our investigation on the contribution of treatment-induced 
intracellular ROS to cell death. The modes of action of the two compounds and their 
combination were also assessed. 
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5.2 Results 
5.2.1 Reduced cell death upon elimination of ROS 
To elucidate the role of elevated intracellular ROS in cell death, cell viability of the 
Ishikawa and Caco-2 cells was evaluated upon the elimination of treatment-induced ROS 
by ROS scavenger. The MTS assay results showed that the cell death induced by CDDP, 
DQA and the combined treatment was significantly reduced by pre-incubation with         
N-Acetylcysteine (NAC; a powerful antioxidant) (Figure 5.1 a & b). Those data showed 
that cell death attenuation with the combined therapy in Caco-2 was more significant than 
that with the single treatments, whereas the attenuation in Ishikawa was comparable 
amongst different treatments. Furthermore, cell death attenuation upon pre-incubation 
with NAC was more significant in Ishikawa compared to Caco-2 (Figure 5.1 c). 
 
Figure 5.1. Effect of ROS generation on cell viability in the Caco-2 and Ishikawa cells detected by MTS 
assay. (a & b) Increased cell viability of Caco-2 and Ishikawa upon pre-incubation with NAC (10 mM) 
prior to the drug treatments. The columns represent the fold changes in cell viability normalised against 
NAC-free treatment. Data are mean ± SEM (N=3 separate experiments); p values comparing NAC-free and 
NAC-pre-incubated cells were calculated using one-way ANOVA with Tukey multiple comparison post-
hoc analysis; ns, not significant, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. (c) Comparison of 
the changes in cell viability between Caco-2 and Ishikawa upon pre-incubation with NAC. Data are mean 
± SEM (N=3 separate experiments); p values comparing Caco-2 and Ishikawa were calculated using two-
tailed t-test; *p<0.05 and **p<0.01.  
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The same trend of results was observed using the ApoTox-Glo™ Triplex Assay kit where 
cell viability and cytotoxicity were assessed by measuring two protease activities; one is 
a marker for cell viability and the other a marker for cytotoxicity. Results might not be 
statistically significant as they present data from just two experiments, however they 
appear to be consistent with the previous results. 
Data in Figure 5.2 a & b confirm that the IC50s of CDDP and DQA (determined using 
MTS assay) caused 50% cell death and the combined treatment of CDDP and DQA at 
half of their IC50 concentrations resulted in further cell death in both cell lines. Data in 
Figure 5.2 c & d also show that the combined treatment of CDDP and DQA at half of 
their IC50 concentrations caused a marked increase in cytotoxicity compared to the single 
treatment in both cell lines. More importantly, the pre-incubation with NAC resulted in 
attenuations in cell death and cytotoxicity in both cell lines, more observed in the 
Ishikawa cells (Figure 5.2 a-d). 
 
Figure 5.2. Effect of ROS generation on cell viability and cytotoxicity in the Caco-2 and Ishikawa cells 
detected using the ApoTox-Glo™ Triplex Assay kit. (a & b) Increased cell viability of Caco-2 and Ishikawa 
upon pre-incubation with NAC (10 mM) prior to the drug treatments. The columns represent cell viability 
under various treatment conditions normalised against the untreated controls. (c & d) Decreased 
cytotoxicity of Caco-2 and Ishikawa upon pre-incubation with NAC (10 mM) prior to the drug treatments. 
The columns represent cytotoxicity under various treatment conditions normalised against the untreated 
controls. Data are mean ± SEM (N=2 separate experiments).  
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5.2.2 Apoptosis events revoked upon elimination of ROS 
Apoptosis and necrosis events were analysed by determining the cell surface exposure of 
phosphatidylserine (PS) and measuring propidium iodide (PI)-stained cells using flow 
cytometry. Early (annexin V-FITC (+)/PI (-)) and late (annexin V-FITC (+)/PI (+)) 
apoptosis events were significantly observed in both cell lines after 24 hours of incubation 
with CDDP, DQA and their combination. Data in Figure 5.3 show that pre-incubation 
with NAC resulted in a significant decrease in apoptosis events. Greater degrees of 
attenuation in apoptosis were clearly observed in the Ishikawa cells compare to the Caco-
2 cells in all treatments. 
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Figure 5.3. Effect of ROS generation on apoptotic cell death in the Caco-2 and Ishikawa cells detected by 
Annexin V-FITC/PI double staining. (a & b) Representative dot plot diagrams of flow cytometry assays 
with Annexin V-FITC/PI double staining of untreated cells, treated cells with/without NAC pre-incubation 
for Caco-2 and Ishikawa. Dots in the lower left quadrant area represented intact cells which were A-/PI-; 
dots in the lower right quadrant area represented early apoptotic cells which were A+/PI-; dots in the upper 
right quadrant area represented late apoptotic or necrotic cells which were A+/PI+; dots in the upper left 
quadrant area represented necrotic cells which were A-/PI+. (c & d) Percentage of cells obtained from the 
corresponding dot plot diagrams of Caco-2 and Ishikawa. Percentages are presented as the mean ± SEM 
(N=3 separate experiments); p values comparing NAC-free and NAC-pre-incubated cells undergone the 
same CDDP/DQA treatments were calculated using two-tailed t-test; **p<0.01 and ***p<0.001.  
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To confirm apoptosis cascades and the impact of ROS generation induced by the 
treatments, caspase activation was measured using the ApoTox-Glo™ Triplex Assay kit. 
Data in Figure 5.4 a & b show a marked level of caspase-3/7 activation upon the 
treatments which was suppressed by NAC pre-incubation in both cell lines. Results might 
not be statistically significant as they present data from just two experiments, however 
they appear to be consistent with the previous results. 
 
Figure 5.4. Effect of ROS generation on caspase activation. Caspase activity assay showing changes in 
caspase-3/7 activity in the Caco-2 (a) and Ishikawa (b) cells upon the treatments for 24 h and the effect 
of NAC pre-incubation in attenuating these changes in both cell lines. The columns represent the fold 
changes of caspase-3/7 activity normalised against the untreated cells. Data are mean ± SEM (N = 2 
separate experiments); p values comparing CDDP/DQA-treated and -untreated cells without NAC pre-
incubation were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; 
**p<0.01 and ***p<0.001. p values comparing NAC-free and NAC-pre-incubated cells undergone the 
same CDDP/DQA treatments were calculated using two-tailed t-test; *p<0.05 and **p<0.01.  
 
5.2.3 Excessive level of ROS provoked intrinsic apoptosis pathway 
To further confirm that the cell death was due to ROS-induced apoptosis upon the 
treatments, apoptosis-associated proteins were measured in cells with or without the pre-
incubation of NAC. For the cells without NAC pre-incubation, western blotting data 
showed significant decreases in the anti-apoptotic protein, BCL-XL, upon the treatments 
in both cell lines (p<0.0001; Figure 5.5 a & b), whereas the release of cytochrome c was 
significantly increased upon the treatments (p<0.0001; Figure 5.5 c & d). All the above 
events were significantly attenuated by NAC pre-incubation (Figure 5.5). 
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Figure 5.5. Effect of ROS generation on apoptosis-related proteins. Western blots showing changes in 
the protein levels of BCL-XL (lower bands, a & b) and the release of cytochrome c (c & d) in the Caco-
2 and Ishikawa cells upon the treatments at 24 h and the effect of NAC pre-incubation in attenuating 
these changes. The columns represent the fold changes of the protein levels normalised against the 
loading control protein, β-actin. Data are mean ± SEM (N = 3 separate experiments); p values comparing 
CDDP/DQA-treated and -untreated cells without NAC pre-incubation were calculated using one-way 
ANOVA with Tukey multiple comparison post-hoc analysis; ***p<0.001 and ****p<0.0001. p values 
comparing NAC-free and NAC-pre-incubated cells undergone the same CDDP/DQA treatments were 
calculated using two-tailed t-test; **p<0.01, ***p<0.001 and ****p<0.0001.  
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Mitochondrial permeability transition pore (MPTP) is a mega channel complex involved 
in the intrinsic apoptosis process by releasing cytochrome c from intermembrane space 
(IMS) to cytosol. The main components of MPTP are VDAC in the outer mitochondrial 
membrane and ANT in the inner mitochondrial membrane (IMM) (reviewed in Ref. 
[334]). To determine the effect of the treatments on the structure of MPTP and the 
possible changes in MPTP caused by increased ROS production, the expression level of 
the voltage-dependent anion channel 1 (VDAC1) protein was measured in cells with or 
without the pre-incubation of NAC.  
Western blotting data showed no significant changes in the VDAC1 protein expression 
upon the treatments irrespective of NAC pre-incubation in both cell lines (Figure 5.6 a & 
b). 
 
Figure 5.6. Effect of ROS generation on the VDAC1 protein expression. Western blots showing no 
significant changes in the protein levels of VDAC1 in the Caco-2 (a) and Ishikawa (b) cells upon treatments 
at 24 h and no obvious effect of NAC pre-incubation in both cell lines. The columns represent the fold 
changes of the protein levels normalised against the loading control protein, β-actin. Data are mean ± SEM 
(N = 3 separate experiments); p values comparing CDDP/DQA-treated and -untreated cells without NAC 
pre-incubation were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; 
ns, not significant. p values comparing NAC-free and NAC-pre-incubated cells undergone the same 
CDDP/DQA treatments were calculated using two-tailed t-test; ns, not significant.  
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5.2.4 Expression levels of mitochondrial function-associated genes altered upon 
the treatments 
To assess potential mitochondrial dysfunction caused by the treatments, the expression 
levels of optic atrophy 1 (OPA1), endonuclease G (ENDOG) and ribonucleotide reductase 
regulatory TP53 inducible subunit M2B (RRM2B) were evaluated by TaqMan qPCR. 
OPA1 was downregulated in the Caco-2 and Ishikawa cells in the presence of all 
treatments with a further decrease in the combined therapy in both cell lines (Figure 5.7 
a & d). ENDOG was upregulated in both cell lines in the presence of all treatments with 
a further elevation in the DQA-alone and the combined treatments in Caco-2 (Figure 5.7 
b), and in the cisplatin-alone treatment in Ishikawa (Figure 5.7 e). RRM2B was also 
upregulated in both cell lines with a further increase in the DQA-treated Caco-2 cells 
(Figure 5.7 c & g). 
 
Figure 5.7. Expression level changes of the OPA1, ENDOG and RRM2B genes in the Caco-2 (a-c) and 
Ishikawa (d-f) cells upon the treatments at 24 h. The columns represent the fold changes of the relative 
expression levels of the genes normalised against the untreated controls. Data are mean ± SEM (N = 3 
separate experiments); p values comparing treated and untreated cells were calculated using one-way 
ANOVA with Tukey multiple comparison post-hoc analysis; ns, not significant, *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001.  
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5.2.5 Expression levels of anti-oxidant genes altered upon treatments 
To gain further insight into the mechanisms underlying treatment-induced ROS 
production, the expression levels of the antioxidant genes upon the treatments were 
investigated by TaqMan qPCR.  
Interestingly, all genes were significantly upregulated in the Caco-2 cells in the presence 
of DQA but no significant changes were observed with CDDP or the combined therapy 
for SOD1, SOD2 and CAT (Figure 5.8 a-c). However, the GPx and Nrf2 genes were 
significantly upregulated in the presence of all treatments (Figure 5.8 d & e).  
In the Ishikawa cells, SOD1 was significantly upregulated in the presence of CDDP, 
whereas a significant downregulation in the combined therapy was observed (Figure 5.8 
f). SOD2 did not show any significant changes upon the treatments (Figure 5.8 g) while 
CAT was significantly downregulated in the presence of all treatments with a further 
decrease in the combined therapy (Figure 5.8 h). GPx was significantly upregulated only 
in the presence of CDDP (Figure 5.8 i) while Nrf2 showed a significant upregulation only 
with DQA (Figure 5.8 j). 
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Figure 5.8. Changes in expression levels of major antioxidant genes in the Caco-2 (a-e) and Ishikawa (f-
j) cells upon the treatments at 24 h. The columns represent the fold changes of the relative expression 
levels of the genes normalised against the untreated controls. Data are mean ± SEM (N = 3 separate 
experiments); p values comparing treated and untreated cells were calculated using one-way ANOVA 
with Tukey multiple comparison post-hoc analysis; ns, not significant, *p<0.05, **p<0.01 and 
***p<0.001.  
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5.3 Discussion 
As previously reported, CDDP and DQA accumulate in mitochondria and exert their 
antitumor effect through increased ROS generation and mitochondrial disruption 
[240,267,270]. To confirm this, NAC was administered to the cells prior to the drug 
treatments to elucidate the role of treatment-induced ROS in cell death.  
In this chapter, the implication of ROS production upon the treatments in cell death is 
analysed and discussed. 
5.3.1 ROS as the main contributor in cell death 
When NAC was administered to the cells prior to the drug treatments, cell viability was 
significantly restored, indicating the critical role of enhanced ROS production in 
triggering cell death upon various CDDP and DQA treatments. It should be noted that in 
the Caco-2 cells, the rescue of cell viability with the combined therapy was more 
significant than that with the single treatment, which was in alignment with the highest 
ROS production level upon the combined treatment as compared to the single treatment 
(discussed in Chapter 3). However, comparable rescue effects were observed in the 
Ishikawa cells irrespective of the treatments, indicating an equal (or non-treatment-
specific) production level of ROS following the treatments, which was indeed the case as 
supported by the ROS data of the Ishikawa cells (discussed in Chapter 3). Furthermore, 
the rescue of cell viability by NAC was generally more effective for Ishikawa compared 
to Caco-2, indicating that ROS had a more important role in mediating cell death in 
Ishikawa. 
Those results were further confirmed by a parallel trend in terms of the rescue of cell 
viability and the attenuation of cell toxicity with NAC pre-incubation, as indicated by 
data from the ApoTox-Glo™ Triplex Assay experiments. 
Once the cytotoxic effects of CDDP/DQA on the Caco-2 and Ishikawa cells were 
demonstrated, the capacity of CDDP/DQA to induce cell death by apoptosis or necrosis 
was analysed. The translocation of PS to the external layer of the cell membrane (the 
characteristic early event of apoptosis; [335]) and the membrane permeability were 
analysed through the annexin V-FITC/PI double staining. 
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The mode of CDDP/DQA-induced cell death after 24 hours in the Caco-2 and Ishikawa 
cells seems to be apoptosis followed by necrosis secondary to apoptosis. It has been 
described that a fundamental difference between necrosis and apoptosis lies in the kinetics 
of membrane integrity loss during these types of cell death [335]. Apoptotic cells exclude 
dyes for several hours whereas necrotic cells undergo rapid swelling and lysis within 
minutes. The annexin V-FITC/PI double staining assay showed the presence of cells in 
the late apoptosis and necrosis-secondary-to-apoptosis phases which demonstrated PS 
exposure on the cell surface as well as membrane permeability allowing the entry of PI 
(i.e. A+/PI+). Apoptotic cell death was further confirmed by measuring caspase-3/7 
activation which is a typical event during apoptosis.  
Our data showed a significant attenuation in apoptosis events and caspase-3/7 activation 
in both cell lines when the cells were pre-incubated with NAC. Those data proved that 
the mode of action of the two compounds and their combination was through ROS-
induced apoptosis. Moreover, it is worth mentioning that the attenuation in the apoptosis 
related events by NAC was more effective for Ishikawa compared to Caco-2, which is in 
alignment with the results regarding the rescue of cell viability by NAC. 
Those results collectively confirm that baseline ROS levels could influence how cancer 
cells respond to the same treatment, as demonstrated by the Caco-2 and Ishikawa cells in 
this study. Moreover, our data highlight the fact that cancer cells with lower baseline 
levels of intracellular ROS would respond better to ROS-stimulating therapy by 
generating more ROS compared to cells with higher baseline levels of ROS. Hence, the 
excessive ROS induced by the treatments could be the main cause of cell death in cells 
with low baseline ROS, whereas different mechanisms might play a role in parallel with 
ROS in causing cell death in cells with high baseline ROS. 
 
5.3.2 BCL-XL as the main target of ROS 
The anti-apoptotic protein BCL-XL antagonises the pro-apoptotic family of proteins such 
as BAX and BAK. This antagonism prevents the activation and oligomerisation of BAX 
and BAK, which in turn inhibits the formation of MPTP and the release of cytochrome c 
that plays a central role in the execution of apoptosis. Once cytochrome c is released from 
mitochondria, various events will lead to the activation of caspase-3 which is considered 
as the non-return point in the apoptotic signalling cascade (reviewed in Ref. [35]). 
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As mentioned previously (Chapter 1, 1.3.6), excessive ROS level is a key factor in 
facilitating MPTP opening by promoting the ubiquitination of the anti-apoptotic BCL-2 
proteins, thus allowing the activation and oligomerisation of BAX / BAK and the release 
of   cytochrome c (reviewed in Refs. [99,160]). It has been reported that oxidation of 
ANT, a main component of MPTP, by ROS is also linked to the regulation of the MPTP 
opening (reviewed in Ref. [160]). However, the expression of ANT was not covered in 
this study. 
In order to confirm that the observed cytotoxicity was caused by ROS-induced 
mitochondria-dependent apoptosis pathway, changes in the protein expression of       
BCL-XL and VDAC1 and the release of cytochrome c were analysed in the Caco-2 and 
Ishikawa cells.  
Indeed, our data showed a significant decrease in the BCL-XL protein expression at 24 
hours of the treatments in both cell lines followed by marked cytochrome c release and 
caspase-3 activation. Our results indicate that the reduced BCL-XL protein level resulted 
either in the activation and oligomerisation of proapoptotic proteins (BAX and BAK) 
leading to formation of the pores on the OMM, or in less suppression of VDAC1 allowing 
its oligomerisation and consequently the formation of VDAC-containing pore.  
As mentioned earlier, it is well documented that ROS cause a direct damage to ANT by 
oxidation, however little is known about the direct impact of excessive levels ROS on 
VDAC1. It worth mentioning that no changes were observed in the VDAC1 protein 
expression either upon the treatments or with NAC pre-incubation in both cell lines. This 
observation indicates that the confirmation state of VDAC1 (homodimerisation or 
heterodimerisation with proapoptotic proteins) rather that its oxidation and degradation 
regulates the MPTP opening. Moreover, the observed changes in BCL-XL protein levels 
upon treatments further confirmed the pivotal role of the BCL-2 proteins in the formation 
of MPTP by facilitating VDAC1 oligomerisation, rather than regulating VDAC1 
expression.   
All those aforementioned changes in BCL-XL, cytochrome c and caspase-3 were reversed 
when the cells were pre-incubated with NAC. Such findings clearly suggest that ROS-
induced BCL-XL oxidation and degradation facilitates the formation of a channel 
complex with sufficient pore size capable of releasing cytochrome c from the IMS to the 
cytosol and consequently triggers caspase-initiated apoptosis. Moreover, these 
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observations indicate that BCL-XL protein is the main target of ROS and further prove 
that the mode of action of the two compounds is through ROS-induced apoptosis. 
 
5.3.3 Mitochondria as the main target of ROS 
As mentioned previously, CDDP and DQA accumulate in mitochondria so certain 
mitochondrial damage is expected in cells exposed to the treatments. To test this 
hypothesis, three key markers of mitochondrial damage (OPA1, RRM2B and ENDOG) 
have been investigated in our study. 
The OPA1 protein is well known to regulate mitochondrial fusion and to stabilise cristae 
structure for maintenance of normal mitochondrial activities [336]. It has been reported 
that stabilisation of mitochondrial cristae by OPA1 prevents mitochondrial dysfunction 
and protects the cell from intrinsic apoptosis [310]. Our data showed that the OPA1 gene 
was downregulated in the presence of all treatments in both cell lines, which is in 
alignment with the observed cytochrome c release upon the treatments. 
As mentioned earlier, RRM2B plays an important role in DNA damage repair and 
maintenance of mtDNA content [28,29]. In addition, Kuo et al. [337] evidenced that 
RRM2B was induced upon oxidative stress to protect the mtDNA content. Our data 
demonstrated that RRM2B was upregulated in the presence of all the treatments in both 
cell lines, which could be a counteract mechanism by the cells against the observed 
mtDNA depletions upon the treatments (discussed in Chapter 3). 
On the other hand, ENDOG has a pro-apoptotic function and participates in apoptosis via 
DNA degradation [338]. Under oxidative stress, ENDOG is released from mitochondria 
and migrates to the nucleus where it degrades DNA to effect apoptosis. Therefore, 
maintaining low levels of EndoG could prevent cell death caused by stress conditions 
[339].  
Our data showed that ENDOG was upregulated in the presence of all the treatments in 
both cell lines, which is in alignment with the observed caspase activation upon the 
treatments. 
All aforementioned results are in agreement with a study conducted by Choi et al. [240] 
who observed downregulation of OPA1 and upregulation of RRM2B and ENDOG upon 
the treatment with CDDP in the HEK-2 cells.  
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Our microscopic analysis (Chapter 3) revealed an enhanced ROS generation upon the 
treatments largely localised within mitochondria causing MMP disruption, mtDNA 
depletion, downregulation of mitochondrial stability markers and upregulation of 
mitochondrial DNA damage markers (demonstrated through qPCR data). Hence, it was 
evident from these results that CDDP/DQA induced mitochondrial damage through 
oxidative stress.  
Having established the critical role of excessive ROS in cell death in our study, the 
potential antioxidant systems counteracting treatment-induced ROS production were 
investigated by analysing the expression levels of the antioxidant genes. 
Interestingly, all the antioxidant genes and Nrf2 were significantly upregulated in the 
Caco-2 cells treated with DQA, whereas only GPx and Nrf2 were significantly 
upregulated in the Caco-2 cells undergone all the treatments. Those results indicated that 
DQA treatment provoked wider antioxidant responses in the Caco-2 cells while some of 
the genes remained silent upon exposure to CDDP. It is possible (as seen in our study) 
that in the Caco-2 cells, CDDP and its combination with DQA had a direct regulatory 
impact only on specific antioxidants such as GPX and certain transcription factors such 
as Nrf2 which regulates the expression of genes involved in the cellular antioxidant 
system [164,166].  
As to the Ishikawa cells, the expression profiles of the tested antioxidant genes were less 
consistent compared to those in the Caco-2 cells. However, both SOD1 and CAT were 
significantly downregulated in Ishikawa upon the combined treatment whereas no 
significant changes occurred in the expression levels of SOD2, GPX and Nrf2 in any of 
the treatments except for CDDP and DQA in GPX (upregulated) and Nrf2 (upregulated) 
respectively.  
Our results presented in Chapter 4 suggest that cancer cells with high baseline ROS levels 
might have relatively low expressions of antioxidant genes. However, upon ROS-
stimulating treatments, those cells could upregulate their antioxidants significantly as a 
protective mechanism, rendering them more resistant to the treatment. On the other hand, 
cells with low baseline ROS levels might have saturated their antioxidant system, and 
therefore could not defend themselves efficiently against ROS-stimulating compounds, 
as demonstrated by the significantly higher sensitivity levels of Ishikawa compared to 
those of Caco-2 in this study.  
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5.4 Summary 
The above observations indicate that excessive intracellular ROS induced by CDDP/DQA 
is the essential mediator of mitochondrial dysfunction and cell death, which are in line 
with previous studies where scavenging of ROS by antioxidants results in the attenuation 
in cell death. 
More importantly, this chapter has demonstrated that cells with lower baseline ROS levels 
respond better to ROS scavengers when undergoing ROS-stimulating treatment, which 
grants better cell death attenuation. This indicates that excessive ROS could be the main 
cause of cell death in cells with relatively low baseline ROS levels, whereas other 
mechanisms might play a role alongside with ROS in killing cells with relatively high 
baseline ROS levels. Our results also highlight the possibility of achieving greater 
efficacy of ROS-stimulating agents in treating cancers with low baseline ROS levels 
compared to those with high baseline ROS levels.
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Chapter 6  
Evaluation of mitochondrial genetic 
abnormalities as effective biomarkers 
to predict drug sensitivity in cancer 
cells 
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6.1 Introduction 
Cancer is considered as a group of multi-process and multifactorial genetic diseases, and 
it has been revealed that all cancer cells accumulate somatic mutations in both 
mitochondrial and nuclear genomes that drive normal cells to become progressively 
malignant [340]. As previously described, mtDNA is independent of nuclear DNA and 
consists of protein-coding regions for 13 mitochondrial complex subunits, 22 tRNA and 
2 rRNA sequences as well as the D-loop region that regulates mtDNA replication and 
transcription (discussed in Chapter 1).  
Mitochondria are implicated in many cellular processes such as cell communication, 
differentiation and apoptosis so a little mitochondrial dysfunction can lead to the 
development of several human diseases, including cancers [26]. Mitochondrial 
dysfunction can be associated with mtDNA alterations such as mutations and changes in 
the mtDNAcn (reviewed in Ref.s [65,160]). This chapter focuses on the implications of 
mtDNA abnormalities in ROS related cancer cell death/survival and drug resistance. 
It is well known that mitochondria are considered a primary intracellular site of ROS 
generation via OXPHOS during ATP generation [297]. ROS play important roles in cell 
signalling pathways such as growth, differentiation, metabolism and death signalling 
(reviewed in Ref. [160]). MtDNA mutations could influence intracellular ROS levels, and 
consequently be responsible for mitochondrial dysfunction and genome instability 
[76,341]. In particular, mutations in complexes I and III coding regions in both nDNA 
and mtDNA can affect the normal function of corresponding complexes. Since these two 
complexes are the main ROS generation sites, mutations in their coding regions can have 
an impact on ROS production (reviewed in Ref. [163]). Moreover, researchers have 
indicated the existence of particular mutation patterns in mtDNA of various types of 
cancer, and abnormal apoptotic procedures are considered a consequence of these 
mutations [79]. It is known that dysregulation of apoptosis contributes to cancer cell 
survival and drug resistance. 
In addition, as mtDNA is continuously exposed to ROS and lacks protective histones and 
efficient DNA repair machinery, it is more susceptible to ROS-induced mutations and has 
a mutation rate 10 times higher than nDNA (reviewed in Ref. [65]). 
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Furthermore, mitochondrial DNA copy number (mtDNAcn) per cell is preserved within 
a stable range to achieve the required cellular energy and hence ensure normal 
physiological functions. It ranges among the population from 103 to 104 per cell type 
[145]. Such variations also reflect the imbalance between ROS production and the 
antioxidant capacity, so mtDNAcn has been considered as a potential diagnostic and 
prognostic biomarkers for several cancer types (discussed in Chapter 1) [146]. 
To date, mitochondrial dysfunction and various mtDNA alterations including point 
mutations, large deletions and copy number changes have been observed in several human 
cancers such as breast, colon, stomach, kidney, thyroid, head and neck and ovarian 
cancers [18,80,81]. Mitochondrial genetic abnormalities have also been strongly linked 
to oxidative stress, risk of metastasis and resistance of cancer cells to apoptosis (reviewed 
in Ref.s. [53,78,342]). 
ROS have been purported to have a double-edged-sword effect in living cells since low 
levels of ROS can play a critical role in promoting cell proliferation and invasion, whereas 
excessive levels of ROS can cause oxidative damage to intracellular bio-macromolecules 
and consequently induce cell death (reviewed in Ref.s [168,196]). Therefore, it is 
speculated that induction of ROS may be a promising approach to cancer therapy 
(reviewed in Ref.s [144,160]). Indeed, some conventional chemotherapies and 
mitochondria-targeting agents have been proven to cause cell death by affecting the redox 
balance via excessive accumulation of ROS [175,271]. However, due to the strong side 
effects of the chemotherapies and different levels of response to the treatments, their 
clinical use is limited (reviewed in Ref. [305]). For that reason, finding effective 
biomarkers to predict response to ROS-stimulating therapy is a main objective of this 
PhD study. 
This chapter aimed to explore the mitochondrial genetic abnormalities in all the cell lines 
enrolled in this study and also to investigate the implications of certain mitochondrial 
DNA mutations in ROS levels and other mitochondrial functional parameters, as well as 
in cells’ response to cisplatin and dequalinium. 
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6.2 Results 
6.2.1 Increased mitochondrial DNA copy number in cancer cells 
As shown in Figure 6.1 a, cancer cell lines had increased mtDNAcn compared to the non-
cancerous cells (PNT-2). Amongst the cancer cell lines, Caco-2 had the highest mtDNAcn 
whereas Ishikawa had the lowest.  
It is worth noting that the mtDNAcn values showed the same trend as those of the 
intracellular ROS and mitochondrial superoxide levels observed in the cell lines. These 
results demonstrated positive correlations between mtDNAcn and ROS levels as well as 
mitochondrial superoxide levels in the cell lines (Figure 6.1 b & c). 
 
Figure 6.1. Relative content of mtDNA in PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2 normalised 
against the house keeping gene (β-actin). The columns represent the relative mtDNAcn of the cell lines. 
Data are mean ± SEM (N=3 separate experiments); p values were calculated using one-way ANOVA with 
Tukey multiple comparison post-hoc analysis; ns, not significant, *p<0.05, ***p<0.001 and ****p<0.0001. 
Positive correlation between the relative content of mtDNAcn and the baseline intracellular ROS levels (b) 
and mitochondrial superoxide levels (c). Data points representing the cell lines are in the same sequence as 
the columns in panel a. r and p values were calculated using the Pearson correlation method; *p<0.05 and 
**p<0.01.  
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6.2.2 Increased number of non-synonymous mutations in the mtDNA protein 
coding regions in cancer cells 
The complete mitochondrial genome of each cell line was PCR amplified via 17 
overlapping amplicons (in-house primers and PCR sizes listed in Chapter 2), and the 
expected PCR product sizes were confirmed by agarose gel electrophoresis (a 
representative gel image is shown in Figure 6.2).  
 
Figure 6.2. Representative image of agarose gel electrophoresis of PCR products amplified using 17 pairs 
of primers. mt 1-17: seventeen fragments (~ 1,1 kb) of mitochondrial genome; ng: negative control.  
 
Sequencing data revealed that the total number of mtDNA mutations in each cancer cell 
line was comparable (30, 25, 26 and 36 mutations in Ishikawa, MDA-MB-231, PC-3 and 
Caco-2, respectively). However, these numbers were significantly higher than that in the 
non-cancerous cell line (PNT-2), in which only 9 mutations were identified (Figure 6.3 
a). Progressive increases in the number of non-synonymous point mutations in complexes 
I and III (1, 3, 4, 5 and 9 mutations) and in the whole coding regions (2, 4, 5, 6, 11) were 
observed in PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2, respectively (Figure 6.3 
b & c). 
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Figure 6.3. Number of mutations identified in the mitochondrial genome by Sanger sequencing. (a) 
Number of the total mutations observed in the cell lines. (b) Number of non-synonymous mutations 
observed in mtDNA coding regions for complex I and III subunits. (c) Number of non-synonymous 
mutations observed in the whole mtDNA coding regions.  
Numerous common mutations in cell lines were observed within the mitochondrial 
genome (Appendix Table 1). Our results indicated that the A8860G mutation was 
detected in all the cell lines whereas C14766T was detected only in the cancer cells. 
G13708A was identified only in the PC-3 and Caco-2 cells, whereas A15326G was a 
common mutation in the PNT-2, Ishikawa, MDA-MB-231 and Caco-2 cells. On the 
contrary, greater numbers of unique mutations, mainly in complexes I and III, were 
observed in the cancer cells (Appendix Table 2). The T3394C point mutation was found 
only in the Ishikawa cells; C12084T and A13966G were found only in the MDA-MB-
231 cells; T11120C, C13802T and A14793G were found only in the PC-3 cells. Caco-2 
had the highest number of unique mutations including T4216C, G7977C, A10398G, 
A13681G, T14798C, A14927G and C15452A. No unique mutations within complexes I 
and III were found in the non-cancerous cells (PNT-2).  
All the identified mutations within the mitochondrial DNA protein coding regions and 
their disease association using MitoMAP and Human Mitochondrial DataBase (HmtDB) 
are listed in Appendix Table 3.  
Briefly, all of the identified mutations have been previously reported in different diseases 
including cancers, and some of the mutations have been linked to escalated ROS 
production (discussed below in 6.3.3). 
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6.2.3 Mapping of complexes I, III, IV and V mutations 
In total 37 mutations were identified in complexes I, III, IV and V, amongst which 17 
were non-synonymous (i.e. causing amino acid changes). Nine non-synonymous 
substitutions were found in complex I, of which 2 were present in ND1, 1 in ND3, 2 in 
ND4 and 4 in ND 5. A total of 6 MT-CYB substitutions were identified in complex III. 
One substitution was identified in complex IV located in MT-COII and one substitution 
was identified in complex V located in ATP6 (Figure 6.4). 
 
Figure 6.4. Mapping of all the identified non-synonymous mutations in the mitochondrial OXPHOS 
protein complexes. Mutations are mapped to Homo sapiens complex I homolog [PDB:5XTD], Homo 
sapiens complex III homolog [PDB:5XTE], Homo sapiens complex IV homolog [PDB:5Z6N] and Bos 
taurus complex V homolog [PDB:5ARA]. All complexes are depicted as ribbon models. The nuclear DNA 
encoded subunits are coloured in grey whereas the mitochondrial DNA encoded subunits are coloured 
differently. Mutation sites are highlighted as red spheres.   
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6.2.4 Prediction of functional mutations 
6.2.4.1 Complex I functional mutations 
The A10398G mutation could cause the disruption of complex I assembly and stability 
by affecting the association of ND3 and ND1. The replacement of T114 by A114 removes 
the polar sidechain property of threonine, which is likely to affect the formation of 
hydrogen bonds with the ND1 residue (N382) and weaken the interaction between the 
two subunits, and consequently affect the assembly of the two subunits and the stability 
of complex I (Figure 6.5). Similarly, the A13681G, C13802T and A13966G mutations 
cause the disruption of ND5 subunit stability. The replacements of T449 by A449, T489 
by M489 and T544 by A544 result in the loss of the hydrogen bonds formed with the 
W106, Y485 and L540 residues in the ND5 subunit, respectively. Consequently, these 
mutations weaken the interaction within the subunit, hence affect the stability of complex 
I. 
 
Figure 6.5. Detailed view of the complex I mutation A10398G (T114A). T114 is located at the surface of 
complex I within the mitochondrial DNA encoded ND3 subunit. ND3 is shown in purple and ND1, an 
adjacent subunit, in yellow. The wild type T114 is shown in orange as sticks and spheres (a & c, 
respectively) and the mutant A114 is shown in red (b & d). Alanine is non-polar and smaller than threonine 
in size meaning the change is likely to hinder the interaction with the N382 residue of ND1, and therefore 
affect the association of the two subunits and consequently the stability of complex I.  
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The C12084T mutation results in the disruption of ND4 stability. This mutation replaces 
serine with phenylalanine (a larger amino acid) at position 442 (S442F) which is unlikely 
to be accommodated within the structure. Apart from being of a larger size, this 
phenylalanine at position 442 may disrupt and repel another phenylalanine nearby within 
the ND4 subunit (i.e. F438) and consequently affect the stability of complex I (Figure 
6.6). Similarly, the T1120C and G13708A mutations cause the disruption of the ND4 and 
ND5 subunits respectively. The replacement of F121 by L121 is unlikely to be 
accommodated within the structure due to the orientation of the leucine side chain at 
position 121 which protrudes and results in its intra-subunit interaction with methionine 
at position 108 (M108) within the same subunit. The replacement of A458 with T458 is 
also unlikely to be accommodated within the structure, since the larger size of threonine 
may well disrupt and repel leucine at position 445 (L455) within the same subunit. These 
intra-subunit disruptions could interfere with the stabilisation of the ND4 and ND5 
subunits and consequently affect the stability of complex I. 
 
Figure 6.6. Detailed view of the complex I mutation C12084T (S442F). S442 is located at the core of 
complex I within the mitochondrial DNA encoded ND4 subunit. ND4 is shown in bright green. The wild 
type S442 is shown in orange sticks and spheres (a & c, respectively) and the mutant F442 is shown in red 
(b & d). Phenylalanine is bigger than serine due to its aromatic side chain and is likely to disrupt and repel 
the hydrophobic F438 residue within ND4, which is predicted to affect the stability of complex I. 
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6.2.4.2 Complex III functional mutations 
T14798C that results in the amino acid change F18L is located at the ubiquinone-binding 
site (i.e. the Qi site) of the MT-CYB subunit. Phenylalanine (F) is one of the residues that 
form the entrance of the Qi site of complex III [44]. Both phenylalanine (F) and leucine 
(L) are hydrophobic. However, they differ in their side chains. Leucine does not have an 
aromatic side chain which makes it smaller than phenylalanine. Therefore, this 
substitution is likely to alter the shape and size of the Qi site because it results in a larger 
cavity at the entrance to the site (Figure 6.7). Such a change may interfere with the binding 
of ubiquinone and consequently the electron transfer from heme bH. Hence, the T14798C 
mutation is predicted to be functional as it may alter the activity of complex III. 
 
Figure 6.7. Detailed view of the complex III mutation T14798C (F18L). F18 is located at the entrance of 
the ubiquinone-binding site (Qi site) within the mitochondrial DNA encoded cytochrome b subunit (MT-
CYB). MT-CYB is shown in yellow and ubiquinone in green. The wild type F18 is shown in purple sticks 
and spheres (a & c, respectively) and the mutant L18 is shown in red (b & d). Phenylalanine is a much 
larger residue than leucine, suggesting that this change is likely to affect the shape and structure of the 
binding site and consequently alter the activity of complex III.  
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All functional mutations predicted by 3D-structural modelling and their occurrences in 
the cell lines are summarised in Table 6.1 
Table 6.1. List of functional mutations predicted by 3D-structural modelling identified in the 5 cell lines.  
Mutations PNT-2 Ishikawa MDA-MB-231 PC-3 Caco-2 Locus 
Amino acid 
change 
A10398G       Complex I T114A 
T11120C        Complex I F121L 
C12084T      Complex I S442F 
A13681G      Complex I T449A 
G13708A      Complex I A458T 
C13802T       Complex I T489M 
A13966G      Complex I T544A 
T14798C       Complex III F18L 
 
6.2.5 Non-functional mutations in protein-coding regions 
Of the seventeen non-synonymous mutations identified within the mtDNA protein-
coding regions, nine were predicted to be non-functional. These were: T3394C (Y30H) 
and T4216C (Y304H) in complex I; C14766T (T7I), A14793G (H16R), A14927G 
(T61A), A15326G (T194A) and C15452A (L236I) in complex III; G7977C (G131A) in 
complex IV; A8860G (T112A) in complex V. The structural analysis revealed that all 
those residues were distal from any known electron or proton route or major catalytic 
sites, and did not have any direct interaction with amino acids from neighbouring 
mitochondrial or nuclear subunits. There also appeared to be sufficient room to 
accommodate the amino acid change in each case. 
To summarise, all the mutations predicted to be non-functional locate on the surface of 
the subunits and could therefore affect their interaction with the inner mitochondrial 
membrane and the formation of the MRC super-complexes [343]. However, this 
hypothesis is difficult to prove because currently, none of the 3D structures of the MRC 
super-complexes is available to have them sufficiently characterised. With improved 
understanding of the structures and the complex-membrane interactions, it is possible that 
the aforementioned predictions can be validated in the future. 
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All the non-synonymous mutations and their structural modelling data are summarised in 
Table 6.2. 
Table 6.2. Summary of the non-synonymous mutations and the 3D structural modelling results.  
   
Mutations Locus Complex 
Amino Acid 
change 
Sequence Location Interaction Prediction 
T3394C ND1 I Y30H Conserved Surface None Non-functional 
T4216C ND1 I Y304H Non-conserved Surface None Non-functional 
A10398G ND3 I T114A Non-conserved Surface ND3-ND1 Functional 
T11120C ND4 I F121L Conserved Surface ND4 intra-subunit   Functional 
C12084T ND4 I S442F Conserved Core  ND4 intra-subunit   Functional 
A13681G ND5 I T449A Conserved Surface ND5 Intra-subunit  Functional 
G13708A ND5 I A458T Conserved Core  ND5 Intra-subunit  Functional 
C13802T ND5 I T489M Conserved Surface ND5 Intra-subunit  Functional 
A13966G ND5  I T544A Conserved Surface ND5 Intra-subunit  Functional 
C14766T CYB III T7I Conserved Surface None Non-functional 
A14793G CYB III H16R Conserved Surface None Non-functional 
T14798C CYB III F18L Conserved Surface 
Substrate binding 
site 
Functional 
A14927G CYB III T61A Conserved Surface None Non-functional 
A15326G CYB III T194A Conserved Surface None Non-functional 
C15452A CYB III L236I Conserved Surface None Non-functional 
G7977C CO2 IV G131A Conserved Surface None Non-functional 
A8860G ATP6  V T112A Non-conserved Surface None Non-functional 
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6.2.6 D-loop region as a hotspot for mtDNA mutations 
The sequencing data revealed that the D-loop region was a hotspot for mutations 
identified in the present study. Ishikawa, PC-3 and Caco-2 showed greater numbers of 
mutations in this region compared to PNT-2 and MDA-MB-231 (Figure 6.8). 
 
Figure 6.8. Number of mutations identified in the D-loop region in the 5 cell lines.  
Numerous mutations common amongst the cancer cell lines were observed in the D-loop 
region (summarised in Appendix Table 1). Our results indicated that A73G was detected 
in Ishikawa, PC-3 and Caco-2; T195C was identified only in MDA-MB-231 and PC-3; 
A263G was a common mutation in all the cancer cell lines; 310insC was observed only 
in Ishikawa, PC-3 and MDA-MB-231; T16172C was detected in Ishikawa and PC-3; 
C16261T occurred in Ishikawa and Caco-2. None of the common mutations seen in the 
cancer cells was detected in the non-cancerous cell line (PNT-2). 
On the other hand, each cell line harboured a number of unique mutations in the D-loop 
region (listed in Appendix Table 2). 513insCA, G16319A, T16325C and T16519C were 
found only in the PNT-2 cells; C150T, C338T, C16223T, C16257A, T16304C and 
A16497G were found only in Ishikawa; A153G was found only in MDA-MB-231; 
T195C, C16192T, C16256T, C16270T, C16320T and A16399G were found only in     
PC-3; G47A, G185A, G228A, C295T, C462T, T489C, C16069T and T16126C were 
found only in Caco-2.  
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All the identified D-loop mutations and their disease association using MitoMAP and 
Human Mitochondrial DataBase (HmtDB) are listed in Appendix Table 3.  
Briefly, majority of the identified mutations have been previously reported in different 
diseases including cancers, and some of the mutations (C16223T, A16399G and C295T) 
have been associated with increased mtDNAcn, (discussed below in 6.3.5). 
 
6.2.7 Mutations outside the protein coding and D-loop regions 
Our sequencing data also revealed several mutations outside the protein coding and          
D-loop regions with certain common mutations amongst the cancer cell lines 
(summarised in Appendix Table 1). A750G was a common mutation in all the cancer and 
non-cancerous cell lines; A1438 was detected in PNT-2, Ishikawa, PC-3 and Caco-2; 
2800insA occurred in Ishikawa and MDA-MB-231; 3107delN was observed only in 
Ishikawa, MDA-MB-231 and Caco-2. A750G and A1438 are mutations affecting the 
coding sequence for the 12S ribosomal RNA subunit whereas A2706, 2800insA and 
3107delN are mutations affecting the 16S rRNA sequence. 
On the other hand, each cell line harboured a number of unique mutations outside the 
protein coding and D-loop regions (listed in Appendix Table 2). T691C and A1937C were 
found only in the Ishikawa cells; 646insA, 653insT, G709A and G1719A were found only 
in MDA-MB-231; A12308G was found only in PC-3. None of these unique mutations 
was detected in Caco-2 or the non-cancerous cell line (PNT-2). T691C, 653insT and 
G709A are located in the coding region for the 12S ribosomal RNA subunit, whereas 
A1937C and G1719A affect the 16S ribosomal RNA sequence, and 646insA and 
A12308G affect tRNA-Phe and tRNA-Leu respectively. 
 
6.2.8 Increased lactate production and PDK1 expression in cancer cells 
To investigate whether there was an association between the number of non-synonymous 
mutations observed within the mitochondrial genome of cancer cells and mitochondrial 
functional alterations, the baseline lactate levels of the cells were measured. Lactate is 
produced during glycolysis following the catalysis of pyruvate by lactate dehydrogenase 
(LDH), and can be measured to assess the efficiency of glycolysis.  
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Using a colorimetric assay, the relative content of lactate in respect of the total cellular 
protein was determined in all the cell lines enrolled in the study. As shown in Figure 6.9, 
the 4 cancer cell lines had increased lactate compared to the non-cancerous line (PNT-2). 
Amongst the cancer cell lines, Caco-2 had the highest lactate level whereas Ishikawa had 
the lowest. These results demonstrated a positive correlation between lactate levels and 
numbers of non-synonymous mutations. 
 
 
Figure 6.9. Relative lactate levels in the PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2 cells 
normalised against the total protein content. The columns represent the relative lactate level. Data are mean 
± SEM (N=3 separate experiments); p values were calculated using one-way ANOVA with Tukey multiple 
comparison post-hoc analysis; ns, not significant, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.  
Transformation between OXPHOS and glycolysis is controlled by the relative activities 
of pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH). Given the fact that 
pyruvate dehydrogenase kinase 1 (PDK1), a key suppressor of PDH and an indirect 
activator of LDH, is highly regulated by oxidative stress and since Ishikawa and Caco-2 
had been selected in this study to represent cancer cells with the lowest and the highest 
baseline levels of ROS, the expression level of PDK1 was investigated in both cell lines   
to elucidate its impact on the difference in glycolysis efficiency observed in this study 
and also to confirm the correlation between the oxidative status and the metabolic profile. 
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The TaqMan qPCR results showed that the relative gene expression level of PDK1 was 
significantly higher in the Caco-2 cells compared to the Ishikawa cells (Figure 6.10). 
 
Figure 6.10. Comparison of the relative baseline expression levels of the PDK1 gene between the untreated 
Ishikawa and Caco-2 cells. The columns represent the relative expression levels of the gene using TaqMan 
qPCR. Data are mean ± SEM (N=3 separate experiments); p values comparing the Ishikawa and Caco-2 
cells were calculated using two-tailed t-test; *p<0.05.  
 
6.2.9 Implication of mitochondrial DNA mutations in baseline ROS level, drug 
resistance and lactate production 
In order to investigate how mitochondrial genetic abnormalities might affect the baseline 
ROS level and drug response in the cancer cells, linear regression was employed to model 
the relationship between the numbers of non-synonymous mutations and redox statues as 
well as CDDP/DQA IC50s and baseline lactate levels.  
Data in Figure 6.11 show that numbers of non-synonymous mutations identified in the 
coding regions for all the mitochondrial OXPHOS subunits were positively correlated 
with the overall ROS and mitochondrial superoxide levels (Figure 6.11 a & b). Those 
non-synonymous mutation numbers were also positively correlated with the IC50s of 
both CDDP and DQA (Figure 6.11 c & d). Moreover, they were positively correlated with 
the baseline lactate levels (Figure 6.11 e). 
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Figure 6.11. Positive correlations between the numbers of non-synonymous mutations identified in the 
protein coding regions and baseline ROS levels (a), mitochondrial superoxide levels (b), CDDP IC50s (c), 
DQA IC50s (d) and relative lactate levels (e). Data points representing the cell lines are in the sequence of 
PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2. r and p and values were calculated using the Pearson 
correlation coefficient method; *p<0.05 and **p<0.01.  
Similarly, numbers of non-synonymous mutations identified only in the complexes I and 
III coding regions were also positively correlated with ROS, mitochondrial superoxide, 
CDDP/DQA IC50s and relative lactate levels (Figure 6.12). 
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Figure 6.12. Positive correlations between the numbers of non-synonymous mutations identified in the 
complexes I & III coding regions and baseline ROS levels (a), mitochondrial superoxide levels (b), CDDP 
IC50s (c), DQA IC50s (d) and relative lactate levels (e). Data points representing the cell lines are in the 
sequence of PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2. r and p and values were calculated using 
the Pearson correlation coefficient method; *p<0.05 and **p<0.01.  
Interestingly, numbers of non-synonymous mutations predicted to be functional in our 
study by 3D-structural modelling were also positively correlated with ROS, 
mitochondrial superoxide, CDDP/DQA IC50s and relative lactate levels (Figure 6.13). 
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Figure 6.13. Positive correlations between the numbers of functional mutations identified in the complex I 
& III coding regions and baseline ROS levels (a), mitochondrial superoxide levels (b), CDDP IC50s (c), 
DQA IC50s (d) and lactate levels (e). Data points representing the cell lines are in the sequence of PNT-2, 
Ishikawa, MDA-MB-231, PC-3 and Caco-2. r and p and values were calculated using the Pearson 
correlation coefficient method; *p<0.05 and **p<0.01. 
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6.3 Discussion 
ROS can be generated from both endogenous and exogenous sources, and mitochondria 
are considered a primary intracellular site of ROS generation when some of the electrons 
in the mitochondrial electron transport chain escape from the mitochondrial respiratory 
complexes (mainly I and III) and react with oxygen to generate ROS (reviewed in Ref. 
[160]). Results presented in Chapters 3, 4 and 5 suggested a correlation between the 
baseline intracellular ROS levels and drug responses in human cancer cell lines, and 
addressed how different levels of ROS can influence drug sensitivity. Therefore, ROS 
was proposed as a novel biomarker to predict drug sensitivity. However, since measuring 
ROS in tissues is technically challenging, a more efficient biomarker to indicate the 
response to ROS-stimulating agents is still needed. 
In this chapter, specific mitochondrial genetic mutations in cancer cells were identified, 
and the possibility that mitochondrial genetic alterations could be utilised to predict drug 
sensitivity is discussed. The discussion will focus on the link between mtDNAcn and 
baseline intracellular ROS and the implication of mutations in the mitochondrial 
OXPHOS subunits coding regions as well as in the D-loop region. 
6.3.1 Correlation between mitochondrial copy numbers and ROS levels 
Cancer cells have various levels of mtDNAcn which are strictly correlated to the demand 
of ATP generated by OXPHOS, “the major site of ROS production” [302,303]. Indeed, 
our data showed a positive correlation between mtDNAcn and baseline intracellular ROS 
and mitochondrial superoxide levels amongst the non-cancerous and 4 cancer cell lines 
of different tissue origins, which confirmed the previous observation that cells containing 
larger mtDNAcn also have higher levels of ROS [344]. 
Moreover, our result confirmed that the prostate cancer cell line (PC-3) had higher 
mtDNAcn compared to the non-cancerous counterpart cell line (PNT-2), which is in 
agreement with previous observations obtained from prostate cancer cells and their non-
cancerous counterparts (Discussed in Chapter 1, 1.2.6) [345]. Interestingly, all the cancer 
cell lines in this study showed higher levels of mtDNAcn compared to PNT-2. However, 
to confirm a greater mtDNAcn in each of the other 3 cancer cell lines (i.e. Ishikawa, 
MDA-MB-231 and Caco-2), a head-to-head comparison with their non-cancerous 
counterpart of the same tissue origin is still needed (not conducted in the PhD study). 
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As discussed above, the good correlation between mtDNAcn and baseline intracellular 
ROS levels in naïve cancer cells also means that mtDNAcn could be measured instead to 
indicate the response to mitochondria-targeting therapy, and therefore make a potential 
biomarker to indicate drug sensitivity. 
 
6.3.2 Correlation between numbers of non-synonymous mutation and ROS 
levels/drug response in cancer cells 
Our data have shown that the non-cancerous cell line, PNT2, had the lowest number of 
mutations compared to the cancer lines including PC-3. Moreover, the total numbers of 
non-synonymous mutations within the mitochondrial genome, in particular those in 
complexes I and III, are strongly correlated with baseline ROS levels and the associated 
drug resistance. In our study, the conventional chemotherapy (cisplatin) and 
mitochondria-targeting therapy (dequalinium) compounds as well as their combination 
caused cell death through the excessive production of ROS as seen in the previous 
Chapters. A progressive increase in the number of non-synonymous mutations in 
complexes I and III was observed in Ishikawa (3), MDA-MB-231 (4), PC-3 (5) and Caco-
2 (9) cells, which showed the same trend as the baseline ROS level and drug resistance 
among those cells. Based on these results, it is speculated that cancer cells generally carry 
more mutations in their mitochondrial genome than non-cancerous cells, which renders 
higher baseline ROS levels in cancer cells and consequently increased drug resistance/cell 
survival. 
 
6.3.3 Correlation between numbers of non-synonymous mutation and glycolysis 
It is well known that cancer cells reprogramme their energy metabolism by depending 
more on glycolysis instead of OXPHOS in order to optimise ROS levels and thereby 
improve survival. Cells under high stress will try to reduce ROS to avoid apoptosis by 
either upregulating antioxidant enzymes or increasing glycolysis (reviewed in Ref. [303]). 
Otto Warburg was the first to characterise cancer as preferably utilising glycolysis for 
ATP production due to mitochondrial dysfunction, a phenomenon coined the “Warburg 
Effect” (reviewed in Ref. [17]). 
The cancer cells enrolled in our study exhibited different levels of mitochondrial 
dysfunction as indicated by the elevated number of mitochondrial genetic abnormalities 
compared to the normal cells. Those genetics data were in alignment with increased levels 
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of intracellular ROS in the cancer cells. Therefore, it was well expected that cells with 
higher number of non-synonymous mutations within complexes I and III would rely more 
on glycolysis for ATP generation due to dysfunctional OXPHOS. 
The best way to determine the shift between mitochondrial respiration and cytoplasmic 
glycolysis for ATP generation is to measure oxygen consumption rate and extracellular 
acidification rate. However, since lactate is produced through glycolysis following the 
catalysis of pyruvate by lactate dehydrogenase,  it can be measured to assess the level of 
glycolysis in the cytoplasm. Indeed, our data showed a positive correlation between the 
numbers of non-synonymous mutations in the mitochondrial genome and the glycolysis 
levels, confirming the metabolic adaption by the cells undergoing oxidative stress. 
Since reactive oxygen species are by-products of OXPHOS, cells that are more glycolysis 
dependent should have less ROS production. Interestingly, this was not the case in our 
study. Our explanation is that cells with a high baseline ROS level (likely due to 
mitochondrial dysfunction and relatively low antioxidant activities) will in fact upregulate 
glycolysis for ATP generation in order to avoid extra ROS generation through OXPHOS. 
However, the Warburg Effect does not imply a complete switch from OXPHOS to 
glycolysis. Therefore, a certain level of OXPHOS is expected to occur alongside the 
enhanced glycolysis in those cancer cells.  
As previously described, the metabolic switch between OXPHOS and glycolysis is 
controlled by the relative activities of pyruvate dehydrogenase (PDH) and lactate 
dehydrogenase (LDH) (reviewed in Ref. [99]). TCA cycle dysfunction and the resultant 
oxidative stress have been demonstrated to activate hypoxia-inducible factor 1 (HIF-1) 
which is well known to catalyses key steps of glycolysis by regulating the expression of 
glycolytic enzymes (reviewed in Ref. [101]). HIF-1 has been reported to induce pyruvate 
dehydrogenase kinase 1 (PDK1) that inactivates PDH and consequently supresses the 
Krebs cycle and mitochondrial respiration (reviewed in Ref. [99]). 
In this respect, the expression of PDK1 in Ishikawa and Caco-2 was examined to confirm 
the correlation between the oxidative status and the metabolic profile. Our data showed 
that the Caco-2 cells had significantly upregulated expression of PDK1 compared to the 
Ishikawa cells, which supported the higher glycolysis level observed in Caco-2. 
Considering a much higher ROS level compared to Ishikawa, the Caco-2 cells may well 
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have an overexpression of ROS-activated HIF-1 and consequently an upregulation of 
PDK1 and glycolysis. 
 
6.3.4 Previously reported non-synonymous mutations confirmed by the present 
study 
All the identified non-synonymous mutations in the present study were transitions while 
only one cytosine → adenine transversion (C15452A) was detected in the Caco-2 cells. 
A8860G, defined as a polymorphism in complex V in the Human Mitochondrial Genome 
Database [346,347], was found in all the cell lines involved in the study. A15326G, 
another known polymorphism located in complex III [348], was found in all the cell lines 
except PC-3. Both mutations had been previously reported to have negligible impact on 
mitochondrial function [348]. The C14766T mutation in the cytochrome b subunit of 
complex III causes a threonine to isoleucine change in the protein product. This mutation 
was found only in the 4 cancer cell lines, indicating that this mutation could interfere with 
complex III function and contribute to the elevated levels of ROS in the cancer cell lines. 
However, no previous reports can be found on C14766T. G13708A in complex I has been 
reported in various types of cancer such as breast and colorectal cancer [349,350]. This 
mutation was identified only in the PC-3 and Caco-2 cells, which may account for the 
significantly higher levels of ROS in these two cell lines compared to other cell lines. 
Several non-synonymous mutations in complexes I and III observed in the cancer cell 
lines but not in the non-cancerous PNT-2 cells might have contributed to the elevated 
levels of ROS in the cancer cells. For example, the T3394C mutation which resulted in 
the substitution of tyrosine with histidine in complex I was found only in the Ishikawa 
cells. This variation was previously observed in the tumour lesion but not in the adjacent 
normal mucosa of non-small cell lung carcinoma (NSCLC) and colon cancer [351]. It 
was also identified in Leber's Hereditary Optic Neuropathy (LHON) [352]. Both previous 
studies suggested an association between T3394C and reduced complex I activity 
[351,352]. It is, therefore, possible that T3394C could interfere with complex I function 
and as a result, increase electron leakage and ROS generation. The C12084T and 
A13966G mutations in complex I were found only in the MDA-MB-231 cells in the 
present study. Both mutations were previously reported to be responsible for reduced 
complex I activity and enhanced metastatic potential in the MDA-MB-231 cells 
[353,354]. In fact, mitochondrial respiration defects and ROS overproduction induced by 
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certain mtDNA mutations can manipulate the malignant transformation of tumour cells 
in order to promote metastasis. It has been shown that C12084T and A13966G can induce 
complex I defects in mouse lung carcinoma cells and increase the cells’ metastatic 
potential via ROS overproduction and the resultant overexpression of Hif-1α [353]. 
The T11120C and C13802T mutations in complex I and the A14793G mutation in 
complex III were found only in the PC-3 cells. A14793G has not been reported in the 
literature, but both T11120C and C13802T were previously reported in the PC-3 cell line 
[355]. Given the fact that mtDNA mutations which inhibit the electron transport chain 
(ETC) and increase ROS production could act as both tumour initiators and promoters, 
the study suggested that reversing the C13802T mutation to the wild type sequence might 
reduce the tumorigenic potential of the PC-3 cells. Furthermore, increased frequency of 
complex I mutation in PC-3 was found to inhibit OXPHOS and increase ROS production, 
and consequently promote tumour growth in vivo when those PC-3 cells were injected 
into nude mice [355].  
The highest number of non-synonymous mutations was observed in the Caco-2 cells. 
Such mutations include T4216C, G7977C, A10398G, A13681G, T14798C, A14927G 
and C15452A. Amongst these 7 unique mutations, A10398G results in the substitution of 
threonine with alanine in complex I. This mutation was reported in various types of cancer 
including brain, breast and cervical cancer, and strongly associated with elevated levels 
of ROS [356–359]. T14798C results in the substitution of phenylalanine with leucine 
alanine in complex III. A study conducted by Kathleen et al. [21] demonstrated that 
T14798C carriers amongst patients with glioblastoma had elevated oxidative stress. 
The remaining mutations unique to Caco-2 were also observed in several types of cancer 
[79,360,361] but so far, no published data on their involvement in ROS production are 
available. However, since the Caco-2 cells had the highest ROS level amongst the cancer 
cells tested in this study and the previously reported A10398G and T14798C mutations 
were only identified in Caco-2, we speculate that the other 5 unique non-synonymous 
mutations found in Caco-2 are likely to be also functional and may have an impact on 
ROS production. 
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6.3.5 Potential biomarkers highlighted by structural analysis 
One weakness in the aforementioned previous studies is that the researchers could only 
observe a collective effect of mtDNA mutation on ROS production. It was not clear how 
individual mutations might have interfered with the ROS level independently. Therefore, 
it was not possible to rely on the literature only to establish an accurate list of mutations 
as efficient biomarkers for the prediction of response to ROS-stimulating agents. 
Cytoplasmic hybrid (cybrid) experiments allow the examination of the impact of a single 
mutation on the cell’s redox status. However, cybrid experiments were not performed in 
this study due to time and funding limitations.  In order to investigate the impact of each 
non-synonymous mutation identified in our study on ROS production, in silico three-
dimensional protein structure mapping [21,42,45,48] was used to assess how those 
mutations could potentially affect the structure and function of the corresponding protein 
subunit and complex.  
One previous study has shown that online predictive algorithms such as SIFT, Mutation 
Assessor and PolyPhen are not always accurate in predicting the impact of mitochondrial 
mutations located in subunit interaction regions, since those algorithms are designed for 
analysing nuclear DNA mutations [45]. Instead, 3D-structural modelling using 
programmes such as PyMol and Coot provides a detailed visualisation of the complete 
protein and can take into account of the close interactions between mitochondrial 
subunits. 3D-strucutral modelling also allows amino acid changes to be visualised. 
Therefore, it can be a powerful tool for predicting the impact of individual mtDNA 
mutations on protein structure and function.  
Each of the complex I, III, IV and V mutations was analysed using PyMol and Coot as 
described in Chapter 2, 2.4.5. The location of the changed amino acid was examined and 
its proximity to the important catalytic regions within the subunit such as binding pockets 
and active sites was studied. Consequently, the prediction was made according to whether 
the amino acid change could be tolerated or not at a specific position. 
Of the 17 complex I, III, IV and V mutations studied, 9 were predicted to be non-
functional mutations. Our predictions for T4216C, C14766T, A14793G, A15326G and 
C15452A as non-functional mutations were in agreement with previous studies conducted 
by Lloyd et al. and McGeehan et al. [42,48] on mitochondrial genomes isolated from 
glioblastoma cell lines and tissues. 
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On the other hand, eight mutations were predicted to be functional and the most 
represented class of functional mutation was Subunit Interaction Mutation whilst only 
one Binding Pocket Mutation was identified (i.e. T14798C). Our prediction for T14798C 
as a functional mutation aligns with previous reports by Lloyd et al. and Katthleen et al. 
[21,48] where they observed that patient derived glioblastoma multiforme (GBM) cell 
cultures and primary tissues harboured the T14798C mutation and showed elevated ROS 
compared to the non-carrier cancer cells.  
Interestingly, all the predicted functional mutations locate in complexes I and III. As both 
complexes are the main producers of ROS, it is well accepted that alterations to those 
complexes would affect their normal function and lead to changes in ROS production. It 
is worth noting that the numbers of functional complexes I and III mutations (predicted 
by 3D-structural modelling) are positively correlated with ROS levels among the cancer 
cells. This confirms the efficiency of 3D-structural modelling in predicting the impact of 
these mutations on ROS production. More importantly, it allows us to screen for such 
mutations as potentially effective biomarker to predict cancer cells’ redox status and 
response to ROS-stimulating agents. 
 
6.3.6 Implication of D-loop mutations in mtDNAcn variations and redox status 
The D-loop region consists of two hypervariable regions: hypervariable region 1 (HVR1) 
located at positions 16,024-16,383 and hypervariable region 2 (HVR2) at positions 57-
372; both HV regions exhibit a high frequency of mtDNA mutations [362]. Since the D-
loop region is a major control site for mtDNA replication and transcription, mutations in 
this region can alter the sequence of the light and heavy strand promoters, rendering the 
loss of their binding affinities to the initiators and modulators of mtDNA transcription, 
thus, disturbing the rate of transcription, RNA primer synthesis as well as mtDNA 
replication at the H-strand origin of replication (OH) [363]. Various studies have 
documented that D-loop mutations are associated with several multi-factorial genetic 
diseases, and higher mtDNAcn has also been reported in various types of cancer carrying 
D-loop mutations [364,365]. 
Indeed, the D-loop region was a hotspot for mutations identified in the present study. It 
is difficult to speculate the role of these mutations on mtDNAcn changes due to the 
limited information in the literature. Moreover, none of the identified mutations was 
located in the L-strand origin of replication (OL) and only one mutation (i.e. 310insC) was 
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in one of the three conserved sequence blocks (CSB 1, 2 and 3) within the H-strand origin 
of replication (OH) that harbours critical functional motifs for the initiation and regulation 
of H-strand replication (Figure 1.4).  
Interestingly, the 310insC mutation located in CSB2 was a common mutation in Ishikawa, 
MDA-MB-231 and PC-3. Given that insertion mutations have a real fundamental impact 
on DNA function, as they completely change the sequence of the region and result in the 
shift of the original functional motifs, it is likely that the 310insC mutation may interfere 
with DNA-primer interaction and have a negative impact on the replication of the H-
strand in those cell lines. This observation might explain why the above cell lines had 
lower mtDNA copy numbers compared to Caco-2 that did not harbour this insertion. 
Nevertheless, it is worth mentioning that a few mutations outside the CSBs but still within 
the OH were identified in the cancer cells but not the non-cancerous cells (PNT-2) in this 
study. This might explain the higher copy numbers of mtDNA observed in the cancer 
cells since those mutations might interfere with the replication of the mitochondrial 
genome. 
However, we were unable to explain the reason behind the different levels of mtDNAcn 
in the cancer cells as they all had a comparable total number of mutations in the OH region 
as well as in the whole D-loop region. It is still worth mentioning that the Caco-2 cells 
harboured the highest number of unique mutations within the OH, which may indicate that 
those Caco-2-specific mutations could be responsible for the highest mtDNAcn observed. 
Some mutations identified in our study have already been reported to be associated with 
increased mtDNAcn, such as C16223T, A16399G and C295T in the Ishikawa, PC-3 and 
Caco-2 cells respectively [366–368]. Amongst these three mutations, only C295T locates 
in the OH region and was identified in Caco-2 only. This observation supports our 
previous suggestion that the Caco-2-specific mutations might be implicated in the highest 
mtDNAcn detected in the Caco-2 cells in comparison to other cell lines. 
Since the mtDNA mutations in the cells were identified using the Sanger sequencing 
method, it has not been possible to ascertain whether those mutations were homoplasmy 
or heteroplasmy. However, the fact that those mutations were successfully detected by 
Sanger sequencing indicates that they are significantly abundant in the collective 
mitochondrial genome and may well be pathogenic. Nevertheless, a more advanced 
technique such as Next Generation Sequencing (NGS) would be able to provide 
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information on the heteroplasmy rate of those mutations. Furthermore, some of the 
mutations identified in the cell lines are previously reported SNPs. Unfortunately, it was 
not realistic to obtain matched white blood cell (WBC) samples of the donors from whose 
tissues the commercial cell lines were derived. Without the sequencing data from the 
matched WBC DNA that represents the germline genome of the donor, somatic mutations 
and SNPs in the derived cell line cannot be differentiated. This is an inherent weakness 
of the present study because commercial cell lines were employed. In order to keep the 
terminology simple, all identified mtDNA variants were described as mutations in this 
thesis.      
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6.4 Summary 
The above observations indicate that high frequency of non-synonymous mutations in 
complexes I and III would result in increased baseline ROS level and reprogramming of 
the metabolic pathways to overcome oxidative stress. The positive correlation between 
the numbers of non-synonymous complexes I/III mutations and ROS/drug response in 
cancer cells suggests that such mitochondrial genetic abnormalities could be an efficient 
biomarker to indicate the response to mitochondria-targeting therapy. Indeed, a 
comprehensive literature search following the structural analysis revealed that a panel of 
specific mutations within the mitochondrial genome, including A10398G, T11120C, 
C12084T, A13681G, G13708A, C13802T, A13966G and T14798C, could be used to 
indicate elevated intracellular ROS and therefore to predict drug resistance to ROS-
stimulating agents. 
In addition, mtDNA copy number also showed a good correlation with baseline ROS 
levels. Therefore, mtDNA copy number could be another useful biomarker to predict 
cancer cells’ response to mitochondria-targeting therapy.
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Chapter 7  
Summary of key findings and future 
directions 
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7.1 General discussion of key findings 
This study focused on the different baseline intracellular ROS levels among the cancer 
cells and their impact on the cytotoxic efficacy of cisplatin (CDDP) and dequalinium 
chloride hydrate (DQA).  
The intracellular redox imbalance and the abnormal levels of ROS within the cell may 
lead to damages to macromolecules that are important for maintaining normal cell 
functions. Such damages can cause activation of protein kinases and inhibition of protein 
phosphatases resulting in malignant transformation and cancer development and 
progression. These events are accompanied by activation of transcription factors, 
accumulation of defective proteins, and adaptation to high levels of ROS and resistance 
to ROS-dependent apoptosis. Moreover, prolonged operation of cells at abnormal yet 
steady-state levels of ROS provokes genetic mutations, which makes the cells well 
adapted to oxidative stress by mobilising a set of adaptive mechanisms such as activating 
anti-oxidant systems to mitigate the oxidative stress and inhibit ROS-induced apoptosis. 
Recent evidences suggest that such adaptation contributes to malignant transformation, 
metastasis and resistance to anticancer drugs (reviewed in Ref. [168]). The 
aforementioned data might explain the increased resistance observed in cancer cells with 
higher baseline intracellular ROS levels. 
It is suggested from this study that cancer cells exhibit different baseline intracellular 
ROS levels due to cell-specific mitochondrial abnormalities and antioxidant capacity. It 
is concluded that cancer cells with low baseline ROS levels are more sensitive to ROS-
stimulating agents compared to cells with high baseline ROS levels. It is possible that 
cells with low baseline ROS levels are poorly adapted to a robust increase in oxidative 
stress upon ROS-stimulating therapy and hence become more sensitive, whereas cells 
with high baseline ROS levels are well adapted to oxidative stress via their developed 
mitochondrial adaptation mechanisms, enhanced DNA repair mechanisms and 
upregulated anti-apoptotic pathways to resist ROS-induced cell death.  
Observations in this study confirmed that CDDP/DQA exerted their cytotoxic effects 
through excessive production of ROS. It was revealed that an enhanced ROS generation 
upon the treatments was largely localised within mitochondria and caused MMP 
disruption, mtDNA depletion, downregulation of mitochondrial stability markers and 
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upregulation of mtDNA damage markers. Hence, it was evident from these results that 
CDDP/DQA induced mitochondrial damage through oxidative stress.  
It is also indicated that excessive intracellular ROS induced by the treatments is the 
essential mediator of mitochondrial dysfunction and cell death, which are in line with 
previous studies where scavenging of ROS by antioxidants results in the attenuation in 
cell death. More importantly, this study has demonstrated that cells with lower baseline 
ROS levels respond better to ROS scavengers when undergoing ROS-stimulating 
treatment, which grants better cell death attenuation. This indicates that excessive ROS 
could be the main cause of cell death in cells with relatively low baseline ROS levels, 
whereas other mechanisms might play a role alongside with ROS in killing cells with 
relatively high baseline ROS levels. 
Our results support the theory that combining conventional chemotherapy with 
mitochondria-targeting therapy enhances cell death and allows reduced doses of the 
conventional drug. They also clearly suggest that combining mitochondria-targeting 
agents could provide improved efficacy while reducing side effects of conventional 
therapy in treating cancer. Our study highlights the possibility of achieving greater 
synergistic efficacy of ROS-stimulating agents in treating cancers especially those with 
low baseline ROS levels compared to others with high baseline ROS levels.  
In conclusion, the present study suggests that baseline ROS level in cancer cells could be 
an efficient predictive biomarker for drug response [369]. However, since measuring ROS 
in tissues is technically challenging, more efficient biomarkers linked to ROS to indicate 
the response to ROS-stimulating agents were also investigated in this study. 
Mitochondrial dysfunction can be associated with mtDNA alterations such as mutations 
and changes in the mtDNAcn (reviewed in Ref.s [65,160]). Therefore, this study also 
focused on the implications of mtDNA abnormalities in ROS related cancer cell 
death/survival and drug response. Indeed, our data showed a positive correlation between 
mtDNAcn and baseline intracellular ROS level, which confirmed previous observations 
that cells containing larger mtDNAcn also have higher levels of ROS. The positive 
correlation between mtDNAcn and baseline intracellular ROS levels in naïve cancer cells 
also means that mtDNAcn could be measured instead to indicate the response to 
mitochondria-targeting therapy, and therefore could be utilised as a potential biomarker 
to indicate drug sensitivity. 
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Our data have also shown that the total numbers of non-synonymous mutations within 
the mitochondrial genome, in particular those in complexes I and III, are strongly 
correlated with baseline ROS levels and the associated drug resistance. It is speculated 
that cancer cells generally carry more mutations in their mitochondrial genome than non-
cancerous cells, which renders higher baseline ROS levels in cancer cells and 
consequently increased drug resistance/cell survival. These observations indicate that 
high frequency of non-synonymous mutations in complexes I and III would result in 
increased baseline ROS level and reprogramming of the metabolic pathways to overcome 
oxidative stress. The positive correlation between the numbers of non-synonymous 
complexes I/III mutations and ROS/drug response in cancer cells suggests that such 
mitochondrial genetic abnormalities could be an efficient biomarker to indicate the 
response to mitochondria-targeting therapy. Indeed, a comprehensive literature search 
following the structural analysis revealed that a panel of specific mutations within the 
mitochondrial genome could be used to indicate elevated intracellular ROS and hence to 
predict drug resistance to ROS-stimulating agents. 
To our knowledge, this is the first study showing that baseline intracellular ROS levels of 
cancer cells are associated with drug response and specific mtDNA mutations (e.g. 
A10398G, T11120C, C12084T, A13681G, G13708A, C13802T, A13966G and 
T14798C) as well as large mtDNA copy numbers could be linked to elevated intracellular 
ROS and therefore utilised as biomarkers to predict drug resistance to ROS-stimulating 
agents. 
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7.2 Future directions 
As the above conclusions have been drawn based on limited in vitro work, further studies 
engaging a wider range of cell lines and ROS-stimulating agents, patient-derived primary 
cell cultures and tissues, and in vivo experiments will be required to validate the present 
findings. 
One of the limitations in this study is that only one non-cancerous cell line (PNT-2) was 
used in our investigation, which restricted us to compare the redox statuses and genetic 
profiles of the cancer cell lines from different origins to the same non-cancerous cell line. 
Therefore, using matched normal–cancer primary cultures or tissues from the same 
patient will allow more accurate and efficient comparisons in future studies. More 
importantly, testing those matched samples will enable us to differentiate somatic 
mutations from germline variations for the mtDNA sequence changes identified in the 
cancer tissue. In addition, the predicted functional mtDNA mutations and the correlation 
between mtDNAcn and drug responses observed in this study also need to be tested and 
verified in clinical samples. 
Another limitation of the study lies in the fact that all the cancer cell lines carried multiple 
mutations in their mitochondrial genomes, which had made it impossible to ascertain any 
physiobiological impact of those individual mtDNA mutations predicted to be functional 
by the 3D modelling work. Advanced technologies could be employed in future studies 
where targeted single mutations would be introduced to the wild type mtDNA in non-
cancerous cells, and the genetically modified mitochondria would replace their 
counterpart organelles in cancer cells to generate cybrids. Those cybrid cells can be useful 
tools to investigate the biological behaviour of cancer cells carrying a specific single 
mtDNA mutation or a combination of several specific mutations.    
Finally, since mitochondrial respiratory chain complexes are composed of both 
mitochondrial and nuclear subunits to form this elegant molecular machine, screening for 
functional mutations within the nuclear subunits should be also considered. 
Nevertheless, this study has provided an insight into understanding the influence of 
intracellular ROS on drug sensitivity, and may lead to the development of new therapeutic 
strategies to improve anticancer drug efficacy. 
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Appendix Table 1. List of common mutations identified in the 5 cell lines.  
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Appendix Table 2. List of unique mutations identified in the 5 cell lines.  
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Appendix Table 3. List of disease association of mutations in the 5 cell lines. 
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Appendix Figure 1. Alignment of the three reference protein sequences of the ND1 subunit used in the 
3D modelling analyses with the identified mutation positions marked. rCRS: NCBI Reference Sequence, 
5XTD: Homo sapiens homolog, 5LC5: Bos taurus homolog.  
 
 
Appendix Figure 2. Alignment of the three reference protein sequences of the ND3 subunit used in the 
3D modelling analyses with the identified mutation position marked. rCRS: NCBI Reference Sequence, 
5XTD: Homo sapiens homolog, 5LC5: Bos taurus homolog.  
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Appendix Figure 3. Alignment of the three reference protein sequences of the ND4 subunit used in the 
3D modelling analyses with the identified mutation positions marked. rCRS: NCBI Reference Sequence, 
5XTD: Homo sapiens homolog, 5LC5: Bos taurus homolog.  
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Appendix Figure 4. Alignment of the three reference protein sequences of the ND5 subunit used in the 
3D modelling analyses with the identified mutation positions marked. rCRS: NCBI Reference Sequence, 
5XTD: Homo sapiens homolog, 5LC5: Bos taurus homolog.  
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Appendix Figure 5. Alignment of the two reference protein sequences of the MT-CYB subunit used in 
the 3D modelling analyses with the identified mutation positions marked. rCRS: NCBI Reference 
Sequence, 5XTE: Homo sapiens homolog.  
 
 
 
Appendix Figure 6. Alignment of the two reference protein sequences of the MT-CO2 subunit used in 
the 3D modelling analyses with the identified mutation position marked. rCRS: NCBI Reference 
Sequence, 5Z6N: Homo sapiens homolog.  
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Appendix Figure 7. Alignment of the two reference protein sequences of the MT-ATP6 subunit used in 
the 3D modelling analyses with the identified mutation position marked. rCRS: NCBI Reference 
Sequence, 5ARA: Bos taurus homolog.  
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